var title_f42_61_43984="Olopatadine: Patient drug information";
var content_f42_61_43984=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Olopatadine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/60/35779?source=see_link\">",
"       Olopatadine (nasal): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/2/8228?source=see_link\">",
"       Olopatadine (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10923 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-85BFFBD9BA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43984=[""].join("\n");
var outline_f42_61_43984=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/60/35779?source=related_link\">",
"      Olopatadine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/2/8228?source=related_link\">",
"      Olopatadine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_61_43985="Mobilization of the hepatic flexure";
var content_f42_61_43985=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mobilization of the hepatic flexure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates a mobilized hepatic flexure of the right colon. The second portion of&nbsp;the duodenum and the head of the pancreas are exposed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43985=[""].join("\n");
var outline_f42_61_43985=null;
var title_f42_61_43986="Technetium Tc-99m exametazime: Patient drug information";
var content_f42_61_43986=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Technetium Tc-99m exametazime: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/0/36866?source=see_link\">",
"     see \"Technetium Tc-99m exametazime: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13374724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with a special imaging test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13374723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to technetium Tc 99m exametazime or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13374727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13374728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Facial swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15252232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13374726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13374731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17081 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43986=[""].join("\n");
var outline_f42_61_43986=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374724\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374723\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374727\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374728\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15252232\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374726\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374731\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/0/36866?source=related_link\">",
"      Technetium Tc-99m exametazime: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_61_43987="DeLancey levels pelvic support";
var content_f42_61_43987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60888&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    DeLancey levels of female pelvic floor support: Level 1 (apical suspension) and level 2 (lateral attachment)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Level 1: paracolpium suspends the vaginal apex from the lateral pelvic sidewall via the uterosacral-cardinal complex.",
"    <br>",
"     Level 2: the anterior vaginal wall is attached laterally to arcus tendinous fascia pelvis and the posterior vaginal wall is attached laterally to the facia overlying the levator ani muscle.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: DeLancey, JO. Anatomic aspects of vaginal eversion after hysterectomy. Am J Obstet Gynecol 1992; 166(6 Pt 1):1717. Copyright &copy; 1992 Elsevier Inc.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43987=[""].join("\n");
var outline_f42_61_43987=null;
var title_f42_61_43988="Paregoric: Pediatric drug information";
var content_f42_61_43988=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Paregoric: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?20/32/20997?source=see_link\">",
"    see \"Paregoric: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/46/4837?source=see_link\">",
"    see \"Paregoric: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiarrheal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Due to potential adverse effects from the additives in paregoric, other agents are preferred for treatment of neonatal abstinence syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Full-term neonates: Neonatal abstinence syndrome (not a preferred agent): Initial: 0.1 mL/kg or 2 drops/kg with feedings every 3-4 hours; increase dosage by 0.1 mL/kg or 2 drops/kg every 3-4 hours until withdrawal symptoms are controlled; it is rare to exceed 0.7 mL/dose. Stabilize withdrawal symptoms for 3-5 days, then gradually decrease the dosage (keeping the same dosing interval) over a 2- to 4-week period.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/32/20997?source=see_link\">",
"      see \"Paregoric: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 0.25-0.5 mL/kg 1-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 5-10 mL 1-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral: Morphine equivalent 2 mg/5 mL (473 mL) [contains ethanol &le;47.7% and benzoic acid]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F206427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with food to decrease GI upset; shake well before use",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store in light-resistant, tightly closed container; protect from freezing",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of diarrhea or relief of pain; neonatal abstinence syndrome (neonatal opiate withdrawal)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F206433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Camphorated tincture of opium is an error-prone synonym (mistaken as opium tincture)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Paregoric may be confused with Percogesic&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Use care when prescribing opium tincture; each mL contains the equivalent of morphine 10 mg; paregoric contains the equivalent of morphine 0.4 mg/mL",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F206431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, peripheral vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: CNS depression, dizziness, drowsiness, headache, increased intracranial pressure, insomnia, malaise, mental depression, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, biliary tract spasm, constipation, nausea, stomach cramps, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Decreased urination, ureteral spasms, urinary tract spasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Increased liver function tests",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Histamine release physical and psychological dependence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to opium or any component; diarrhea caused by poisoning until the toxic material has been removed",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with respiratory, hepatic or renal dysfunction, severe prostatic hypertrophy, or history of narcotic abuse; opium shares the toxic potential of opiate agonists, usual precautions of opiate agonist therapy should be observed; infants &lt;3 months of age are more susceptible to respiratory depression, use with caution and in reduced doses in this age group",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Abrupt discontinuation after prolonged use may result in symptoms of withdrawal. Do",
"     <b>",
"      not",
"     </b>",
"     confuse this product (paregoric) with opium tincture which is 25 times",
"     <b>",
"      more",
"     </b>",
"     potent. Each 5 mL of paregoric contains 2 mg morphine equivalent, 0.02 mL anise oil, 20 mg benzoic acid, 20 mg camphor, 0.2 mL glycerin and alcohol; final alcohol content 45%; paregoric also contains papaverine and noscapine; because all of these additives may be harmful to neonates,",
"     <b>",
"      a 25-fold dilution of opium tincture",
"     </b>",
"     is often preferred for treatment of neonatal abstinence syndrome (opiate withdrawal). Some centers prefer to use morphine oral solution.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Paregoric contains benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use paregoric products containing benzoic acid with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to morphine monograph.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory rate, blood pressure, heart rate, level of sedation; neonatal abstinence syndrome (opiate withdrawal): Monitor for resolution of withdrawal symptoms (such as irritability, high-pitched cry, stuffy nose, rhinorrhea, vomiting, poor feeding, diarrhea, sneezing, yawning, etc) and signs of over treatment (such as bradycardia, lethargy, hypotonia, irregular respirations, respiratory depression, etc); an abstinence scoring system (eg, Finnegan abstinence scoring system) can be used to more objectively assess neonatal opiate withdrawal symptoms and the need for dosage adjustment",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases smooth muscle tone in GI tract, decreases motility and peristalsis, diminishes digestive secretions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Opium is metabolized in the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine, primarily as morphine glucuronide conjugates and as parent compound (morphine, codeine, papaverine, etc)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/46/4837?source=see_link\">",
"      see \"Paregoric: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may be habit-forming; avoid abrupt discontinuation after prolonged use",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kraus DM and Pham JT, \"Neonatal Therapy,\"",
"      <i>",
"       Applied Therapeutics: The Clinical Use of Drugs",
"      </i>",
"      , 9th ed, Koda-Kimble MA, Young LY, Kradjan WA, et al, eds, Baltimore, MD: Lippincott Williams &amp; Wilkins, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy M and Spino M, &ldquo;Neonatal Withdrawal Syndrome: Associated Drugs and Pharmacologic Management,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1993, 13(3):202-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/61/43988/abstract-text/8321734/pubmed\" id=\"8321734\" target=\"_blank\">",
"        8321734",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Neonatal Drug Withdrawal. American Academy of Pediatrics Committee on Drugs,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 101(6):1079-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?42/61/43988/abstract-text/9614425/pubmed\" id=\"9614425\" target=\"_blank\">",
"        9614425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12679 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43988=[""].join("\n");
var outline_f42_61_43988=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054712\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444089\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054705\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206397\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206382\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206427\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054717\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054708\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054716\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206433\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206431\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054720\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054704\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054703\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299824\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206391\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206393\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079700\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054711\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054702\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054719\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054710\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12679\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12679|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/32/20997?source=related_link\">",
"      Paregoric: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/46/4837?source=related_link\">",
"      Paregoric: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_61_43989="Transient hyperphosphatasemia of infancy and early childhood";
var content_f42_61_43989=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transient hyperphosphatasemia of infancy and early childhood",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43989/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43989/contributors\">",
"     Rima Fawaz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43989/contributors\">",
"     Esther Israel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43989/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43989/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43989/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43989/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/61/43989/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient hyperphosphatasemia (TH) of infancy and early childhood is characterized by a marked elevation of serum alkaline phosphatase in the absence of detectable liver or bone disease, and a return to normal levels within weeks or months. The condition is thought to be benign; thus, this disorder is also called benign transient hyperphosphatasemia. Recognition of this phenomenon permits avoidance of unnecessary procedures and concerns, provided that underlying liver and bone disease are appropriately excluded.",
"   </p>",
"   <p>",
"    The clinical presentation and evaluation of an infant or young child with marked elevation of serum alkaline phosphatase will be reviewed here. Evaluation of an older child or adult with elevated alkaline phosphatase, or of any individual with elevations of multiple liver enzymes, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;TH occurs most commonly in infants and children younger than five years of age. A few adults with similar patterns have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The serum alkaline phosphatase (AP) is typically elevated four to five times the upper limit of normal, but elevations up to 20 times the pediatric upper reference limit (or 50 times the adult upper reference limit) have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In most cases there are elevations in both liver and bone isoenzymes, and (rarely) in intestinal isoenzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/6,9\">",
"     6,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum AP levels gradually return to normal within two to three months but have persisted as long as six months in a few cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The half-life of AP ranges from 5 to 25 days, depending upon coexisting morbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/12\">",
"     12",
"    </a>",
"    ]. In series reporting the results of long-term follow-up, no clinical sequelae were noted up to four years after the episode of TH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of TH is not known. In a series of 260 healthy infants, three (1.5 percent) had unexplained and transient elevations in serum AP, all more than three times the upper limit of normal for the assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/15\">",
"     15",
"    </a>",
"    ]. Similar prevalence rates were seen in a separate study in which serum alkaline phosphatase levels &gt;1000",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    (2.5 times the upper limit of normal) were found in 2.8 percent of healthy children under two years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/16\">",
"     16",
"    </a>",
"    ]. More moderate elevations of alkaline phosphatase, between 400 and 1000",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    were found in 5.1 percent of the subjects.",
"   </p>",
"   <p>",
"    Most children with TH are healthy, although TH has occurred in association with a variety of clinical conditions, including gastroenteritis, respiratory infection, failure to thrive, and asthma. TH has also been reported with viral infections such as respiratory syncytial virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/17-19\">",
"     17-19",
"    </a>",
"    ], enteroviruses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/20\">",
"     20",
"    </a>",
"    ], and HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/21\">",
"     21",
"    </a>",
"    ]; following liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] or kidney transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/22\">",
"     22",
"    </a>",
"    ]; and in children receiving chemotherapy for leukemia and lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/12,24\">",
"     12,24",
"    </a>",
"    ]. Some of these apparent disease associations may reflect more frequent laboratory testing to monitor the underlying disease. Indeed, in the largest study that prospectively evaluated a healthy population of infants and toddlers, no association with growth parameters was found [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/16\">",
"     16",
"    </a>",
"    ]. A seasonal distribution of cases has been noted in some series, with more cases identified in late summer and early fall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/6,12\">",
"     6,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NORMAL RANGES FOR SERUM AP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum alkaline phosphatase (AP) activities are generally higher in children than in adults because of physiologically higher rates of osteoblastic activity. In infants, activities are approximately three times the upper reference limit for adults, peaking between one and six months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/7\">",
"     7",
"    </a>",
"    ]. By two years of age, serum AP levels fall to approximately twice the upper reference limit for adults (",
"    <a class=\"graphic graphic_figure graphicRef56695 \" href=\"mobipreview.htm?12/30/12783\">",
"     figure 1",
"    </a>",
"    ). A second peak occurs in early puberty for girls (around 12 years) and mid-puberty for boys (around 14 years), coinciding with maximum growth velocity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10073?source=see_link&amp;anchor=H3#H3\">",
"     \"The child with tall stature or abnormally rapid growth\", section on 'Growth velocity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of TH is not well understood, as both liver and bone isoenzymes are usually increased. Several investigators have demonstrated that a fraction of both isoenzymes has a characteristic increase in electrophoretic mobility, due to increased content of sialic acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. This observation has led to the hypothesis that the hyperphosphatasemia is caused by excessive sialylation of alkaline phosphatase (AP), which slows clearance of the isoenzymes.",
"   </p>",
"   <p>",
"    The cause of the increased sialylation remains uncertain. By definition, TH is not caused by vitamin D deficiency. However, one hypothesis is that TH develops because there is increased production of AP during a period of catch-up growth after weight loss or vitamin D insufficiency, at a rate that overwhelms the mechanisms that normally desialylate the enzyme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/12\">",
"     12",
"    </a>",
"    ]. If so, children with TH might display subclinical vitamin D insufficiency at the time of diagnosis. However, this was not the case in one series of healthy infants and children, in which there was no difference in serum levels of vitamin D, parathyroid hormone, calcium, or phosphorus among subjects with TH as compared to those with normal AP levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Awareness of the entity of TH can avoid unnecessary tests in infants and children with this disorder. A careful history, physical examination, and abbreviated laboratory evaluation are usually sufficient to rule out other causes of the elevated alkaline phosphatase (AP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should inquire about bone disease (unexplained fractures, family history of bone disease, or complaints of bone pain); symptoms suggestive of liver disease (right upper quadrant pain, pruritus, steatorrhea, or dark-colored urine); drugs; renal disease; and nonspecific symptoms including anorexia, weight loss, fever, and lethargy.",
"   </p>",
"   <p>",
"    Risk factors for nutritional rickets should be assessed, including exclusive breast feeding or intake of less than one liter of vitamin D-fortified formula or milk daily, dark skin pigmentation, low exposure to sunlight, or prematurity. These infants and children are at risk for rickets unless given vitamin D supplements of at least 400 IU daily. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be examined for deformities, tenderness, or other abnormalities of bone, including skeletal abnormalities associated with rickets (beading at the costochondral junction or bowing of long bones) and bone tenderness. The examination should also include assessment for hepatomegaly, splenomegaly, liver tenderness, scleral icterus, jaundice, and stigmata of chronic liver disease (palmar erythema, spider telangiectasia, clubbing, caput medusae).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial laboratory testing should include serum aspartate aminotransferase, alanine aminotransferase, total and direct bilirubin, gamma-glutamyl transpeptidase (GGT), calcium, phosphorus, 25-hydroxyvitamin D (calcidiol), parathyroid hormone (PTH), blood urea nitrogen, and creatinine.",
"   </p>",
"   <p>",
"    A normal result for each of these tests is adequate to establish a provisional diagnosis of TH in an otherwise healthy infant or young child. Of note, the serum GGT activity is six to seven times the upper limit of the adult reference range in normal full-term neonates; levels decline and reach adult levels by five to seven months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurement of alkaline phosphatase isoenzymes by electrophoresis may be helpful but is usually not needed. The presence of excessive bone and liver fractions supports the diagnosis of TH and argues against primary hepatic or bone disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possibility of rickets should be raised by low serum levels of 25-hydroxyvitamin D with low serum calcium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    phosphorus, elevated levels of PTH, a history of risk factors for vitamin D deficiency (exclusive breast feeding without vitamin D supplementation), or typical skeletal abnormalities. Any of these findings should prompt further evaluation for rickets, with radiographs of long bones. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone pain or other bone abnormalities should be evaluated radiographically for evidence of tumor, fracture, or juvenile Paget disease (a rare autosomal recessive disorder of bone turnover associated with bone deformities and susceptibility to fracture). Limb pain also can be caused by a variety of orthopedic, infectious, rheumatic, and neoplastic disorders, as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7978?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Paget disease of bone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/47/5882?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical assessment of the child with suspected cancer\", section on 'Bone and joint pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23706?source=see_link\">",
"     \"Overview of the causes of limp in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with vitamin D deficient rickets should be treated with replacement doses of vitamin D (ergocalciferol). All other children should be evaluated to ensure adequate intake of vitamin D and supplemented with at least 400 IU daily if needed; steps should also be taken to ensure adequate intake of calcium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=see_link\">",
"     \"Etiology and treatment of calcipenic rickets in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/3/39990?source=see_link\">",
"     \"Overview of vitamin D\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Follow-up to document return of serum alkaline phosphatase (AP) levels to normal is critical for confirmation of the diagnosis of TH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43989/abstract/26\">",
"     26",
"    </a>",
"    ]. In our practice, we repeat serum AP measurement in a child with the provisional diagnosis of TH within four to six weeks until a downward trend is noted and normal values are attained. Sustained serum AP elevation beyond three to four months should prompt reconsideration of other causes of hyperphosphatasemia, including the bone disorders mentioned in the preceding section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient hyperphosphatasemia (TH) of infancy and early childhood is characterized by a marked elevation of serum alkaline phosphatase (AP) in the absence of detectable liver or bone disease. Almost all cases occur in infants and children younger than five years of age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In TH, the serum AP is typically elevated four to five times the upper limit of the pediatric reference range, and gradually returns to normal within two to three months. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum AP activities are higher in children than in adults because of physiological osteoblastic activity. The upper limit of the pediatric reference range is up to three times higher than in adults, peaking in late infancy and again during puberty (",
"      <a class=\"graphic graphic_figure graphicRef56695 \" href=\"mobipreview.htm?12/30/12783\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Normal ranges for serum AP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TH is characterized by elevations in both bone and liver alkaline phosphatase isoenzymes. The pathogenesis has not been fully established, but is thought to include reduced clearance of AP due to increased sialic acid content, perhaps caused by or compounded by a transient surge in alkaline phosphatase production. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation should include a history and physical examination to assess for evidence of primary liver or bone disease. Laboratory testing should include measurement of serum aspartate aminotransferase, total and direct bilirubin, gamma-glutamyl transpeptidase calcium, phosphorus, 25-hydroxyvitamin D, parathyroid hormone, blood urea nitrogen, and creatinine. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The possibility of rickets should be raised by low serum levels of 25-hydroxyvitamin D, calcium or phosphorus, elevated serum parathyroid hormone, a history of risk factors for vitamin D deficiency such as exclusive breast feeding without vitamin D supplementation, or typical skeletal abnormalities. Any of these findings should prompt further evaluation, including radiographs of long bones. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Laboratory testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=see_link\">",
"       \"Overview of rickets in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Even if rickets is excluded, all children should be evaluated to ensure adequate intake of vitamin D and supplemented with at least 400 IU daily if needed. Steps should also be taken to ensure adequate intake of calcium. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If there is no evidence of liver or bone disease in an infant or young child, then the provisional diagnosis of TH can be made. Repeat measurement of serum AP should be performed at intervals until normal values are attained. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/1\">",
"      Rosalki SB, Hurst NP. Transient presence in serum of an atypical alkaline phosphatase. Clin Chim Acta 1976; 73:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/2\">",
"      Schambeck CM, Kopp A, Mora-Maza G, Keller F. Transient alkaline hyperphosphatasaemia in an adult: biochemical peculiarities. Eur J Clin Chem Clin Biochem 1997; 35:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/3\">",
"      Rosalki SB, Foo AY, Went J, et al. \"Transient hyperphosphatasemia of infancy and childhood\" in an adult. Clin Chem 1991; 37:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/4\">",
"      Onica D, Torssander J, Waldenlind L. Recurrent transient hyperphosphatasemia of infancy in an adult. Clin Chem 1992; 38:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/5\">",
"      Ilham MA, Cookson A, Dheerendra S, et al. Idiopathic severe elevation of serum alkaline phosphatase following adult renal transplantation: case reports. Transplant Proc 2008; 40:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/6\">",
"      Beh&uacute;lov&aacute; D, Bzd&uacute;ch V, Holesov&aacute; D, et al. Transient hyperphosphatasemia of infancy and childhood: study of 194 cases. Clin Chem 2000; 46:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/7\">",
"      Stein P, Rosalki SB, Foo AY, Hjelm M. Transient hyperphosphatasemia of infancy and early childhood: clinical and biochemical features of 21 cases and literature review. Clin Chem 1987; 33:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/8\">",
"      Rosalki SB, Foo Y. Transient hyperphosphatasemia of infancy: four new cases, and a suggested etiology. Clin Chem 1980; 26:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/9\">",
"      Kruse K, Kracht U. [Isolated elevation of serum alkaline phosphatase]. Dtsch Med Wochenschr 1985; 110:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/10\">",
"      Garrote de Marcos JM, Molina Arias M, Ech&aacute;varri Olvarr&iacute;a F, Arregui Sierra A. [Benign transient hyperphosphatasemia: the contribution of 20 new cases]. An Esp Pediatr 1996; 44:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/11\">",
"      Carroll AJ, Coakley JC. Transient hyperphosphatasaemia: an important condition to recognize. J Paediatr Child Health 2001; 37:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/12\">",
"      Crofton PM. What is the cause of benign transient hyperphosphatasemia? A study of 35 cases. Clin Chem 1988; 34:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/13\">",
"      Steinherz PG, Steinherz LJ, Nisselbaum JS, Murphy ML. Transient, marked, unexplained elevation of serum alkaline phosphatase. JAMA 1984; 252:3289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/14\">",
"      Posen S, Lee C, Vines R, et al. Transient hyperphosphatasemia of infancy--an insufficiently recognized syndrome. Clin Chem 1977; 23:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/15\">",
"      Asanti R, Hultin H, Visakorpi JK. Serum alkaline, phosphatase in healthy infants. Occurrence of abnormally high values without known cause. Ann Paediatr Fenn 1966; 12:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/16\">",
"      Huh SY, Feldman HA, Cox JE, Gordon CM. Prevalence of transient hyperphosphatasemia among healthy infants and toddlers. Pediatrics 2009; 124:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/17\">",
"      Goto M. [Is respiratory syncytial virus one of the causative agents for transient hyperphosphatasemia?]. Rinsho Byori 2002; 50:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/18\">",
"      Holt PA, Steel AE, Armstrong AM. Transient hyperphosphatasaemia of infancy following rotavirus infection. J Infect 1984; 9:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/19\">",
"      Sch&ouml;nau E, Herzog KH, B&ouml;hles HJ. Transient hyperphosphatasaemia of infancy. Eur J Pediatr 1988; 148:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/20\">",
"      Suzuki M, Okazaki T, Nagai T, et al. Viral infection of infants and children with benign transient hyperphosphatasemia. FEMS Immunol Med Microbiol 2002; 33:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/21\">",
"      Fennoy I, Laraque D. Benign transient hyperphosphatasia and HIV infection. Clin Pediatr (Phila) 1989; 28:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/22\">",
"      Ranchin B, Villard F, Andr&eacute; JL, et al. Transient hyperphosphatasemia after organ transplantation in children. Pediatr Transplant 2002; 6:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/23\">",
"      Arikan C, Arslan MT, Kilic M, Aydogdu S. Transient hyperphosphatasemia after pediatric liver transplantation. Pediatr Int 2006; 48:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/24\">",
"      Massey GV, Dunn NL, Heckel JL, et al. Benign transient hyperphosphatasemia in children with leukemia and lymphoma. Clin Pediatr (Phila) 1996; 35:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/25\">",
"      Cabrera-Abreu JC, Green A. Gamma-glutamyltransferase: value of its measurement in paediatrics. Ann Clin Biochem 2002; 39:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43989/abstract/26\">",
"      Tolaymat N, de Melo MC. Benign transient hyperphosphatasemia of infancy and childhood. South Med J 2000; 93:1162.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5946 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-33CB703E27-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43989=[""].join("\n");
var outline_f42_61_43989=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NORMAL RANGES FOR SERUM AP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5946\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5946|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/30/12783\" title=\"figure 1\">",
"      Alk phos range child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7978?source=related_link\">",
"      Clinical manifestations and diagnosis of Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19353?source=related_link\">",
"      Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=related_link\">",
"      Etiology and treatment of calcipenic rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/9/23706?source=related_link\">",
"      Overview of the causes of limp in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/3/39990?source=related_link\">",
"      Overview of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/53/10073?source=related_link\">",
"      The child with tall stature or abnormally rapid growth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_61_43990="SVC veins mediastinum";
var content_f42_61_43990=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Anatomy of the superior vena cava and veins of the mediastinum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 559px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43990=[""].join("\n");
var outline_f42_61_43990=null;
var title_f42_61_43991="Breast cellulitis: Clinical manifestations, diagnosis, and management";
var content_f42_61_43991=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Breast cellulitis: Clinical manifestations, diagnosis, and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43991/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43991/contributors\">",
"     J Michael Dixon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43991/contributors\">",
"     Larry M Baddour, MD, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43991/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43991/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43991/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43991/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43991/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43991/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/61/43991/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellulitis is an uncommon infection in the breast and can be difficult to distinguish from inflammatory breast cancer or benign erythematous conditions of the breast. Pain is a prominent feature of breast cellulitis and is associated with erythema, swelling, and warmth. Inflammatory conditions of the breast not related to cellulitis are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/857?source=see_link\">",
"     \"Erythematous disorders of the breast\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3786583\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellulitis and erythema of the breast is an uncommon presentation for women seeking medical care for a breast related-problem. For example, a prospective study of 3762 consecutive female patients evaluated in a dedicated breast center found that only 22 women (0.6 percent) presented with erythema of the breast during a 14-month interval, and of those 22, only 2 patients (9 percent) had cellulitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/1\">",
"     1",
"    </a>",
"    ]. In comparison, breast cellulitis occurs in approximately 1 to 8 percent of patients managed by breast conservation treatment (partial mastectomy and radiation therapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/2-7\">",
"     2-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8779316\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Independent risk factors for breast cellulitis include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/1-5,7-9\">",
"     1-5,7-9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/28/454?source=see_link\">",
"       \"Lactational mastitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Breast surgery within previous 30 days (surgical site infection) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36406?source=see_link\">",
"       \"Epidemiology and pathogenesis of and risk factors for surgical site infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prior breast cellulitis or infection",
"     </li>",
"     <li>",
"      Trauma (eg, bites, nipple piercing, tattoos)",
"     </li>",
"     <li>",
"      Infected skin lesions (eg, eczema, dryness, dermatitis)",
"     </li>",
"     <li>",
"      Breast conservation treatment for breast cancer (partial mastectomy and radiation therapy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7047054\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-hemolytic streptococcus is an important cause of breast cellulitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/3,9,10\">",
"     3,9,10",
"    </a>",
"    ]. A case-control study conducted in three metropolitan areas in the United States demonstrated that breast cancer was a risk factor for the development of group B streptococcal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/11\">",
"     11",
"    </a>",
"    ]. Group B beta-hemolytic streptococci have a proclivity to produce soft-tissue infections in the setting of venous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphatic compromise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/12\">",
"     12",
"    </a>",
"    ]. Staphylococcus aureus, including methicillin-resistant S. aureus, can also be an important pathogen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36936?source=see_link\">",
"     \"Group B streptococcal infections in nonpregnant adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12681954\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12681962\">",
"    <span class=\"h2\">",
"     Patient presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients present with a painful, warm, and erythematous breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/2,4,5,8,13,14\">",
"     2,4,5,8,13,14",
"    </a>",
"    ]. Systemic symptoms (eg, fever, chills) are uncommon, occurring in only 6 of 50 cases in one series, and, when present, most often consist of low-grade fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/4\">",
"     4",
"    </a>",
"    ]. The physical examination of the breast reveals localized or diffuse erythema, edema, marked tenderness, and warmth. Axillary nodes can be enlarged and tender.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12681978\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12681986\">",
"    <span class=\"h3\">",
"     Mammogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mammogram may show no specific radiographic abnormality for cellulitis or may show mild skin thickening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12681994\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ultrasound may reveal no specific findings for cellulitis alone or there may be skin edema visible. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12682002\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellulitis can appear as thickening of the skin on magnetic resonance imaging (MRI) evaluation as well as separation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    septation of subcutaneous adipose tissue. Signal intensity abnormalities are found in the subcutaneous tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1319557\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1321326\">",
"    <span class=\"h3\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A leukocytosis may be identified in patients with systemic symptoms (eg, fever, chills) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/7\">",
"     7",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1321333\">",
"    <span class=\"h3\">",
"     Blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures are typically negative in patients without systemic symptoms. Beta-hemolytic streptococcus or Staphylococcus aureus may be identified in a small minority of patients; patients with positive blood cultures usually have systemic symptoms of infection and some may present with sepsis with or without shock. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42551?source=see_link\">",
"     \"Group A streptococcal (Streptococcus pyogenes) bacteremia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1321202\">",
"    <span class=\"h3\">",
"     Skin aspirate culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin aspirates are generally not diagnostic and do not often identify causative pathogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/3,4,7,9,10,14\">",
"     3,4,7,9,10,14",
"    </a>",
"    ]. The negative cultures may be a reflection of the low concentration of organisms present in the involved tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1320906\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic evaluation of a full-thickness skin biopsy (punch or elliptical) can reveal a leukocyte infiltration, capillary dilatation, soft-tissue inflammation, and possible bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114719493\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation for breast cellulitis includes a history to assess for pain, trauma, breast-feeding, and previous breast surgery, breast cancer diagnosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    local radiation treatments. The clinical evaluation includes a breast examination to assess for extent of erythema, swelling, and tenderness, and an axillary examination to assess for tender",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enlarged lymph nodes.",
"   </p>",
"   <p>",
"    Neither laboratory tests nor skin aspirates are required. Blood cultures are indicated if the patient appears septic or is neutropenic. Radiographic imaging is useful if there is any clinical suspicion of an underlying fluid collection, abscess, malignancy, or if there is no improvement in signs and symptoms from oral antibiotic therapy after 48 to 72 hours of use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=see_link&amp;anchor=H4#H4\">",
"     \"Cellulitis and erysipelas\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12682018\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of breast cellulitis is made clinically, based upon the presentation and physical examination findings: breast erythema, edema, tenderness, warmth, and pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/6,18-23\">",
"     6,18-23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12681954\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3786712\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cellulitis must be distinguished from other inflammatory processes of the breast, including malignancy and other benign conditions. Disruption of cutaneous lymphatics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    circulation in the absence of an infectious process, such as a malignancy or an inflammatory process, can lead to a diffuse pattern of erythema that mimics cellulitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16334891\">",
"    <span class=\"h2\">",
"     Benign etiologies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16334823\">",
"    <span class=\"h3\">",
"     Mondor's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mondor&rsquo;s disease, also known as Mondor&rsquo;s syndrome of superficial thrombophlebitis, is a self-limiting disease that involves the superficial veins of the breast and anterior chest wall (",
"    <a class=\"graphic graphic_picture graphicRef64826 \" href=\"mobipreview.htm?32/20/33088\">",
"     picture 1",
"    </a>",
"    ). Patients present with acute superficial pain, erythema, and swelling, as well as a thickened tender cord, which can occur following an operation, radiation treatments, trauma, or unrelated to any antecedent event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/857?source=see_link&amp;anchor=H52640110#H52640110\">",
"     \"Erythematous disorders of the breast\", section on 'Superficial thrombophlebitis of the breast (Mondor disease)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16334930\">",
"    <span class=\"h3\">",
"     Abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abscess is a localized collection of purulent fluid that is seen in lactating and nonlactating women. Patients typically present with a localized, painful, fluctuant mass of the breast associated with fever and malaise (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62711 \" href=\"mobipreview.htm?31/34/32288\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/30\">",
"     30",
"    </a>",
"    ]. An ultrasound confirms the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9495?source=see_link\">",
"     \"Breast abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16335164\">",
"    <span class=\"h3\">",
"     Postoperative dermal lymphedema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative dermal lymphedema appears as cutaneous erythema and induration, without pain or tenderness, fever or leukocytosis, and mimics cellulitis and inflammatory breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/3,27,31\">",
"     3,27,31",
"    </a>",
"    ]. The involvement of the breast may be localized or diffuse. The lymphedema is a manifestation of lymphatic obstruction. This can occur following an operation alone or in conjunction with radiation treatments to the breast for cancer therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Clinical evaluation and surveillance are adequate; a biopsy is performed when malignancy is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16335995\">",
"    <span class=\"h3\">",
"     Morphea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast-associated morphea, or localized scleroderma, is an idiopathic, often self-limiting, inflammatory cutaneous disorder that causes fibrotic changes in the skin which then transition through an early inflammatory stage followed by sclerosis and subsequent atrophy. The depth of involvement may be superficial (primarily dermal) or deep (involving the deep dermis plus the subcutis, fascia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone) (",
"    <a class=\"graphic graphic_picture graphicRef73769 \" href=\"mobipreview.htm?4/8/4225\">",
"     picture 2",
"    </a>",
"    ). Etiology includes external beam radiation therapy, trauma, breast implants, and autoimmune disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/34\">",
"     34",
"    </a>",
"    ]. The interval between completion of radiation treatments and onset of the skin disorder is variable, ranging from one month to 32 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. This entity is distinct from radiation induced dermatitis or radiation induced fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/133?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial sign of morphea is often an abrupt development of an inflammatory, erythematous patch or edematous plaque. Some patients may note unexplained pain or itching at the site of disease prior to the development of a clinically evident lesion. Sclerosis usually begins in the center of inflammatory lesions, initially leaving an erythematous or violaceous border. Later, the skin becomes pale and glassy in appearance. The clinical manifestations of postirradiation morphea include moderate to severe mixed dermal inflammatory infiltrate, with hyperpigmentation, retraction, skin thickening, and dermal fibrosis extending into the subcutaneous adipose tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/133?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/14/17640?source=see_link\">",
"     \"Treatment of morphea (localized scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16336509\">",
"    <span class=\"h3\">",
"     Dermatologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin disorders, such as atopic dermatitis (eczema) (",
"    <a class=\"graphic graphic_picture graphicRef55375 \" href=\"mobipreview.htm?41/10/42147\">",
"     picture 3",
"    </a>",
"    ) or psoriasis (",
"    <a class=\"graphic graphic_picture graphicRef81412 \" href=\"mobipreview.htm?39/55/40831\">",
"     picture 4",
"    </a>",
"    ) can appear as erythematous skin lesions with papules. These lesions are generally not painful and not associated with swelling or warmth. A biopsy, if needed, can confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9257835\">",
"    <span class=\"h2\">",
"     Malignant etiologies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9257862\">",
"    <span class=\"h3\">",
"     Inflammatory breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory breast cancer (IBC) is a rare and aggressive cancer. Patients present with diffuse erythema and edema of the breast (",
"    <a class=\"graphic graphic_picture graphicRef70894 \" href=\"mobipreview.htm?13/8/13442\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef82220 \" href=\"mobipreview.htm?2/34/2592\">",
"     picture 6",
"    </a>",
"    ). The skin over the breast is thickened and sometimes warm, with a peau d'orange (skin of an orange) appearance, with or without nipple involvement (can include flattening, erythema, crusting, blistering, or retraction). Diagnosis is confirmed on a biopsy of the breast and or any pathological axillary lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/20/31048?source=see_link\">",
"     \"Inflammatory breast cancer: Clinical features and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9257869\">",
"    <span class=\"h3\">",
"     Paget's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of Paget&rsquo;s disease of the breast (PDB) is a scaly, raw, vesicular, or ulcerated lesion that begins on the nipple and then spreads to the areola (",
"    <a class=\"graphic graphic_picture graphicRef60575 \" href=\"mobipreview.htm?2/23/2423\">",
"     picture 7",
"    </a>",
"    ). Occasionally, a bloody discharge is present. PDB is usually unilateral, although bilateral cases have been described. Nipple retraction is also a rare finding, but may occur with more advanced disease. The diagnosis is usually established by full-thickness wedge, core biopsy, or punch biopsy of the nipple. Wedge biopsy and core biopsy have the advantage of frequently containing lactiferous ducts, which can disclose whether the underlying ducts show evidence of any invasive or in situ breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/14?source=see_link\">",
"     \"Paget disease of the breast\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1325712\">",
"    <span class=\"h2\">",
"     Post-radiation treatment etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with a history of breast cancer surgery (eg, partial mastectomy) and radiation treatments to the breast, the differential diagnosis also includes:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1325751\">",
"    <span class=\"h3\">",
"     Radiation induced dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation induced dermatitis is one of the most common side effects reported by patients undergoing radiation treatments for breast cancer. The acute erythematous skin reaction resulting from breast irradiation begins at a dose of 20 Gy to 30 Gy, is strictly confined to the irradiated volume, and is not associated with fever or leukocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43991/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1326298\">",
"    <span class=\"h3\">",
"     Radiation induced fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation induced fibrosis can develop as a late effect of radiation treatments. Clinical presentation includes induration, thickening, and lymphedema in the skin and subcutaneous tissue of the breast. Typical histologic features include the presence of inflammatory infiltrates, particularly macrophages in the earlier stages of fibrosis, differentiation of fibroblasts into postmitotic fibrocytes, and changes in the vascular connective tissue with excessive production and deposition of extracellular matrix proteins and collagen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17129?source=see_link\">",
"     \"Clinical manifestations and treatment of radiation-induced fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1315688\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16336420\">",
"    <span class=\"h2\">",
"     Guiding principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The guiding principles for treating cellulitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide pain control and symptomatic relief. Anti-inflammatory agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      ) along with ice packs can reduce local pain and swelling.",
"     </li>",
"     <li>",
"      Treat with antibiotics. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antibiotics'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      If the infection does not show evidence of a response (eg, pain resolution, partial clearing of erythema and edema) within 48 to 72 hours of antibiotic therapy, further evaluation is necessary, including a mammogram",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultrasound to assess for a fluid collection (ie, abscess should be drained) or findings suspicious for cancer, which should prompt referral to a surgeon. (See",
"      <a class=\"local\" href=\"#H3786712\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perform a skin biopsy for histologic evaluation and",
"      <span class=\"nowrap\">",
"       culture/sensitivity",
"      </span>",
"      for neutropenic patients who do not respond to antibiotic therapy within 48 hours of administration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of risk for MRSA (",
"    <a class=\"graphic graphic_table graphicRef53504 \" href=\"mobipreview.htm?5/9/5275\">",
"     table 1",
"    </a>",
"    ), the following antibiotics are administered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the patient who is systemically ill,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      (2 g intravenously every six hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      (2 g intravenously every eight hours) is administered with monitoring for clinical response (eg, reduced pain, erythema, fever). In the setting of beta-lactam allergy,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (600 mg intravenously every eight hours) may be administered. Once there is evidence of clinical improvement, treatment should be continued with oral therapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/11/3253?source=see_link\">",
"       dicloxacillin",
"      </a>",
"      500 mg oral every six hours,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      500 mg orally every six hours or clindamycin 300 to 450 mg orally every eight hours). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=see_link&amp;anchor=H8#H8\">",
"       \"Cellulitis and erysipelas\", section on 'Antibiotics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For the patient with uncomplicated cellulitis, oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/11/3253?source=see_link\">",
"       dicloxacillin",
"      </a>",
"      (500 mg orally every six hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"       cephalexin",
"      </a>",
"      (500 mg orally every six hours) is administered. In the setting of beta-lactam allergy, oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (300 mg to 450 orally every eight hours) is administered (",
"      <a class=\"graphic graphic_table graphicRef64128 \" href=\"mobipreview.htm?23/12/23756\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=see_link&amp;anchor=H8#H8\">",
"       \"Cellulitis and erysipelas\", section on 'Antibiotics'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the setting of risk for MRSA (",
"    <a class=\"graphic graphic_table graphicRef53504 \" href=\"mobipreview.htm?5/9/5275\">",
"     table 1",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously in two divided doses every 24 hours) is administered as well as a cephalosporin for coverage against streptococci (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    1 g intravenously every 24 hours). Treatment may be continued with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (300 mg orally four times daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (1 to 2 tabs orally twice daily) (",
"    <a class=\"graphic graphic_table graphicRef76937 \" href=\"mobipreview.htm?31/58/32684\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who have received recent chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    are neutropenic, the antibiotic regimen must be broadened to include coverage for aerobic gram-negative bacilli, including Pseudomonas aeruginosa. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal duration of oral antibiotic therapy is uncertain; 10 to 14 days is generally appropriate for most patients, but the duration of antimicrobial therapy can be shorter or longer, depending on patient response. In general, antibiotics are continued until the clinical signs of infection have resolved, including pain, fever, erythema, and edema. In general, patients report improvement in pain before there is a noticeable decrease in erythema and swelling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16336427\">",
"    <span class=\"h2\">",
"     Recurrent cellulitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with breast cellulitis are at risk for recurrent infection. The antibiotic management of a recurrent episode should be guided by microbiologic data obtained during a prior episode, if any. Otherwise the choice of antibiotic therapy is the same as the approach to treatment of an initial episode of cellulitis (",
"    <a class=\"graphic graphic_table graphicRef64128 \" href=\"mobipreview.htm?23/12/23756\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef76937 \" href=\"mobipreview.htm?31/58/32684\">",
"     table 3",
"    </a>",
"    ). Chronic dermatologic conditions that predispose to cellulitis should be treated aggressively, and the skin of the lower breast should be kept as clean and dry as possible.",
"   </p>",
"   <p>",
"    For some patients with multiple recurrent episodes, long-term suppressive antibiotic therapy may be appropriate. Management of these patients should be done in concert with infectious disease specialists or others with extensive expertise in the management of patients with breast cellulitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical manifestation of breast cellulitis include pain, diffuse erythema, tenderness, and warmth. (See",
"      <a class=\"local\" href=\"#H12681954\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-group A beta-hemolytic streptococci is the most common pathogen for postoperative cellulitis of the breast, although in many cases no pathogen is isolated from skin aspirates or blood cultures. (See",
"      <a class=\"local\" href=\"#H1321333\">",
"       'Blood cultures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1321202\">",
"       'Skin aspirate culture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with uncomplicated breast cellulitis following radiation treatments for breast cancer may be treated with empiric oral antibiotic therapy (",
"      <a class=\"graphic graphic_table graphicRef64128 \" href=\"mobipreview.htm?23/12/23756\">",
"       table 2",
"      </a>",
"      ). Patients with signs of systemic toxicity or rapidly progressing erythema should be treated with parenteral antibiotics. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of clinical response to antibiotic therapy within 48 to 72 hours, ultrasound should be performed to assess for abscess. Alternative diagnoses such as inflammatory breast cancer should also be considered. (See",
"      <a class=\"local\" href=\"#H16336420\">",
"       'Guiding principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment for patients with recurrent cellulitis should be guided by microbiologic data (if available). Otherwise the approach to antibiotic selection is the same as for an initial episode of cellulitis. Chronic dermatologic conditions that predispose to cellulitis should be treated aggressively, and the skin of the lower breast should be kept as clean and dry as possible. (See",
"      <a class=\"local\" href=\"#H16336427\">",
"       'Recurrent cellulitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/1\">",
"      Froman J, Landercasper J, Ellis R, et al. Red breast as a presenting complaint at a breast center: an institutional review. Surgery 2011; 149:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/2\">",
"      Hughes LL, Styblo TM, Thoms WW, et al. Cellulitis of the breast as a complication of breast-conserving surgery and irradiation. Am J Clin Oncol 1997; 20:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/3\">",
"      Mertz KR, Baddour LM, Bell JL, Gwin JL. Breast cellulitis following breast conservation therapy: a novel complication of medical progress. Clin Infect Dis 1998; 26:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/4\">",
"      Indelicato DJ, Grobmyer SR, Newlin H, et al. Delayed breast cellulitis: an evolving complication of breast conservation. Int J Radiat Oncol Biol Phys 2006; 66:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/5\">",
"      Brewer VH, Hahn KA, Rohrbach BW, et al. Risk factor analysis for breast cellulitis complicating breast conservation therapy. Clin Infect Dis 2000; 31:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/6\">",
"      Zippel D, Siegelmann-Danieli N, Ayalon S, et al. Delayed breast cellulitis following breast conserving operation. Eur J Surg Oncol 2003; 29:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/7\">",
"      Baddour LM. Breast cellulitis complicating breast conservation therapy. J Intern Med 1999; 245:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/8\">",
"      Miller SR, Mondry T, Reed JS, et al. Delayed cellulitis associated with conservative therapy for breast cancer. J Surg Oncol 1998; 67:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/9\">",
"      Rescigno J, McCormick B, Brown AE, Myskowski PL. Breast cellulitis after conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 1994; 29:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/10\">",
"      Simon MS, Cody RL. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am J Med 1992; 93:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/11\">",
"      Jackson LA, Hilsdon R, Farley MM, et al. Risk factors for group B streptococcal disease in adults. Ann Intern Med 1995; 123:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/12\">",
"      Baddour LM, Bisno AL. Non-group A beta-hemolytic streptococcal cellulitis. Association with venous and lymphatic compromise. Am J Med 1985; 79:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/13\">",
"      Peltecu G. Images in clinical medicine. Cellulitis after treatment for breast cancer. N Engl J Med 2007; 357:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/14\">",
"      Staren ED, Klepac S, Smith AP, et al. The dilemma of delayed cellulitis after breast conservation therapy. Arch Surg 1996; 131:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/15\">",
"      Peters F, Petersen EE, Kirkpatrick CJ. Isolated erythema (cellulitis) of the breast. Breast 2002; 11:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/16\">",
"      Rahmouni A, Chosidow O, Mathieu D, et al. MR imaging in acute infectious cellulitis. Radiology 1994; 192:493.",
"     </a>",
"    </li>",
"    <li>",
"     Chapter 23: Bacterial and rickettsial infections. Cellulitis. In: Weedon's Skin Pathology, 3rd, Weedon D.  (Ed), Churchill Livingstone Elsevier, Philadelphia 2010. p.552.",
"    </li>",
"    <li>",
"     Dixon JM. Breast infection. In: ABC of Breast Diseases, Dixon JM (Ed), Blackwell Publishing, Oxford 2006. p.19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/19\">",
"      Foxman B, D'Arcy H, Gillespie B, et al. Lactation mastitis: occurrence and medical management among 946 breastfeeding women in the United States. Am J Epidemiol 2002; 155:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/20\">",
"      Committee on Health Care for Underserved Women, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 361: Breastfeeding: maternal and infant aspects. Obstet Gynecol 2007; 109:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/21\">",
"      Stafford I, Hernandez J, Laibl V, et al. Community-acquired methicillin-resistant Staphylococcus aureus among patients with puerperal mastitis requiring hospitalization. Obstet Gynecol 2008; 112:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/22\">",
"      Jahanfar S, Ng CJ, Teng CL. Antibiotics for mastitis in breastfeeding women. Cochrane Database Syst Rev 2009; :CD005458.",
"     </a>",
"    </li>",
"    <li>",
"     Hale TW, Berens PD. Clinical Therapy in Breastfeeding Patients, 2nd ed, Pharmasoft, Amarillo 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/24\">",
"      Vitug AF, Newman LA. Complications in breast surgery. Surg Clin North Am 2007; 87:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/25\">",
"      Throckmorton AD, Boughey JC, Boostrom SY, et al. Postoperative prophylactic antibiotics and surgical site infection rates in breast surgery patients. Ann Surg Oncol 2009; 16:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/26\">",
"      McNeely ML, Binkley JM, Pusic AL, et al. A prospective model of care for breast cancer rehabilitation: postoperative and postreconstructive issues. Cancer 2012; 118:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/27\">",
"      Milgrom S, Higgins SA. Management of cellulitis associated with treatment of breast cancer. J Support Oncol 2009; 7:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/28\">",
"      Catania S, Zurrida S, Veronesi P, et al. Mondor's disease and breast cancer. Cancer 1992; 69:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/29\">",
"      Shetty MK, Watson AB. Mondor's disease of the breast: sonographic and mammographic findings. AJR Am J Roentgenol 2001; 177:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/30\">",
"      Dixon JM. Breast abscess. Br J Hosp Med (Lond) 2007; 68:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/31\">",
"      King R, Duncan L, Shupp DL, Googe PB. Postsurgical dermal lymphedema clinically mimicking inflammatory breast carcinoma. Arch Dermatol 2001; 137:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/32\">",
"      Browse NL, Stewart G. Lymphoedema: pathophysiology and classification. J Cardiovasc Surg (Torino) 1985; 26:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/33\">",
"      Marcks P. Lymphedema. Pathogenesis, prevention, and treatment. Cancer Pract 1997; 5:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/34\">",
"      Clark CJ, Wechter D. Morphea of the breast--an uncommon cause of breast erythema. Am J Surg 2010; 200:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/35\">",
"      Walsh N, Rheaume D, Barnes P, et al. Postirradiation morphea: an underrecognized complication of treatment for breast cancer. Hum Pathol 2008; 39:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/36\">",
"      Schaffer JV, Carroll C, Dvoretsky I, et al. Postirradiation morphea of the breast presentation of two cases and review of the literature. Dermatology 2000; 200:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43991/abstract/37\">",
"      Dubner S, Bovi J, White J, Susnik B. Postirradiation morphea in a breast cancer patient. Breast J 2006; 12:173.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 797 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-189.44.181.18-7163832E31-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43991=[""].join("\n");
var outline_f42_61_43991=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3786583\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8779316\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7047054\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12681954\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12681962\">",
"      Patient presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12681978\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12681986\">",
"      - Mammogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12681994\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12682002\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1319557\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1321326\">",
"      - Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1321333\">",
"      - Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1321202\">",
"      - Skin aspirate culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1320906\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114719493\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12682018\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3786712\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16334891\">",
"      Benign etiologies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16334823\">",
"      - Mondor's disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16334930\">",
"      - Abscess",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16335164\">",
"      - Postoperative dermal lymphedema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16335995\">",
"      - Morphea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16336509\">",
"      - Dermatologic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9257835\">",
"      Malignant etiologies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9257862\">",
"      - Inflammatory breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9257869\">",
"      - Paget's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1325712\">",
"      Post-radiation treatment etiologies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1325751\">",
"      - Radiation induced dermatitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1326298\">",
"      - Radiation induced fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1315688\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16336420\">",
"      Guiding principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16336427\">",
"      Recurrent cellulitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/797\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/797|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/34/32288\" title=\"diagnostic image 1\">",
"      Ultrasound appearance of a breast abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/797|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/20/33088\" title=\"picture 1\">",
"      Mondor disease of the breast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/8/4225\" title=\"picture 2\">",
"      Circumscribed morphea - inflammatory plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/10/42147\" title=\"picture 3\">",
"      Adult atopic dermatitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/55/40831\" title=\"picture 4\">",
"      Plaque type psoriasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/8/13442\" title=\"picture 5\">",
"      Inflammatory breast cancer with peau d orange appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/34/2592\" title=\"picture 6\">",
"      Inflammatory breast cancer appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/23/2423\" title=\"picture 7\">",
"      Paget disease of the breast presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/797|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/9/5275\" title=\"table 1\">",
"      Risk factors for MRSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/12/23756\" title=\"table 2\">",
"      Empiric antibiotics cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/58/32684\" title=\"table 3\">",
"      Empiric oral treatment for MRSA and beta-hemolytic streptococci",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9495?source=related_link\">",
"      Breast abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17129?source=related_link\">",
"      Clinical manifestations and treatment of radiation-induced fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36406?source=related_link\">",
"      Epidemiology and pathogenesis of and risk factors for surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/53/857?source=related_link\">",
"      Erythematous disorders of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42551?source=related_link\">",
"      Group A streptococcal (Streptococcus pyogenes) bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36936?source=related_link\">",
"      Group B streptococcal infections in nonpregnant adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/20/31048?source=related_link\">",
"      Inflammatory breast cancer: Clinical features and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/28/454?source=related_link\">",
"      Lactational mastitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/0/14?source=related_link\">",
"      Paget disease of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/8/133?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/14/17640?source=related_link\">",
"      Treatment of morphea (localized scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_61_43992="Retropharyngeal infections in children";
var content_f42_61_43992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Retropharyngeal infections in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43992/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43992/contributors\">",
"     Ellen R Wald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43992/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43992/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43992/contributors\">",
"     Ellen M Friedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43992/contributors\">",
"     Stephen J Teach, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43992/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/61/43992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suppurative infections of the neck are uncommon in children. However, they are potentially very serious. Suppurative cervical lymphadenitis is the most common superficial neck infection. Deep neck infections include peritonsillar abscess, retropharyngeal abscess, and lateral pharyngeal space infection (also known as pharyngomaxillary or parapharyngeal space infection). Lateral pharyngeal space infection most often arises via contiguous spread of infection from a peritonsillar or retropharyngeal abscess.",
"   </p>",
"   <p>",
"    The clinical features, evaluation, and management of retropharyngeal cellulitis and abscess in children will be discussed here. Cervical lymphadenitis, peritonsillar cellulitis and abscess, and other deep neck space infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8632?source=see_link\">",
"     \"Etiology and clinical manifestations of cervical lymphadenitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/61/31705?source=see_link\">",
"     \"Peritonsillar cellulitis and abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36569?source=see_link\">",
"     \"Deep neck space infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The retropharyngeal space extends from the base of the skull to the posterior mediastinum (",
"    <a class=\"graphic graphic_figure graphicRef74998 \" href=\"mobipreview.htm?11/33/11797\">",
"     figure 1",
"    </a>",
"    ). The anterior boundary is the middle layer of the deep cervical fascia (abutting the posterior esophageal wall). The posterior boundary is the deep layer of the deep cervical fascia. These fascia fuse inferiorly at the level between the first and second thoracic vertebrae. The retropharyngeal space communicates with the lateral pharyngeal space. The lateral pharyngeal space is bounded laterally by the carotid sheath, which contains the carotid artery and jugular vein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The retropharyngeal space contains two chains of lymph nodes that are prominent in the young child, but atrophy before puberty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. These lymph nodes drain the nasopharynx, adenoids, posterior paranasal sinuses, middle ear, and eustachian tube. Infections in these areas may lead to suppurative adenitis of the retropharyngeal lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,2,5,6\">",
"     1,2,5,6",
"    </a>",
"    ]. Retropharyngeal abscess is associated with antecedent upper respiratory tract infection in approximately one-half of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In approximately one-fourth of cases (usually in older children or adults), retropharyngeal infection is secondary to pharyngeal trauma (eg, penetrating foreign body, endoscopy, intubation attempt, dental procedures) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,5,7-11\">",
"     1,5,7-11",
"    </a>",
"    ]. It also may occur in association with pharyngitis, vertebral body osteomyelitis, and petrositis.",
"   </p>",
"   <p>",
"    Retropharyngeal infections progress from cellulitis to organized phlegmon to mature abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1\">",
"     1",
"    </a>",
"    ]. Early institution of appropriate antimicrobial therapy may halt progression to mature abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retropharyngeal abscess occurs most commonly in children between the ages of two and four years, but can occur in other age groups, including neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Two to four years is the peak age group for numerous viral upper respiratory tract infections (URI) and their attendant complications, acute otitis media and sinusitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=see_link&amp;anchor=H17#H17\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Bacteria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11273?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retropharyngeal abscess often is a polymicrobial infection. The predominant bacterial species are Streptococcus pyogenes (group A streptococcus [GAS]), Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA]), and respiratory anaerobes (including Fusobacteria, Prevotella, and Veillonella species) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/3,16-21\">",
"     3,16-21",
"    </a>",
"    ]. Haemophilus species are found occasionally. If appropriate microbiologic techniques are used, it is not uncommon for aerobes and anaerobes to be recovered simultaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/3,19\">",
"     3,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of retropharyngeal abscess depends upon the stage of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/22\">",
"     22",
"    </a>",
"    ]. Early in the disease process, the findings may be indistinguishable from those of uncomplicated pharyngitis. With disease progression, symptoms related to inflammation and obstruction of the upper aerodigestive tract develop.",
"   </p>",
"   <p>",
"    Children with retropharyngeal abscess generally appear ill with moderate fever. Additional symptoms may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,2,6,14\">",
"     1,2,6,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Difficulty swallowing (dysphagia), pain with swallowing (odynophagia),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      drooling with decreased oral intake",
"     </li>",
"     <li>",
"      Unwillingness to move the neck secondary to pain (torticollis), particularly unwillingness to extend the neck",
"     </li>",
"     <li>",
"      Change in vocal quality (muffled, or with a \"hot potato\" quality [dysphonia]), gurgling sound, or stertor",
"     </li>",
"     <li>",
"      Respiratory distress (stridor, tachypnea, or both); stridor develops as disease progresses",
"     </li>",
"     <li>",
"      Neck swelling, mass, or lymphadenopathy",
"     </li>",
"     <li>",
"      Trismus (in approximately 20 percent)",
"     </li>",
"     <li>",
"      Chest pain (if there is mediastinal extension)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms of retropharyngeal infection usually progress more slowly than those of epiglottitis, but the two conditions can be difficult to distinguish. Symptoms may be present for several days before diagnosis and the child may have received antibiotics for presumed pharyngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/6,14,23\">",
"     6,14,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in the evaluation of the child with potential deep neck space infection is rapid assessment of the degree of upper airway obstruction. Anxious, ill-appearing children with drooling and posturing must be monitored continuously in a setting where emergent artificial airway can be established if necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=see_link&amp;anchor=H22#H22\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\", section on 'Initial rapid assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the oropharynx may be limited if the child is unable to open his or her mouth widely. If drooling is present, suggesting the possibility of epiglottitis, care must be taken not to be too aggressive during examination of the oral cavity. If there is doubt about whether the patient has retropharyngeal infection, epiglottitis, or other deep neck space infection, imaging or examination in the operating room may be necessary. Examination in the operating room permits controlled placement of an artificial airway if necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Imaging'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If visualization is adequate, it may be possible to appreciate midline or unilateral swelling of the posterior pharyngeal wall. The mass may be fluctuant to the examining finger. Digital palpation for fluctuance should be performed by an examiner who is experienced in airway management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1\">",
"     1",
"    </a>",
"    ]. Care must be taken to avoid rupture of the abscess into the upper airway during palpation. The patient should be examined in the head-down (Trendelenburg) position with large-caliber suction equipment ready at the bedside in case the abscess ruptures.",
"   </p>",
"   <p>",
"    Tender anterior cervical lymphadenopathy is frequently present. A neck mass may be palpable if the infection has spread to the lateral pharyngeal space [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial laboratory evaluation of a child with suspected retropharyngeal infection should include a complete blood count and blood culture (it is particularly important to send anaerobic as well as aerobic cultures) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1\">",
"     1",
"    </a>",
"    ]. Phlebotomy in children who require examination in the operating room should be postponed until after the child is sedated and the airway is secured.",
"   </p>",
"   <p>",
"    Patients with retropharyngeal abscess usually have increased white blood cell count (WBC) with a predominance of neutrophils and bands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In one series of 162 children with retropharyngeal abscess, 91 percent had WBC",
"    <span class=\"nowrap\">",
"     &gt;12,000/microL;",
"    </span>",
"    the mean WBC was",
"    <span class=\"nowrap\">",
"     22,400/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/6\">",
"     6",
"    </a>",
"    ]. Blood cultures are rarely positive, but may help to identify a pathogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/4,22\">",
"     4,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specimens for aerobic and anaerobic culture should be obtained at the time of drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1\">",
"     1",
"    </a>",
"    ]. A standard throat culture for group A streptococci should be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiographic evaluation for retropharyngeal infection may include lateral neck radiographs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    computed tomography (CT) with contrast of the neck. The imaging strategy depends upon the clinical condition of the patient and level of suspicion for retropharyngeal infection. If there are no signs of airway compromise and the suspicion is low, a lateral neck radiograph may be the initial study; if the suspicion is high, CT with contrast is the preferred study.",
"   </p>",
"   <p>",
"    CT is usually omitted in children with moderate to severe respiratory distress; such children generally undergo evaluation in the operating room, where, if necessary, a surgical airway can be established if tracheal intubation from above is not possible.",
"   </p>",
"   <p>",
"    Careful monitoring during transportation and imaging is imperative; mild airway distress can be exacerbated by sedation and positioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain radiographs &ndash; A lateral neck radiograph may be helpful in delineating retropharyngeal infection. Proper technique is critical to appropriate interpretation since false-positive studies are common. To avoid a false thickening of the retropharyngeal space, the film should be a perfect lateral obtained during inspiration with the neck held in normal extension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,25,26\">",
"       1,25,26",
"      </a>",
"      ]. False thickening of the retropharyngeal space also may be caused by crying, particularly in infants.",
"      <br/>",
"      <br/>",
"      When retropharyngeal infection (cellulitis or abscess) is present, the prevertebral space is increased in depth compared to the anteroposterior measurement of the adjacent vertebral body (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63233 \" href=\"mobipreview.htm?23/20/23887\">",
"       image 1",
"      </a>",
"      ). Alternatively, the retropharyngeal space is considered pathologically widened if it is greater than 7 mm at C2 or 14 mm at C6 in children and 22 mm at C6 in adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/2,5,27\">",
"       2,5,27",
"      </a>",
"      ].Additional features suggestive of retropharyngeal infection include loss or reversal of the normal cervical lordosis due to muscle spasm or local inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/2,12\">",
"       2,12",
"      </a>",
"      ]. In some cases, a radiopaque foreign body, soft-tissue mass, air-fluid level, or gas are visualized in the prevertebral area [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,11\">",
"       1,11",
"      </a>",
"      ]. The adjacent spine should be examined for vertebral or intervertebral disease because infections of the spine can spread to the retropharyngeal space.",
"      <br/>",
"      <br/>",
"      Anteroposterior and lateral chest radiographs should be obtained in children with suspected retropharyngeal infection to look for extension of infection into the chest (eg, mediastinitis, aspiration pneumonia) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,12,28\">",
"       1,12,28",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Complications'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Computed tomography &ndash; Computed tomography (CT) of the neck with intravenous contrast is the best tool to identify abscesses in the retropharyngeal area. For patients with airway compromise (eg, stridor, stertor, posturing), anesthesia as well as staff capable of creating an artificial surgical airway should be consulted before sedation.",
"      <br/>",
"      <br/>",
"      CT can demonstrate extension of an abscess to contiguous spaces in the neck or chest or nonradiopaque foreign body and can generally differentiate between retropharyngeal abscess and cellulitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,29-31\">",
"       1,29-31",
"      </a>",
"      ]. CT also can identify loculations and the position of the carotid artery and internal jugular vein in relation to the infectious process, which are helpful in planning the surgical approach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/12,32\">",
"       12,32",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Surgical drainage'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      The abscess may be seen as a mass impinging on the posterior pharyngeal wall. Complete rim enhancement and scalloping of abscess wall are indicative of an abscess [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/7,33,34\">",
"       7,33,34",
"      </a>",
"      ]. Additional CT findings that are common to retropharyngeal abscess and cellulitis include low-density core, soft-tissue swelling, obliterated fat planes, and mass effect (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51505 \" href=\"mobipreview.htm?11/46/12015\">",
"       image 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Although CT is the test of choice, it is not a perfect test and clinical judgment must be the ultimate determinant of management. The sensitivity and specificity of CT in predicting purulent material at surgery vary from study to study (ranging from 64 to 100 percent for sensitivity and 45 to 82 percent for specificity) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/6,32-38\">",
"       6,32-38",
"      </a>",
"      ]. These figures must be interpreted with caution since the gold standard test (identification of purulent fluid at surgery) is rarely performed on the same day as the CT scan and the clinical course may progress between the two. CT and surgical findings might be more closely correlated if surgery was performed soon after the CT was obtained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retropharyngeal infection should be considered in children who present with fever, stiff neck (torticollis), dysphagia, and other symptoms related to inflammation or obstruction of the upper aerodigestive tract. CT with intravenous contrast generally differentiates retropharyngeal abscess from cellulitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of retropharyngeal infection includes other conditions that cause upper airway obstruction, sore throat,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neck stiffness.",
"   </p>",
"   <p>",
"    Upper airway obstruction may be caused by [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other infections &ndash; Epiglottitis, peritonsillar abscess, croup, bacterial tracheitis, peritonsillar abscess, uvulitis, laryngopharyngeal diphtheria. (See appropriate topic reviews)",
"     </li>",
"     <li>",
"      Trauma &ndash; Penetrating foreign body, foreign body in the airway or esophagus, thermal or caustic burns of the posterior pharynx",
"     </li>",
"     <li>",
"      Angioedema or anaphylaxis",
"     </li>",
"     <li>",
"      Tumors &ndash; Lymphangioma (cystic hygroma), hemangioma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical features and imaging studies usually distinguish between these possibilities. As an example, epiglottitis is usually more rapidly progressive than retropharyngeal infection and has the characteristic \"thumb sign\" on lateral soft tissue radiograph of the neck (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67878 \" href=\"mobipreview.htm?22/26/22958\">",
"     image 3",
"    </a>",
"    ). The evaluation of acute upper airway obstruction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The causes of sore throat in children of various ages are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60174 \" href=\"mobipreview.htm?2/1/2077\">",
"     table 1",
"    </a>",
"    ). The evaluation of children with sore throat is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39415?source=see_link\">",
"     \"Evaluation of sore throat in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Causes of neck stiffness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    torticollis that must be considered in children with possible retropharyngeal abscess include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,7,39\">",
"     1,7,39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meningitis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/21/10586?source=see_link&amp;anchor=H3#H3\">",
"       \"Viral meningitis: Clinical features and diagnosis in children\", section on 'Clinical features'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cervical spine arthritis or osteomyelitis; retropharyngeal abscess also may occur as a complication of cervical vertebral osteomyelitis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20087?source=see_link\">",
"       \"Clinical features of hematogenous osteomyelitis in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tuberculous abscess of the cervical spine (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/49/37656?source=see_link\">",
"       \"Skeletal tuberculosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Spinal injury (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=see_link\">",
"       \"Evaluation of cervical spine injuries in children and adolescents\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dystonic reaction",
"     </li>",
"     <li>",
"      Various toxins (tetanus, black widow spider bite, scorpion sting)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with upper airway obstruction, clinical features (eg, history of trauma or exposure to tuberculosis, drugs, toxins) may distinguish these conditions from retropharyngeal abscess. The evaluation of torticollis in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/26/8616?source=see_link\">",
"     \"Acquired torticollis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Overview of strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials evaluating management of retropharyngeal infections are lacking. Recommendations for treatment are based upon the causative pathogens and response to therapy described in observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/4,14,36,40-45\">",
"     4,14,36,40-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children with suspected retropharyngeal infection should be hospitalized and managed in consultation with an otolaryngologist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/22,46\">",
"     22,46",
"    </a>",
"    ]. Particular attention must be paid to maintenance of the airway. Intubation, or less commonly, tracheotomy may be necessary in patients with respiratory compromise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,46\">",
"     1,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial therapy depends upon the severity of respiratory distress and likelihood of drainable fluid (based upon CT findings, and clinical features such as duration of symptoms and clinical course):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate surgical drainage is necessary in patients with airway compromise. Empiric antibiotic therapy should be initiated as soon as is possible. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Surgical drainage'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H15\">",
"       'Antimicrobial therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Early in the disease process (cellulitis or phlegmon), antimicrobial therapy may prevent progression, precluding the need for surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,7,40\">",
"       1,7,40",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antimicrobial therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The optimal management of retropharyngeal abscess in patients without imminent airway obstruction is a matter of debate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/6\">",
"       6",
"      </a>",
"      ]. Some experts advocate immediate drainage in conjunction with antimicrobial therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/34\">",
"       34",
"      </a>",
"      ]. Others favor a trial of antimicrobial therapy in patients with small abscesses (eg, cross-sectional area &lt;2 cm(2)) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/4,14,33,40-45\">",
"       4,14,33,40-45",
"      </a>",
"      ]. Factors that have been associated with drainable fluid at surgery include duration of symptoms for more than two days, and cross-sectional area &gt;2 cm(2) on CT scan [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/6\">",
"       6",
"      </a>",
"      ]. Early surgical drainage in such patients may shorten the length of stay and duration of fever [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest surgical drainage and antimicrobial therapy for children if CT findings are consistent with mature abscess &gt;2 cm(2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Surgical drainage'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We suggest a trial of antibiotic therapy without surgical drainage for children without airway compromise if the CT findings are not consistent with mature abscess, or the abscess is &lt;2 cm(2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/33,41\">",
"       33,41",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antimicrobial therapy'",
"      </a>",
"      below.)&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with retropharyngeal infections must be monitored closely for persistence or progression of symptoms and complications. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care for the child with retropharyngeal infection includes maintenance of the airway, adequate hydration, provision of analgesia, and monitoring for complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients with an unstable airway should be monitored in the intensive care unit; endotracheal intubation may be necessary for airway maintenance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy is a necessary component of the treatment of retropharyngeal infections in children. In the pre-antibiotic era, the mortality rates for deep neck space infections in children ranged from 7 to 15 percent and complications occurred in as many as 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/4\">",
"     4",
"    </a>",
"    ]. With the advent of antibiotic therapy, mortality and complications are uncommon.",
"   </p>",
"   <p>",
"    Successful treatment of suppurative retropharyngeal infection with antimicrobial therapy alone has been reported in observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/4,14,33,40,41,45\">",
"     4,14,33,40,41,45",
"    </a>",
"    ]. Success rates in retrospective series range from 37 to 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/14,33,41\">",
"     14,33,41",
"    </a>",
"    ]. In a small prospective series, 10 of 11 children with suppurative deep neck infections greater than 1 cm(3) responded to antibiotic therapy without developing complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential risks of nonsurgical management include spontaneous rupture, respiratory distress requiring intubation or temporary tracheostomy, and longer hospital stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/6,44,47\">",
"     6,44,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric therapy should include coverage for GAS, S. aureus (including methicillin-resistant S. aureus [MRSA]), and respiratory anaerobes. Empiric therapy can be amended as necessary based upon culture results if drainage is performed. When tailoring therapy based upon culture results, it is important to bear in mind that retropharyngeal infections are frequently polymicrobial, and not all microbes are consistently cultured [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Microbiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In areas where S. aureus remains susceptible to methicillin, potential empiric regimens include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/3/29750?source=see_link\">",
"       Ampicillin-sulbactam",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose every six hours intravenously), or",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       Clindamycin",
"      </a>",
"      (13",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose every eight hours intravenously)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many community-associated MRSA are susceptible to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    . Accordingly, clindamycin is an attractive agent for this indication. In patients who do not respond to clindamycin or in those who present with severe disease,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    should be added to clindamycin.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (40 to 60",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided in three to four doses; maximum daily dose 2 to 4 g), or",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"       Linezolid",
"      </a>",
"      (&lt;12 years: 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided in three doses; &ge;12 years: 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two doses; maximum daily dose 1200 mg) (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children\", section on 'Treatment approach'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=see_link&amp;anchor=H10#H10\">",
"       \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'CA-MRSA strains'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parenteral treatment is maintained until the patient is afebrile and clinically improved. Oral therapy should be continued to complete a 14-day course. Appropriate oral regimens for continuation of therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/26/34214?source=see_link\">",
"       Amoxicillin-clavulanate",
"      </a>",
"      (45",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose every 12 hours), or",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/56/34688?source=see_link\">",
"       Clindamycin",
"      </a>",
"      (13",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose every 8 hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    has been added to the parenteral regimen,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/52/22345?source=see_link\">",
"     linezolid",
"    </a>",
"    may be used for oral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response to antimicrobial therapy is indicated by improvement in symptoms and defervescence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,44,45\">",
"     1,44,45",
"    </a>",
"    ]. CT with contrast should be performed if there is no clinical improvement 24 to 48 hours after initiation of antibiotic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,40\">",
"     1,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment failure is defined by lack of symptomatic improvement or worsening despite 24 to 48 hours of antimicrobial therapy (with or without surgical drainage). Treatment failure may occur in patients who have developed complications, are infected with unusual organisms, or have underlying problems (eg, congenital cyst or tract) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/24\">",
"     24",
"    </a>",
"    ]. Reevaluation of such patients may include repeat imaging (CT with contrast to look for extension of infection) or surgical intervention. Broadening antimicrobial therapy to cover MRSA and gram-negative rods also may be indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surgical drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical drainage in conjunction with antibiotic therapy has played a prominent role in the management of retropharyngeal abscess.",
"   </p>",
"   <p>",
"    Indications for surgical drainage may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/6,14,42\">",
"     6,14,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Airway compromise or other life-threatening complications",
"     </li>",
"     <li>",
"      A large (&gt;2 cm(2)) hypodense area on CT scan",
"     </li>",
"     <li>",
"      Failure to respond to parenteral antibiotic therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If surgical drainage is performed, specimens for aerobic and anaerobic culture should be obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical drainage is usually performed transorally unless the abscess is lateral to the neck vessels or involves multiple deep neck space infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,6,37\">",
"     1,6,37",
"    </a>",
"    ]. A second procedure may be required in a minority of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/6,23\">",
"     6,23",
"    </a>",
"    ]. Complications related to surgical drainage are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Discharge instructions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are discharged from the hospital after treatment for retropharyngeal infection should be instructed that prompt reevaluation is necessary for the following symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Worsening throat pain, neck pain, or trismus",
"     </li>",
"     <li>",
"      Enlarging mass",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Neck stiffness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Follow-up should be arranged within several days of discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early diagnosis and prompt and appropriate management of retropharyngeal space infection is critical to avoiding complications. Complications of retropharyngeal abscess occur rarely, but are potentially fatal. Infection can spread from the retropharyngeal space to other deep neck spaces, to adjacent structures, and to the bloodstream.",
"   </p>",
"   <p>",
"    Complications include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/1,16,48\">",
"     1,16,48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Airway obstruction",
"     </li>",
"     <li>",
"      Septicemia",
"     </li>",
"     <li>",
"      Aspiration pneumonia if the abscess ruptures into the airway",
"     </li>",
"     <li>",
"      Internal jugular vein thrombosis",
"     </li>",
"     <li>",
"      Jugular vein suppurative thrombophlebitis (Lemierre's syndrome) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36569?source=see_link&amp;anchor=H990947896#H990947896\">",
"       \"Deep neck space infections\", section on 'Complications'",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Carotid artery rupture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mediastinitis (suggested by widening of the mediastinum on chest radiograph) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Atlantoaxial dislocation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/15,51,52\">",
"       15,51,52",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When detected early and appropriately treated, retropharyngeal abscess seldom leads to long-term consequences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/6\">",
"     6",
"    </a>",
"    ]. The duration of hospitalization, which is dependent on the response to management, is usually three to five days unless the child requires mechanical ventilation following surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/4,23\">",
"     4,23",
"    </a>",
"    ]. Relapse occurs in 1 to 5 percent of cases, and may be associated with trauma or anatomic abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43992/abstract/7,12,15,51,52\">",
"     7,12,15,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Clinical features and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retropharyngeal abscess occurs most commonly in children between the ages of two and four years. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retropharyngeal abscess often is a polymicrobial infection. The predominant bacterial species are Streptococcus pyogenes (group A streptococcus [GAS]), Staphylococcus aureus, and respiratory anaerobes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retropharyngeal infection should be considered in children who present with fever, stiff neck, dysphagia, and other symptoms related to inflammation or obstruction of the upper aerodigestive tract. Neck stiffness is an important symptom and may occur in the absence of respiratory symptoms. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination of the oropharynx may be limited if the child is unable to open his or her mouth widely. If visualization is adequate, it may be possible to appreciate midline or unilateral swelling of the posterior pharyngeal wall. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomography (CT) of the neck with intravenous contrast is the preferred study to differentiate retropharyngeal abscess from cellulitis and to look for extension of infection. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Management and prognosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with suspected retropharyngeal infection should be hospitalized and managed in consultation with an otolaryngologist. Particular attention must be paid to maintenance of the airway. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Overview of strategy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial therapy depends upon the severity of respiratory distress and likelihood of drainable fluid (based upon CT findings and clinical features such as duration of symptoms, and clinical course). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Overview of strategy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric antibiotic therapy should be initiated as soon as possible in all patients. Empiric therapy should include coverage for GAS, S. aureus, and respiratory anaerobes. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate surgical drainage is necessary in patients with airway compromise. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Surgical drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal management of retropharyngeal abscess in patients without imminent airway obstruction is a matter of debate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest surgical drainage and antimicrobial therapy for children if CT findings are consistent with mature abscess &gt;2 cm(2) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Surgical drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a trial of antibiotic therapy without surgical drainage if the CT findings are not consistent with mature abscess or the abscess is &lt;2 cm(2) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early in the disease process (cellulitis or phlegmon), antimicrobial therapy may prevent progression, precluding the need for surgery. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Response to antimicrobial therapy is indicated by improvement in symptoms. CT with contrast should be performed if there is no clinical improvement 24 to 48 hours after initiation of antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of retropharyngeal abscess are potentially fatal. Infection can spread from the retropharyngeal space to other deep neck spaces, to adjacent structures, and to the bloodstream. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When detected early and appropriately treated, retropharyngeal abscess seldom leads to long-term consequences. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tebruegge M, Curtis N. Infections related to the upper and middle airways. In: Principles and Practice of Pediatric Infectious Diseases, 3rd ed, Long SS, Pickering LK, Prober CG (Eds), Elsevier Saunders, New York 2012. p.205.",
"    </li>",
"    <li>",
"     Goldstein NA, Hammersclag MR. Peritonsillar, retropharyngeal, and parapharyngeal abscesses. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL.  (Eds), Saunders, Philadelphia 2009. p.177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/3\">",
"      Asmar BI. Bacteriology of retropharyngeal abscess in children. Pediatr Infect Dis J 1990; 9:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/4\">",
"      McClay JE, Murray AD, Booth T. Intravenous antibiotic therapy for deep neck abscesses defined by computed tomography. Arch Otolaryngol Head Neck Surg 2003; 129:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/5\">",
"      Ungkanont K, Yellon RF, Weissman JL, et al. Head and neck space infections in infants and children. Otolaryngol Head Neck Surg 1995; 112:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/6\">",
"      Page NC, Bauer EM, Lieu JE. Clinical features and treatment of retropharyngeal abscess in children. Otolaryngol Head Neck Surg 2008; 138:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/7\">",
"      Philpott CM, Selvadurai D, Banerjee AR. Paediatric retropharyngeal abscess. J Laryngol Otol 2004; 118:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/8\">",
"      Poluri A, Singh B, Sperling N, et al. Retropharyngeal abscess secondary to penetrating foreign bodies. J Craniomaxillofac Surg 2000; 28:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/9\">",
"      Sethi DS, Chew CT. Retropharyngeal abscess--the foreign body connection. Ann Acad Med Singapore 1991; 20:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/10\">",
"      Singh B, Kantu M, Har-El G, Lucente FE. Complications associated with 327 foreign bodies of the pharynx, larynx, and esophagus. Ann Otol Rhinol Laryngol 1997; 106:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/11\">",
"      Morrison JE Jr, Pashley NR. Retropharyngeal abscesses in children: a 10-year review. Pediatr Emerg Care 1988; 4:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/12\">",
"      Gaglani MJ, Edwards MS. Clinical indicators of childhood retropharyngeal abscess. Am J Emerg Med 1995; 13:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/13\">",
"      Dawes LC, Bova R, Carter P. Retropharyngeal abscess in children. ANZ J Surg 2002; 72:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/14\">",
"      Craig FW, Schunk JE. Retropharyngeal abscess in children: clinical presentation, utility of imaging, and current management. Pediatrics 2003; 111:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/15\">",
"      Coulthard M, Isaacs D. Neonatal retropharyngeal abscess. Pediatr Infect Dis J 1991; 10:547.",
"     </a>",
"    </li>",
"    <li>",
"     Yellon RF. Head and neck space infections. In: Pediatric Otalrynology, 4th, Bluestone CD, Casselbrant ML, Stool SE, et al.  (Eds), Saunders, Philadelphia 2003. p.1681.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/17\">",
"      Wright CT, Stocks RM, Armstrong DL, et al. Pediatric mediastinitis as a complication of methicillin-resistant Staphylococcus aureus retropharyngeal abscess. Arch Otolaryngol Head Neck Surg 2008; 134:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/18\">",
"      Fleisch AF, Nolan S, Gerber J, Coffin SE. Methicillin-resistant Staphylococcus aureus as a cause of extensive retropharyngeal abscess in two infants. Pediatr Infect Dis J 2007; 26:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/19\">",
"      Brook I. Microbiology and management of peritonsillar, retropharyngeal, and parapharyngeal abscesses. J Oral Maxillofac Surg 2004; 62:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/20\">",
"      Inman JC, Rowe M, Ghostine M, Fleck T. Pediatric neck abscesses: changing organisms and empiric therapies. Laryngoscope 2008; 118:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/21\">",
"      Abdel-Haq N, Quezada M, Asmar BI. Retropharyngeal abscess in children: the rising incidence of methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2012; 31:696.",
"     </a>",
"    </li>",
"    <li>",
"     Sperring JL. Neck and oral cavity infections. In: Comprehensive Pediatric Hospital Medicine, Zaoutis LB, Chiang WV.  (Eds), Mosby, Philadelphia 2007. p.360.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/23\">",
"      Cmejrek RC, Coticchia JM, Arnold JE. Presentation, diagnosis, and management of deep-neck abscesses in infants. Arch Otolaryngol Head Neck Surg 2002; 128:1361.",
"     </a>",
"    </li>",
"    <li>",
"     Baum ED, Elden LM. Bacterial infections of the neck. In: Current Pediatric Therapy, 18th, Burg FD, Ingelfinger JR, Polin RA, Gershon AA.  (Eds), Saunders, Philadelphia 2006. p.1117.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/25\">",
"      Currarino G, Williams B. Air collection in the retropharyngeal soft tissues observed in lateral expiratory films of the neck in 9 infants. Pediatr Radiol 1993; 23:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/26\">",
"      Brechtelsbauer PB, Garetz SL, Gebarski SS, Bradford CR. Retropharyngeal abscess: pitfalls of plain films and computed tomography. Am J Otolaryngol 1997; 18:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/27\">",
"      Barratt GE, Koopmann CF Jr, Coulthard SW. Retropharyngeal abscess--a ten-year experience. Laryngoscope 1984; 94:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/28\">",
"      Sztajnbok J, Grassi MS, Katayama DM, Troster EJ. Descending suppurative mediastinitis: nonsurgical approach to this unusual complication of retropharyngeal abscesses in childhood. Pediatr Emerg Care 1999; 15:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/29\">",
"      Endicott JN, Nelson RJ, Saraceno CA. Diagnosis and management decisions in infections of the deep fascial spaces of the head and neck utilizing computerized tomography. Laryngoscope 1982; 92:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/30\">",
"      Lazor JB, Cunningham MJ, Eavey RD, Weber AL. Comparison of computed tomography and surgical findings in deep neck infections. Otolaryngol Head Neck Surg 1994; 111:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/31\">",
"      Thawley SE, Gado M, Fuller TR. Computerized tomography in the evaluation of head and neck lesions. Laryngoscope 1978; 88:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/32\">",
"      Nagy M, Pizzuto M, Backstrom J, Brodsky L. Deep neck infections in children: a new approach to diagnosis and treatment. Laryngoscope 1997; 107:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/33\">",
"      Vural C, Gungor A, Comerci S. Accuracy of computerized tomography in deep neck infections in the pediatric population. Am J Otolaryngol 2003; 24:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/34\">",
"      Kirse DJ, Roberson DW. Surgical management of retropharyngeal space infections in children. Laryngoscope 2001; 111:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/35\">",
"      Stone ME, Walner DL, Koch BL, et al. Correlation between computed tomography and surgical findings in retropharyngeal inflammatory processes in children. Int J Pediatr Otorhinolaryngol 1999; 49:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/36\">",
"      Daya H, Lo S, Papsin BC, et al. Retropharyngeal and parapharyngeal infections in children: the Toronto experience. Int J Pediatr Otorhinolaryngol 2005; 69:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/37\">",
"      Choi SS, Vezina LG, Grundfast KM. Relative incidence and alternative approaches for surgical drainage of different types of deep neck abscesses in children. Arch Otolaryngol Head Neck Surg 1997; 123:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/38\">",
"      Boucher C, Dorion D, Fisch C. Retropharyngeal abscesses: a clinical and radiologic correlation. J Otolaryngol 1999; 28:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/39\">",
"      Stein MT, Trauner D. The child with a stiff neck. Clin Pediatr (Phila) 1982; 21:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/40\">",
"      Shefelbine SE, Mancuso AA, Gajewski BJ, et al. Pediatric retropharyngeal lymphadenitis: differentiation from retropharyngeal abscess and treatment implications. Otolaryngol Head Neck Surg 2007; 136:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/41\">",
"      Al-Sabah B, Bin Salleen H, Hagr A, et al. Retropharyngeal abscess in children: 10-year study. J Otolaryngol 2004; 33:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/42\">",
"      Lalakea Ml, Messner AH. Retropharyngeal abscess management in children: current practices. Otolaryngol Head Neck Surg 1999; 121:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/43\">",
"      Courtney MJ, Mahadevan M, Miteff A. Management of paediatric retropharyngeal infections: non-surgical versus surgical. ANZ J Surg 2007; 77:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/44\">",
"      Sichel JY, Dano I, Hocwald E, et al. Nonsurgical management of parapharyngeal space infections: a prospective study. Laryngoscope 2002; 112:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/45\">",
"      Broughton RA. Nonsurgical management of deep neck infections in children. Pediatr Infect Dis J 1992; 11:14.",
"     </a>",
"    </li>",
"    <li>",
"     Fleisher GR. Infectious disease emergencies. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.783.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/47\">",
"      Plaza Mayor G, Mart&iacute;nez-San Mill&aacute;n J, Mart&iacute;nez-Vidal A. Is conservative treatment of deep neck space infections appropriate? Head Neck 2001; 23:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/48\">",
"      Goldenberg D, Golz A, Joachims HZ. Retropharyngeal abscess: a clinical review. J Laryngol Otol 1997; 111:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/49\">",
"      Goldenberg NA, Knapp-Clevenger R, Hays T, Manco-Johnson MJ. Lemierre's and Lemierre's-like syndromes in children: survival and thromboembolic outcomes. Pediatrics 2005; 116:e543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/50\">",
"      Waggie Z, Hatherill M, Millar A, et al. Retropharyngeal abscess complicated by carotid artery rupture. Pediatr Crit Care Med 2002; 3:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/51\">",
"      Thompson JW, Cohen SR, Reddix P. Retropharyngeal abscess in children: a retrospective and historical analysis. Laryngoscope 1988; 98:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43992/abstract/52\">",
"      Coulthard M, Isaacs D. Retropharyngeal abscess. Arch Dis Child 1991; 66:1227.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6078 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-CDD449C725-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43992=[""].join("\n");
var outline_f42_61_43992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Overview of strategy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surgical drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Discharge instructions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6078\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6078|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/20/23887\" title=\"diagnostic image 1\">",
"      Retropharyngeal abscess plain radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/46/12015\" title=\"diagnostic image 2\">",
"      Retropharyngeal abscess CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?22/26/22958\" title=\"diagnostic image 3\">",
"      Epiglottitis x-ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6078|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/33/11797\" title=\"figure 1\">",
"      Deep neck space anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6078|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/1/2077\" title=\"table 1\">",
"      Etiology sore throat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/26/8616?source=related_link\">",
"      Acquired torticollis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11273?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36569?source=related_link\">",
"      Deep neck space infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8632?source=related_link\">",
"      Etiology and clinical manifestations of cervical lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39415?source=related_link\">",
"      Evaluation of sore throat in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/61/31705?source=related_link\">",
"      Peritonsillar cellulitis and abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/49/37656?source=related_link\">",
"      Skeletal tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29802?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/21/10586?source=related_link\">",
"      Viral meningitis: Clinical features and diagnosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_61_43993="Patellofemoral pain syndrome";
var content_f42_61_43993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patellofemoral pain syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43993/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43993/contributors\">",
"     Francis G O'Connor, MD, MPH, FACSM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43993/contributors\">",
"     Sean W Mulvaney, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43993/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43993/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43993/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43993/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/61/43993/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patellofemoral pain syndrome (PFPS) is a frequently encountered overuse disorder that involves the patellofemoral region and often presents as anterior knee pain. PFPS is the most common cause of knee pain seen by primary care physicians, orthopedic surgeons, and sports medicine specialists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. PFPS can be difficult to diagnose. Not only do the etiology, diagnosis, and treatment remain challenging, but the terminology used to describe PFPS is used inconsistently and can be confusing. The terms patellofemoral joint syndrome and chondromalacia patellae are also used to describe this condition.",
"   </p>",
"   <p>",
"    This topic review will discuss the pathophysiology, diagnosis, and management of PFPS. An approach to the diagnosis of knee pain and other specific causes of knee pain are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32138?source=see_link\">",
"     \"Anterior cruciate ligament injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patellofemoral pain syndrome (PFPS) can be defined as anterior knee pain involving the patella and retinaculum that excludes other intraarticular and peripatellar pathology. PFPS describes a symptom complex and is a diagnosis of exclusion.",
"   </p>",
"   <p>",
"    Common synonymous terms include retropatellar pain syndrome, runner's knee, lateral facet compression syndrome, and idiopathic anterior knee pain. The term chondromalacia patella is used to describe pathologic changes in the articular cartilage of the patella, such as softening, erosion, and fragmentation. While frequently confused with PFPS, chondromalacia patella is a pathologic diagnosis and constitutes a distinct cause of knee pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patellofemoral pain syndrome (PFPS) is among the most common diagnoses in sports medicine. PFPS affects many running athletes and constitutes nearly 25 percent of all identified knee injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In orthopedic and musculoskeletal clinics, nearly 10 percent of all visits are for evaluation of anterior knee pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PFPS more commonly affects women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/7\">",
"     7",
"    </a>",
"    ]. In a seven year review of patients diagnosed with PFPS at a sports medicine clinic, the ratio of women to men was nearly two to one (33.2 percent versus 18.1 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/8\">",
"     8",
"    </a>",
"    ]. Another retrospective review found similar results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PFPS occurs disproportionately in active adolescents and adults in the second and third decades of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/8\">",
"     8",
"    </a>",
"    ]. One observational study found a prevalence of over 20 percent among adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the knee's extensor mechanism and the complexity of the articulation between the patella and the femoral trochlea are fundamental to understanding patellofemoral pain syndrome (PFPS).",
"   </p>",
"   <p>",
"    The patella is a sesamoid bone that lies within the quadriceps tendon and rides in the trochlear groove of the distal femur. Its primary function is to improve leverage for knee extension. Articular cartilage on both the underside of the patella and the trochlear groove interface at the patellofemoral articulation. Proper tracking within the trochlear groove requires a balance of the forces acting on the patella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/10\">",
"     10",
"    </a>",
"    ]. Key landmarks for the evaluation of PFPS relate to this balance of forces at the patella and include (",
"    <a class=\"graphic graphic_figure graphicRef54565 \" href=\"mobipreview.htm?1/61/2004\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Proximal knee: quadriceps tendon",
"     </li>",
"     <li>",
"      Lateral knee: lateral retinaculum, attachment of the vastus lateralis, iliotibial band",
"     </li>",
"     <li>",
"      Medial knee: medial retinaculum, attachment of the vastus medialis",
"     </li>",
"     <li>",
"      Distal knee: patellar tendon and its attachment at the tibial tubercle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other structures surrounding the patella that should be examined as part of the evaluation for PFPS include the fat pads dorsal to and along alongside the patellar tendon (the fat pad of Hoffa) and the subcutaneous and deep infrapatellar bursae of the patellar tendon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patellofemoral pain syndrome (PFPS) appears to be multifactorial, resulting from a complex interaction among intrinsic anatomic and extrinsic training factors. Although clinicians frequently make the diagnosis of PFPS, no consensus exists about its etiology or the factors most responsible for causing pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/1,10,11\">",
"     1,10,11",
"    </a>",
"    ]. Overuse, malalignment, and trauma are commonly cited causative factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/12\">",
"     12",
"    </a>",
"    ]. Of these, overuse (ie, training overload) is most common. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Overload'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8\">",
"     'Malalignment'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Trauma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The concept of overloading the knee's extensor mechanism is fundamental to all theories of the pathophysiology underlying PFPS. The overload may or may not involve malalignment. Overload likely leads to such injuries as subchondral bone degeneration, retinacular strain, and damage to small nerves, which culminate in PFPS. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Overload'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One theory, commonly referred to as \"patellar tracking,\" suggests that anterior knee pain arises from abnormal force generation and distribution during movement of the patella within the femoral trochlea. Articular cartilage is poorly innervated and pain correlates poorly with the extent of articular cartilage lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/13\">",
"     13",
"    </a>",
"    ]. Therefore, the most likely sources of pain are subchondral bone, synovium, retinaculum, skin, muscle, and nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to traditional structural and biomechanical mechanisms, one alternative explanation emphasizes abnormal tissue homeostasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/11\">",
"     11",
"    </a>",
"    ]. According to this theory, a number of interrelated pathophysiologic processes, including inflamed synovial lining and fat pad tissues, retinacular neuromas, increased intraosseous pressure, and increased osseous metabolic activity of the patella, create pain and dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with PFPS has no history of trauma and do not demonstrate malalignment during physical or radiographic examinations. In contrast, a careful history often identifies activities that overload the patellofemoral joint potentially leading to injury, and possibly disturbances in tissue homeostasis, culminating in PFPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies note that runners' total mileage (or volume) correlates with the development of PFPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Furthermore, patients with PFPS often report that symptoms began during a period of increased physical activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies among military recruits have identified a number of risk factors that consistently correlate with overuse lower extremity injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. These include fitness level upon entry into the service, prior exercise behavior, body mass index (BMI) over 25, and training load. PFPS occurs more often in patients participating in competitive sports than age matched controls, and correlates with increasing levels of physical activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Malalignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper function of the patellofemoral joint requires interplay among numerous static and dynamic structures involving the entire lower extremity as the patella tracks along the trochlea. Multiple authors postulate that patellar malalignment, resulting in abnormal patellar tracking, is the primary cause of PFPS. The many studies of malalignment generally subdivide it into static and dynamic components.",
"   </p>",
"   <p>",
"    Static biomechanical abnormalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leg length discrepancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Abnormal foot morphology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hamstrings and hip musculature tightness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/21-24\">",
"       21-24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Abnormal patellar mobility [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Angular and rotational deformities of the lower extremity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/18,27\">",
"       18,27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Large Q angle (",
"      <a class=\"graphic graphic_figure graphicRef55389 \" href=\"mobipreview.htm?5/4/5184\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hallux valgus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Trochlear morphology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dynamic biomechanical abnormalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Muscle weakness or imbalance (eg, vastus medialis and hip abductors) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/22,32,33\">",
"       22,32,33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Knee abduction impulses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/22,34\">",
"       22,34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ground reaction forces [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Excessive foot pronation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/22,35-37\">",
"       22,35-37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Insufficient foot pronation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies of the biomechanical factors that potentially contribute to PFPS demonstrate conflicting results, a lack of reproducibility, and no firm conclusions. Authors consistently cite the difficulty of research due to the syndrome's likely multifactorial nature. In our clinical experience, seemingly innocent biomechanical abnormalities, when unmasked through overload, can lead to the syndrome of patellofemoral pain.",
"   </p>",
"   <p>",
"    Several studies conclude that dynamic forces may play a greater role, particularly hip abductor weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. In a prospective trial involving military recruits, underpronation best predicted patellofemoral pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/38\">",
"     38",
"    </a>",
"    ]. The authors postulate that both excessive and insufficient pronation may play an important role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/38\">",
"     38",
"    </a>",
"    ]. A systematic review of studies of the role of the Q angle in PFPS found the measurement to be of limited value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct and indirect injuries can damage structures around the patellofemoral joint. Direct blows sustained during falls, contact sports, or motor vehicle collisions (eg, knee striking dashboard) can injure the patella and trochlea, including articular surfaces, and surrounding structures. Indirect injuries from falls may include patellar dislocation or subluxations, retinacular strain, or damage to the articular cartilage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patellofemoral pain syndrome (PFPS) is a clinical diagnosis, with no pathognomonic sign or symptom. For most patients a careful history and physical examination establish the diagnosis, but the clinician must first exclude other conditions that mimic PFPS. Typically knee pain from PFPS worsens with squatting, running, prolonged sitting, or when ascending or descending steps. Pain is often poorly localized \"under\" or \"around\" the patella, and is usually described as \"achy\" but may be \"sharp\". Examination findings consistent with PFPS are described below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Physical examination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Six anatomic areas are thought to contribute to patellofemoral pain: subchondral bone, synovium, retinaculum, skin, nerve, and muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/12\">",
"     12",
"    </a>",
"    ]. The differential diagnosis of anterior knee pain involves these structures (",
"    <a class=\"graphic graphic_table graphicRef59940 \" href=\"mobipreview.htm?12/44/13004\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Etiology and risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The clinician must distinguish PFPS from patellofemoral osteoarthritis, patellofemoral instability, and similar conditions that cause anterior knee pain. Patellofemoral osteoarthritis generally occurs in patients who are older than those who develop PFPS and has characteristic radiographic findings. The patient with patellofemoral instability may have a history of patellar dislocation or describe a sensation of instability or movement of the patella. Both of these disorders, while related to PFPS, require specific treatments unrelated to PFPS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12056?source=see_link\">",
"     \"Clinical manifestations of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of patellofemoral pain syndrome (PFPS) is based primarily upon history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/28\">",
"     28",
"    </a>",
"    ]. The onset of anterior knee pain may be gradual or acute, and may be precipitated by trauma. Pain may occur in one or both knees. Typically knee pain worsens with squatting, running, prolonged sitting, or when ascending or descending steps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/28\">",
"     28",
"    </a>",
"    ]. Pain is often poorly localized \"under\" or \"around\" the patella, and is usually described as \"achy\" but may be \"sharp\". Some patients may describe the affected knee as \"giving way\" or \"buckling\". In PFPS this perceived instability may be due to pain inhibiting proper contraction of the quadriceps, but it must be distinguished from instability arising from a patellar dislocation or subluxation, or from ligamentous injury of the knee.",
"   </p>",
"   <p>",
"    Although some patients may describe a \"catching\" sensation under the patella, true locking of the knee or effusion are signs of intraarticular pathology NOT explained by the diagnosis of PFPS. Such findings require further evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    .) Patients may describe an audible \"popping\" or \"creaking\" often after standing following prolonged sitting, or when ascending or descending stairs.",
"   </p>",
"   <p>",
"    Overload and trauma are important risk factors for PFPS. The clinician should inquire about exercise history to identify changes in training load. It is also important to ask about any prior knee surgery or knee injuries, especially to the patella.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Knee examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed description of a complete knee examination is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6618?source=see_link\">",
"     \"Evaluation of the active adult patient with knee pain\"",
"    </a>",
"    .) Key features relating to PFPS include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Observation: look for obesity, vastus medialis atrophy, angular and rotational deformities of the lower extremity, localized erythema",
"     </li>",
"     <li>",
"      Palpation: determine if the quadriceps or patellar tendons are tender, check for the presence of localized warmth or an effusion",
"     </li>",
"     <li>",
"      Strength: determine whether quadriceps strength is limited, look for hip abductor and external rotator weakness, note strength discrepancies between affected and unaffected lower extremities",
"     </li>",
"     <li>",
"      Range of motion of the knee (crepitus with range of motion is a nonspecific finding)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examine the ipsilateral hip, as knee pain can be referred from the hip. Evaluate for a leg length discrepancy of &ge;1.0 cm, which may have adverse effects on the lower extremity while running [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/42\">",
"     42",
"    </a>",
"    ]. A small leg length difference (&le;0.5 cm) is not uncommon and under most conditions does not contribute to PFPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/43\">",
"     43",
"    </a>",
"    ]. Evaluate the feet and arches. There is an association with cavus foot and lower extremity injuries (",
"    <a class=\"graphic graphic_picture graphicRef82600 \" href=\"mobipreview.htm?14/2/14368\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Special tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests of patellofemoral function have not been rigorously studied. Despite the dearth of evidence, the tests described below are commonly performed and may help to determine the diagnosis when considered in the context of the history and general examination findings. According to one small observational study, combinations of functional signs and tests, such as pain with resisted quadriceps contraction and pain with squatting, may be more diagnostic of patellofemoral pain syndrome than any one examination maneuver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patellar tendon palpation &ndash; Tenderness directly ventral or dorsal to the patellar tendon is associated with patellar bursitis and tendinopathy, while tenderness along either side of the patellar tendon is associated with inflammation of the fat pad of Hoffa. In an adolescent, tenderness at the inferior pole of the patella may be an apophysitis. These findings are not consistent with the diagnosis of PFPS.",
"     </li>",
"     <li>",
"      Patellofemoral compression test &ndash; Directly compress the patella into the trochlear groove while the leg is extended. Pain marks a positive test, which is consistent with PFPS. One prospective study of variants of this test in consecutive patients undergoing arthroscopy found this test to have limited sensitivity and specificity for detecting degenerative change of patellar cartilage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patella",
"      <span class=\"nowrap\">",
"       facet/retinaculum",
"      </span>",
"      tenderness &ndash; With the patient's knee in full extension and the quadriceps relaxed, displace the patella laterally and palpate its lateral facet (undersurface) through the retinaculum and synovium. Repeat on the medial side. Tenderness is a positive finding.",
"     </li>",
"     <li>",
"      Patellar glide &ndash; With the knee extended and the quadriceps relaxed, manually displace the patella laterally and medially. Translation less than one-quarter of the patella's width signifies a tight retinaculum, while translation of three-quarters of the patella's width signifies a hypermobile patella [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Apprehension test &ndash; With the quadriceps relaxed and the knee flexed to 30 degrees, apply pressure to the medial patella to push the patella laterally while looking at the patient's face. Apprehension as the patella reaches maximum passive displacement and the patient attempts to straighten the knee are a positive sign for patellar subluxation. The test has a reported sensitivity of 39 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Popliteal angle &ndash; The popliteal angle is a measure of hamstring flexibility. Tight hamstrings contribute to compressive forces across the patellofemoral joint and are associated with PFPS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/24\">",
"       24",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      With the patient relaxed and supine, flex the knee to 90 degrees, then gently extend the lower leg until you appreciate resistance. The angle of the leg at this point is the popliteal angle and is an objective measure of hamstring flexibility. Measurements greater than 20 degrees are consistent with hamstring inflexibility. At 0 degrees the leg is perpendicular to the exam table (",
"      <a class=\"graphic graphic_picture graphicRef77452 \" href=\"mobipreview.htm?4/36/4674\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Evaluation for dynamic malalignment:",
"      <br/>",
"      <br/>",
"      While the patient is barefoot and in shorts, observe their gait for excessive varus or valgus knee movement. Then, while the patient is walking or running, observe their foot strike for excess supination or pronation.",
"      <br/>",
"      <br/>",
"      Have the patient perform a single leg squat or step down while looking for excessive contralateral pelvic drop, hip adduction and internal rotation, knee abduction, and excessive or insufficient foot pronation (",
"      <a class=\"graphic graphic_picture graphicRef68323 \" href=\"mobipreview.htm?15/15/15615\">",
"       picture 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/10,46\">",
"       10,46",
"      </a>",
"      ]. Perform a Trendelenburg test to assess for gluteus medius weakness. The test is performed by having the patient stand on one leg and observing the pelvis. The ipsilateral iliac crest should remain level or rise slightly; a drop of the iliac crest indicates gluteus medius weakness. Because fatigability of the hip abductors may be a component of dynamic instability, excessive knee valgus motion may not be apparent in the office setting.",
"      <br/>",
"      <br/>",
"      Static testing of hip abductor and external rotator strength may help identify weakness and confirm observations noted on dynamic assessment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/32,39-41\">",
"       32,39-41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patellar grind &ndash; We believe this test is unnecessarily painful and unhelpful and suggest it not be performed. Neither its sensitivity nor its specificity are well studied [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Medial plica &ndash; Palpation of a tender medial plica, a fold of synovium along the medial joint line at the medial femoral condyle, is not associated with the diagnosis of PFPS.",
"     </li>",
"     <li>",
"      Q angle &ndash; The Q angle does not correlate to PFPS, and despite extensive study the clinical utility of this measurement remains uncertain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PFPS is a clinical diagnosis; plain films are unnecessary for initial management. In the absence of a history of trauma, overt instability, effusion, prior surgery, or pain at rest, imaging is not performed until the patient's symptoms fail to improve after one to two months of appropriate conservative therapy. Radiographic findings do not correlate well with clinical complaints and frequently the injured side is difficult to differentiate from the uninjured side [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When imaging is indicated, plain films of the knee (weight bearing PA, weight bearing lateral, and sunrise view) are useful to rule out other sources of anterior knee pain, including bipartite patella, osteoarthritis, loose bodies, and occult fractures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75919 \" href=\"mobipreview.htm?16/15/16638\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Advanced imaging, including magnetic resonance imaging (MRI), computed tomography (CT), musculoskeletal ultrasound (MSK US), and radionuclide scanning, is not indicated in the initial evaluation of the patient with PFPS, but may help identify other pathology. MRI can detect chondromalacia patella, articular cartilage injuries, osteochondritis dissecans, and injuries to the patellar retinaculum and patellofemoral ligament. CT scanning with serial flexion views can identify patellofemoral malalignment and instability. MSK US may show enhanced echogenicity suggestive of patellar tendinopathy. Bone scans can reveal increased bone activity associated with subchondral stress. Even advanced imaging is limited in that there is often poor correlation between radiographic and clinical findings.",
"   </p>",
"   <p>",
"    In one study correlating clinical exam to MRI and ultrasound findings in PFPS, slight effusion or increased signal intensity at the attachment site of the medial retinaculum were present on MRI in two out of five severe cases of PFPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/48\">",
"     48",
"    </a>",
"    ]. The synovium, retinaculum, joint capsule, fat pad of Hoffa, and subchondral bone appeared normal in all cases. MSK US revealed a slight to moderate effusion and enlargement of the synovium in two of five severe cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of treatment for PFPS are to reduce pain, improve patellofemoral tracking and alignment, and return the patient to as a high a level of function as possible. The acute phase of treatment during the first week focuses on pain control; the subsequent recovery phase focuses on modification of risk factors and biomechanical deficits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Acute phase",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activity modification &ndash; Most experts believe that overload plays an important role in the development of PFPS. Patients need to avoid activities that cause pain during rehabilitation. Most runners need to reduce their running volume and those with severe signs or symptoms (eg, limping) should curtail all running activities. Patients with less severe symptoms may need to stop only more extreme training, such as hill running and stadium step running. Athletes can maintain aerobic fitness by using a stationary bicycle (recumbent or upright), an upper body cycle, or by swimming, water running, or other activities, provided they do not cause pain.",
"     </li>",
"     <li>",
"      NSAIDs &ndash; There is no evidence to support the long term use of nonsteroidal antiinflammatory drugs (NSAIDs) for the treatment of PFPS. According to one systematic review, limited evidence supports their use in the short term (two to three weeks) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/49\">",
"       49",
"      </a>",
"      ]. In this review,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      produced more significant pain reduction compared with placebo, but",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      did not.",
"     </li>",
"     <li>",
"      Other modalities &ndash; Although formal studies are lacking, applying ice to the anterior knee is reasonable to relieve pain associated with PFPS. There is no empiric evidence to support the use of ultrasound, iontophoresis, phonophoresis, or electrical stimulation in the treatment of PFPS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/49-51\">",
"       49-51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Recovery phase",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many randomized clinical trials assessing treatments for PFPS have been performed, the results do not support any specific rehabilitation protocol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Evidence does suggest that exercises to increase strength and flexibility improve symptoms and function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. According to one randomized trial, supervised physical therapy may be superior to a home exercise program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/55\">",
"     55",
"    </a>",
"    ]. We have included a sample rehabilitation prescription (",
"    <a class=\"graphic graphic_table graphicRef80867 \" href=\"mobipreview.htm?36/40/37515\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A comprehensive approach to treatment should systematically address potential deficiencies in the interrelated group of muscles and other structures involved in moving the lower body (ie, the lower body kinetic chain). These structures include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hip abductors",
"     </li>",
"     <li>",
"      Iliotibial band",
"     </li>",
"     <li>",
"      Knee extensors (quadriceps)",
"     </li>",
"     <li>",
"      Knee flexors (hamstrings)",
"     </li>",
"     <li>",
"      Feet &ndash; excessive or insufficient pronation",
"     </li>",
"     <li>",
"      Core (ie, mid-body) muscles",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As PFPS appears to be multifactorial, as yet unspecified subtypes of PFPS may respond better to specific therapies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/48\">",
"     48",
"    </a>",
"    ]. Further research is needed.",
"   </p>",
"   <p>",
"    Ideally, patients should begin physical therapy under the guidance of a knowledgeable physical therapist or comparable professional. For those unable to do so, general exercises for the treatment of PFPS can be found at several websites, including the American Academy of Family Practice (",
"    <a class=\"external\" href=\"file://www.aafp.org/afp/991101ap/991101b.html\">",
"     www.aafp.org/afp/991101ap/991101b.html",
"    </a>",
"    ) and the Lennox Hill Hospital Nicholas Institute (",
"    <a class=\"external\" href=\"file://www.nismat.org/ptcor/pfp\">",
"     www.nismat.org/ptcor/pfp",
"    </a>",
"    ). These exercises should not cause pain. Patients experiencing anything more than mild soreness should reduce the intensity of the inciting exercise. Patients with persistent or severe pain from rehabilitation exercises should be reevaluated by their clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Stretching",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although an association between inflexibility and injury remains unproven, the decrease in stress at the patellofemoral joint provided by increased quadriceps, hamstring, and iliotibial band flexibility seems a reasonable therapeutic goal. Observational studies suggest an association exists between decreased quadriceps flexibility and PFPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/21,56\">",
"     21,56",
"    </a>",
"    ]. In a prospective case control study, a regime of quadriceps stretching decreased pain and improved function among patients with PFPS, although these improvements did not correlate closely with the gains in quadriceps flexibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Hip abductor strengthening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observational studies implicate hip abductor weakness in the development of PFPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/32,39-41\">",
"     32,39-41",
"    </a>",
"    ]. In response, many therapists incorporate hip abductor strengthening into their rehabilitation programs.",
"   </p>",
"   <p>",
"    In one small single-blinded randomized trial, improvements in pain and function were noted in patients with PFPS who engaged in hip abductor strengthening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/58\">",
"     58",
"    </a>",
"    ]. In another observational study, a six week program of closed kinetic chain hip strengthening and stretching resulted in significant improvements in pain and function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/59\">",
"     59",
"    </a>",
"    ]. Closed kinetic chain exercises are performed with the feet planted in a fixed position throughout the exercise (eg, squat, leg press). Case reports describe similar rehabilitation programs focused on improving core and hip stability and strength that allowed athletes to return to their previous level of activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Quadriceps strengthening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quadriceps muscle weakness is a common problem among patients with PFPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Treatment plans for PFPS should include general quadriceps strengthening exercises using closed or open kinetic chain movements, depending upon the severity of symptoms and biomechanical dysfunction. Closed kinetic chain (CKC) exercises are performed with the feet planted in a fixed position throughout the exercise (eg, squat, leg press) and thus provide greater stability. With open kinetic chain (OKC) exercises the feet change position.",
"   </p>",
"   <p>",
"    One systematic review concluded that CKC and OKC exercises were equally effective in the treatment of PFPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/53\">",
"     53",
"    </a>",
"    ]. Some researchers believe CKC exercises are better tolerated and produce less patellofemoral joint stress than OKC exercises [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/64\">",
"     64",
"    </a>",
"    ] and may preferentially activate the vastus medialis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/61\">",
"     61",
"    </a>",
"    ]. In one small randomized controlled trial, the selected CKC exercise (semisquat) was more effective than the OKC exercise (straight leg raise) in treating \"patellar chondromalacia\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/65\">",
"     65",
"    </a>",
"    ]. The diagnostic criteria described in the study were consistent with PFPS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Core stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deficiencies in core (ie, mid-body) strength, which affect pelvic stability, are a risk factor for lower extremity injuries, including PFPS, according to one prospective observational study in college athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/66\">",
"     66",
"    </a>",
"    ]. Many experts suggest that exercises to improve core strength be included in rehabilitation programs for PFPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/67\">",
"     67",
"    </a>",
"    ]. Such exercises generally involve multiple joints and incorporate trunk rotation and flexion of the knee and hip.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Adjunctive therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Foot orthoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence suggests that foot orthoses may be useful for symptom relief in some patients with PFPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/10,68,69\">",
"     10,68,69",
"    </a>",
"    ]. Semirigid full length foot orthotics can help control excessive foot overpronation or supination, which are associated with dynamic instability, and reduce impact.",
"   </p>",
"   <p>",
"    According to a systematic review, orthotics and physical therapy are more effective than physical therapy alone in reducing symptoms of PFPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/54\">",
"     54",
"    </a>",
"    ]. However, two subsequent systematic reviews with more stringent inclusion criteria reported that, although the available evidence is weak, there does not appear to be a clear benefit from treatment with foot orthoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. The highest quality trial included in both these systematic reviews included 179 patients with symptoms of PFPS of at least six weeks duration without prior treatment who were randomly assigned to treatment with orthotics, flat inserts, physical therapy, or orthotics plus physical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/69\">",
"     69",
"    </a>",
"    ]. Although there was a trend towards greater short-term improvement among patients treated with orthotics (RR 0.66; 99% CI 0.05-1.17), no significant difference in long term outcomes were noted.",
"   </p>",
"   <p>",
"    An important unresolved clinical issue with foot orthoses is determining which subset of patients may benefit. According to a few observational studies, foot orthoses may be most effective in individuals with increased dynamic foot pronation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/36,72\">",
"     36,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Bracing and patellar taping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies assessing the mechanism and effect of bracing and taping on PFPS are limited and inconclusive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/54,73-75\">",
"     54,73-75",
"    </a>",
"    ]. According to a systematic review of six studies involving 267 patients, the available evidence for these interventions is of limited quality but there does not appear to be a clear benefit when compared to treatment with physical therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/71\">",
"     71",
"    </a>",
"    ]. Some researchers believe there is a subgroup of patients that benefit from patellofemoral bracing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/76\">",
"     76",
"    </a>",
"    ]; taping appears to be less effective in patients with higher body mass indices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/77\">",
"     77",
"    </a>",
"    ]. Although the foundation of treatment for PFPS remains exercise and strengthening, if a patient cannot participate fully in rehabilitation exercises due to pain or does not make progress, it is reasonable to perform taping or patellofemoral bracing if this improves symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1144607\">",
"    <span class=\"h3\">",
"     Barefoot running and minimalist shoes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interest is increasing in running barefoot or in minimalist running shoes and in the possibility that such an approach to running may lower rates of injury, including patellofemoral pain. The potential benefits of barefoot running may be due to the changes in gait that are required when using this approach. These include a shorter stride length and a forefoot strike, which is thought to reduce impact compared with the rearfoot strike performed by runners wearing traditional running shoes. No controlled studies are available, and thus the indications and guidelines for transitioning to a barefoot style or minimalist shoes are currently anecdotal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. A review by a noted authority concludes that little is known about barefoot running, and there is much work to be done to determine whether a barefoot style can be used to treat or prevent injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Corticosteroids and glycosaminoglycans",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence to support the use of intraarticular injection of corticosteroid or glycosaminoglycan polysulfate (GAGPS) to treat PFPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/49,81\">",
"     49,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one double-blind, controlled trial, 53 patients with chronic PFPS were randomly assigned to receive five weekly intraarticular injections of GAGPS, five weekly sham injections (intraarticular isotonic saline), or no injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/81\">",
"     81",
"    </a>",
"    ]. All groups received conservative therapy that consisted of quadriceps strengthening, activity modification, and oral NSAIDs. Although both injection groups had better function at six weeks compared with the no-injection group, this difference was lost at six months. Symptoms resolved completely in over two-thirds of the patients in each group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatments for PFPS show varying degrees of success. Some patients have successful short term outcomes but poor long term outcomes after they return to their preinjury level of activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. If the patient reports recurrence or persistence of knee pain, assess the patient's compliance with and response to the prescribed therapy.",
"   </p>",
"   <p>",
"    Have the patient explain in detail the exercises they have been doing. When did they first see the physical therapist? How many times a week do they go to physical therapy? How often do they do their home program? Have the patient demonstrate some of the exercises. Ask about their tolerance of the therapy and quantify their cardiovascular workouts (eg, \"I can ride the stationary bike for 10 minutes until my knee hurts,\" or \"I'm still running 25 miles per week\").",
"   </p>",
"   <p>",
"    Because overuse is a significant risk factor for PFPS, activity levels need to be quantified. Ask about previously aggravating activities and assess improvement (eg, \"I can walk down stairs without pain now\").",
"   </p>",
"   <p>",
"    If there is improvement, continue physical therapy until the patient can perform all exercises without pain, and then slowly reintroduce activities which previously caused pain (eg, running). Increase activity levels in a gradual, step-wise progression, until the patient achieves the desired level. If symptoms are unchanged and the patient appears to be compliant with both therapy and activity modification, re-examine the patient to confirm the original diagnosis. Imaging with plain radiographs may be useful, as may orthotics, taping, or bracing if not previously done. If the compliant patient has not improved in three to six months of therapy, obtain an MRI or orthopedic consultation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical intervention for patellofemoral pain syndrome (PFPS) is considered when nonoperative therapies have failed. It is a treatment of last resort. Nonoperative therapy should be pursued for 6 to 12 months prior to considering operative intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Before surgery, other causes of anterior knee pain should be carefully excluded and a clearly identified structural abnormality amenable to surgery (eg, tight lateral retinaculum) should exist. Any surgery for PFPS must address the patient's specific characteristics of abnormal patellar tracking; inappropriate and overzealous surgery can lead to significant patient disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patellar alignment, patellar resurfacing, and patellar arthroplasty comprise the three principal categories of operative intervention for PFPS. Most studies evaluating such surgery are uncontrolled case series, so the effectiveness of operative intervention remains unclear. In one randomized controlled trial involving 56 patients with chronic PFPS, no difference in outcome was found in patients treated with arthroscopy and a home exercise program compared with those treated with exercise alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. According to a case series of 34 athletes, patients with demonstrated lateral patellar instability are more likely to benefit from surgical repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While few long term studies document the natural history or treatment of PFPS, the general prognosis is favorable. Long-term observational studies suggest that at two to eight years most patients with PFPS patients report only mild occasional symptoms. In a seven year follow-up of patients from a randomized, controlled trial, nearly 85 percent treated with a home exercise program reported successful outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not all patients with PFPS successfully complete nonoperative therapy and return to sporting activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/82\">",
"     82",
"    </a>",
"    ]. Some must retire prematurely from sports that aggravate PFPS. Persistent abnormal tracking of the patella or patellar instability can lead to patellofemoral osteoarthritis or chronic pain. Risk factors associated with a poor long-term prognosis include a hypermobile patella, older age, and bilateral symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/2,87\">",
"     2,87",
"    </a>",
"    ]. One predictor of a poor functional outcome is fear avoidance behavior; addressing psychological comorbidities may be an important intervention for individuals who are failing to progress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The failure of nonoperative therapy does not imply successful surgical treatment. A significant number of patients do not improve or are made worse by PFPS surgery, at times requiring a salvage procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Indications for orthopedic referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Return to sport for the patient with PFPS follows basic guidelines applicable for all overuse injuries. The patient should demonstrate motion equal to that of the uninvolved extremity, and strength at least 80 percent that of the opposite side. The presence of significant quadriceps atrophy or an effusion precludes a return to full activity. The patient should have no complaints of nocturnal pain or pain with activities of daily living prior to beginning sports. In general, mild pain that diminishes with activity is not concerning. Increased pain should prompt termination of the activity and reassessment by the clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4147527\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to a randomized controlled trial conducted among army recruits in the United Kingdom, an exercise program much like that used to treat PFPS may be effective at preventing the development of anterior knee pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43993/abstract/89\">",
"     89",
"    </a>",
"    ]. In this trial, 36 new cases of PFPS (described as &ldquo;overuse anterior knee pain&rdquo;) developed in the control group of 743 recruits compared to 10 new cases among the 759 recruits who participated in the preventative exercise program (HR 0.25; 95% CI 0.13-0.52).",
"   </p>",
"   <p>",
"    With the exception of the prevention exercises, recruits participated in the exact same training activities over the 14 week trial period. Physicians assessing the recruits were blinded to which groups participated in the intervention. The prevention program consisted of the following exercises:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Isometric hip abduction against a wall",
"     </li>",
"     <li>",
"      Forward lunges",
"     </li>",
"     <li>",
"      Single leg step downs",
"     </li>",
"     <li>",
"      Single leg squats",
"     </li>",
"     <li>",
"      Stretches for the quadriceps, iliotibial band, hamstrings, and calves",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics&rdquo;. The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/10/18594?source=see_link\">",
"       \"Patient information: Patellofemoral pain syndrome (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/36/7747?source=see_link\">",
"       \"Patient information: Knee pain (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/37/11858?source=see_link\">",
"       \"Patient information: Chondromalacia patella (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24642?source=see_link\">",
"       \"Patient information: Knee pain (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PFPS is the most common etiology of anterior knee pain in the general population. PFPS can be defined as pain involving the patella and retinaculum that excludes other intraarticular and peripatellar pathology. There is no consensus about its pathophysiology. Overuse is common among patients with PFPS. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PFPS has no pathognomonic sign or symptom. PFPS is a clinical diagnosis made based upon history, examination, and the exclusion of alternative diagnoses; plain films are not required for initial management. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical presentation and examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical therapy focused upon improving the strength and flexibility of the lower extremity and core muscles, including the hip abductors and quadriceps, are generally effective in the treatment of PFPS. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Recovery phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no evidence to support the long term use of NSAIDs for the treatment of PFPS; limited evidence supports their use for short term pain relief. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Acute phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical intervention for patellofemoral pain syndrome may be considered only when nonoperative therapies have failed. Nonoperative therapy should be pursued for 6 to 12 months prior to considering operative intervention and a clearly identified structural abnormality amenable to surgery (eg, tight lateral retinaculum) should exist. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Indications for orthopedic referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of PFPS patients experience a resolution of symptoms following conservative treatment.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/1\">",
"      Thome&eacute; R, Augustsson J, Karlsson J. Patellofemoral pain syndrome: a review of current issues. Sports Med 1999; 28:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/2\">",
"      Dixit S, DiFiori JP, Burton M, Mines B. Management of patellofemoral pain syndrome. Am Fam Physician 2007; 75:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/3\">",
"      Cutbill JW, Ladly KO, Bray RC, et al. Anterior knee pain: a review. Clin J Sport Med 1997; 7:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/4\">",
"      Baquie P, Brukner P. Injuries presenting to an Australian sports medicine centre: a 12-month study. Clin J Sport Med 1997; 7:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/5\">",
"      Taunton JE, Ryan MB, Clement DB, et al. A retrospective case-control analysis of 2002 running injuries. Br J Sports Med 2002; 36:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/6\">",
"      Kannus P, Aho H, J&auml;rvinen M, Niittym&auml;ki S. Computerized recording of visits to an outpatient sports clinic. Am J Sports Med 1987; 15:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/7\">",
"      Boling M, Padua D, Marshall S, et al. Gender differences in the incidence and prevalence of patellofemoral pain syndrome. Scand J Med Sci Sports 2010; 20:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/8\">",
"      DeHaven KE, Lintner DM. Athletic injuries: comparison by age, sport, and gender. Am J Sports Med 1986; 14:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/9\">",
"      T&aacute;llay A, Kynsburg A, T&oacute;th S, et al. [Prevalence of patellofemoral pain syndrome. Evaluation of the role of biomechanical malalignments and the role of sport activity]. Orv Hetil 2004; 145:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/10\">",
"      Earl JE, Vetter CS. Patellofemoral pain. Phys Med Rehabil Clin N Am 2007; 18:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/11\">",
"      Dye SF. The pathophysiology of patellofemoral pain: a tissue homeostasis perspective. Clin Orthop Relat Res 2005; :100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/12\">",
"      Fulkerson JP. Diagnosis and treatment of patients with patellofemoral pain. Am J Sports Med 2002; 30:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/13\">",
"      Niskanen RO, Paavilainen PJ, Jaakkola M, Korkala OL. Poor correlation of clinical signs with patellar cartilaginous changes. Arthroscopy 2001; 17:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/14\">",
"      Marti B, Vader JP, Minder CE, Abelin T. On the epidemiology of running injuries. The 1984 Bern Grand-Prix study. Am J Sports Med 1988; 16:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/15\">",
"      Macera CA. Lower extremity injuries in runners. Advances in prediction. Sports Med 1992; 13:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/16\">",
"      Heir T, Eide G. Age, body composition, aerobic fitness and health condition as risk factors for musculoskeletal injuries in conscripts. Scand J Med Sci Sports 1996; 6:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/17\">",
"      Reis JP, Trone DW, Macera CA, Rauh MJ. Factors associated with discharge during marine corps basic training. Mil Med 2007; 172:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/18\">",
"      Fairbank JC, Pynsent PB, van Poortvliet JA, Phillips H. Mechanical factors in the incidence of knee pain in adolescents and young adults. J Bone Joint Surg Br 1984; 66:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/19\">",
"      Wen DY, Puffer JC, Schmalzried TP. Injuries in runners: a prospective study of alignment. Clin J Sport Med 1998; 8:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/20\">",
"      Williams DS 3rd, McClay IS, Hamill J. Arch structure and injury patterns in runners. Clin Biomech (Bristol, Avon) 2001; 16:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/21\">",
"      Smith AD, Stroud L, McQueen C. Flexibility and anterior knee pain in adolescent elite figure skaters. J Pediatr Orthop 1991; 11:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/22\">",
"      Boling MC, Padua DA, Marshall SW, et al. A prospective investigation of biomechanical risk factors for patellofemoral pain syndrome: the Joint Undertaking to Monitor and Prevent ACL Injury (JUMP-ACL) cohort. Am J Sports Med 2009; 37:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/23\">",
"      White LC, Dolphin P, Dixon J. Hamstring length in patellofemoral pain syndrome. Physiotherapy 2009; 95:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/24\">",
"      Whyte EF, Moran K, Shortt CP, Marshall B. The influence of reduced hamstring length on patellofemoral joint stress during squatting in healthy male adults. Gait Posture 2010; 31:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/25\">",
"      Cook C, Hegedus E, Hawkins R, et al. Diagnostic accuracy and association to disability of clinical test findings associated with patellofemoral pain syndrome. Physiother Can 2010; 62:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/26\">",
"      Sweitzer BA, Cook C, Steadman JR, et al. The inter-rater reliability and diagnostic accuracy of patellar mobility tests in patients with anterior knee pain. Phys Sportsmed 2010; 38:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/27\">",
"      Rauh MJ, Macera CA, Trone DW, et al. Selected static anatomic measures predict overuse injuries in female recruits. Mil Med 2010; 175:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/28\">",
"      Post WR. Clinical evaluation of patients with patellofemoral disorders. Arthroscopy 1999; 15:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/29\">",
"      Park SK, Stefanyshyn DJ. Greater Q angle may not be a risk factor of patellofemoral pain syndrome. Clin Biomech (Bristol, Avon) 2011; 26:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/30\">",
"      Kaya D, Atay OA, Callaghan MJ, et al. Hallux valgus in patients with patellofemoral pain syndrome. Knee Surg Sports Traumatol Arthrosc 2009; 17:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/31\">",
"      Ali SA, Helmer R, Terk MR. Analysis of the patellofemoral region on MRI: association of abnormal trochlear morphology with severe cartilage defects. AJR Am J Roentgenol 2010; 194:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/32\">",
"      Niemuth PE, Johnson RJ, Myers MJ, Thieman TJ. Hip muscle weakness and overuse injuries in recreational runners. Clin J Sport Med 2005; 15:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/33\">",
"      Souza RB, Powers CM. Predictors of hip internal rotation during running: an evaluation of hip strength and femoral structure in women with and without patellofemoral pain. Am J Sports Med 2009; 37:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/34\">",
"      Stefanyshyn DJ, Stergiou P, Lun VM, et al. Knee angular impulse as a predictor of patellofemoral pain in runners. Am J Sports Med 2006; 34:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/35\">",
"      Messier SP, Davis SE, Curl WW, et al. Etiologic factors associated with patellofemoral pain in runners. Med Sci Sports Exerc 1991; 23:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/36\">",
"      Barton CJ, Menz HB, Levinger P, et al. Greater peak rearfoot eversion predicts foot orthoses efficacy in individuals with patellofemoral pain syndrome. Br J Sports Med 2011; 45:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/37\">",
"      Barton CJ, Bonanno D, Levinger P, Menz HB. Foot and ankle characteristics in patellofemoral pain syndrome: a case control and reliability study. J Orthop Sports Phys Ther 2010; 40:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/38\">",
"      Thijs Y, Van Tiggelen D, Roosen P, et al. A prospective study on gait-related intrinsic risk factors for patellofemoral pain. Clin J Sport Med 2007; 17:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/39\">",
"      Ireland ML, Willson JD, Ballantyne BT, Davis IM. Hip strength in females with and without patellofemoral pain. J Orthop Sports Phys Ther 2003; 33:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/40\">",
"      Cichanowski HR, Schmitt JS, Johnson RJ, Niemuth PE. Hip strength in collegiate female athletes with patellofemoral pain. Med Sci Sports Exerc 2007; 39:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/41\">",
"      Robinson RL, Nee RJ. Analysis of hip strength in females seeking physical therapy treatment for unilateral patellofemoral pain syndrome. J Orthop Sports Phys Ther 2007; 37:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/42\">",
"      McCaw ST. Leg length inequality. Implications for running injury prevention. Sports Med 1992; 14:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/43\">",
"      Duffey MJ, Martin DF, Cannon DW, et al. Etiologic factors associated with anterior knee pain in distance runners. Med Sci Sports Exerc 2000; 32:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/44\">",
"      Cowan DN, Jones BH, Robinson JR. Foot morphologic characteristics and risk of exercise-related injury. Arch Fam Med 1993; 2:773.",
"     </a>",
"    </li>",
"    <li>",
"     Malanga, G, Nadler, SF (Eds). Musculoskeletal physical examination: an evidence-based approach. Elsevier Mosby, Philidelphia 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/46\">",
"      Rabin A, Kozol Z. Measures of range of motion and strength among healthy women with differing quality of lower extremity movement during the lateral step-down test. J Orthop Sports Phys Ther 2010; 40:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/47\">",
"      Haim A, Yaniv M, Dekel S, Amir H. Patellofemoral pain syndrome: validity of clinical and radiological features. Clin Orthop Relat Res 2006; 451:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/48\">",
"      Brush&oslash;j C, H&ouml;lmich P, Nielsen MB, Albrecht-Beste E. Acute patellofemoral pain: aggravating activities, clinical examination, MRI and ultrasound findings. Br J Sports Med 2008; 42:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/49\">",
"      Heintjes E, Berger MY, Bierma-Zeinstra SM, et al. Pharmacotherapy for patellofemoral pain syndrome. Cochrane Database Syst Rev 2004; :CD003470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/50\">",
"      van der Windt DA, van der Heijden GJ, van den Berg SG, et al. Ultrasound therapy for musculoskeletal disorders: a systematic review. Pain 1999; 81:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/51\">",
"      Bolin DJ. Transdermal approaches to pain in sports injury management. Curr Sports Med Rep 2003; 2:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/52\">",
"      Bizzini M, Childs JD, Piva SR, Delitto A. Systematic review of the quality of randomized controlled trials for patellofemoral pain syndrome. J Orthop Sports Phys Ther 2003; 33:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/53\">",
"      Heintjes E, Berger MY, Bierma-Zeinstra SM, et al. Exercise therapy for patellofemoral pain syndrome. Cochrane Database Syst Rev 2003; :CD003472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/54\">",
"      Crossley K, Bennell K, Green S, McConnell J. A systematic review of physical interventions for patellofemoral pain syndrome. Clin J Sport Med 2001; 11:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/55\">",
"      van Linschoten R, van Middelkoop M, Berger MY, et al. Supervised exercise therapy versus usual care for patellofemoral pain syndrome: an open label randomised controlled trial. BMJ 2009; 339:b4074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/56\">",
"      Witvrouw E, Lysens R, Bellemans J, et al. Intrinsic risk factors for the development of anterior knee pain in an athletic population. A two-year prospective study. Am J Sports Med 2000; 28:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/57\">",
"      Peeler J, Anderson JE. Effectiveness of static quadriceps stretching in individuals with patellofemoral joint pain. Clin J Sport Med 2007; 17:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/58\">",
"      Avraham F, Aviv S, Ya'akobi P, et al. The efficacy of treatment of different intervention programs for patellofemoral pain syndrome--a single blinded randomized clinical trial. Pilot study. ScientificWorldJournal 2007; 7:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/59\">",
"      Tyler TF, Nicholas SJ, Mullaney MJ, McHugh MP. The role of hip muscle function in the treatment of patellofemoral pain syndrome. Am J Sports Med 2006; 34:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/60\">",
"      Mascal CL, Landel R, Powers C. Management of patellofemoral pain targeting hip, pelvis, and trunk muscle function: 2 case reports. J Orthop Sports Phys Ther 2003; 33:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/61\">",
"      Irish SE, Millward AJ, Wride J, et al. The effect of closed-kinetic chain exercises and open-kinetic chain exercise on the muscle activity of vastus medialis oblique and vastus lateralis. J Strength Cond Res 2010; 24:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/62\">",
"      Werner S. An evaluation of knee extensor and knee flexor torques and EMGs in patients with patellofemoral pain syndrome in comparison with matched controls. Knee Surg Sports Traumatol Arthrosc 1995; 3:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/63\">",
"      Natri A, Kannus P, J&auml;rvinen M. Which factors predict the long-term outcome in chronic patellofemoral pain syndrome? A 7-yr prospective follow-up study. Med Sci Sports Exerc 1998; 30:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/64\">",
"      Witvrouw E, Lysens R, Bellemans J, et al. Open versus closed kinetic chain exercises for patellofemoral pain. A prospective, randomized study. Am J Sports Med 2000; 28:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/65\">",
"      Bakhtiary AH, Fatemi E. Open versus closed kinetic chain exercises for patellar chondromalacia. Br J Sports Med 2008; 42:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/66\">",
"      Leetun DT, Ireland ML, Willson JD, et al. Core stability measures as risk factors for lower extremity injury in athletes. Med Sci Sports Exerc 2004; 36:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/67\">",
"      Earl JE, Hoch AZ. A proximal strengthening program improves pain, function, and biomechanics in women with patellofemoral pain syndrome. Am J Sports Med 2011; 39:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/68\">",
"      Sutlive TG, Mitchell SD, Maxfield SN, et al. Identification of individuals with patellofemoral pain whose symptoms improved after a combined program of foot orthosis use and modified activity: a preliminary investigation. Phys Ther 2004; 84:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/69\">",
"      Collins N, Crossley K, Beller E, et al. Foot orthoses and physiotherapy in the treatment of patellofemoral pain syndrome: randomised clinical trial. BMJ 2008; 337:a1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/70\">",
"      Hossain M, Alexander P, Burls A, Jobanputra P. Foot orthoses for patellofemoral pain in adults. Cochrane Database Syst Rev 2011; :CD008402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/71\">",
"      Swart NM, van Linschoten R, Bierma-Zeinstra SM, van Middelkoop M. The additional effect of orthotic devices on exercise therapy for patients with patellofemoral pain syndrome: a systematic review. Br J Sports Med 2012; 46:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/72\">",
"      Barton CJ, Menz HB, Crossley KM. The immediate effects of foot orthoses on functional performance in individuals with patellofemoral pain syndrome. Br J Sports Med 2011; 45:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/73\">",
"      Mostamand J, Bader DL, Hudson Z. The effect of patellar taping on EMG activity of vasti muscles during squatting in individuals with patellofemoral pain syndrome. J Sports Sci 2011; 29:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/74\">",
"      Lun VM, Wiley JP, Meeuwisse WH, Yanagawa TL. Effectiveness of patellar bracing for treatment of patellofemoral pain syndrome. Clin J Sport Med 2005; 15:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/75\">",
"      Callaghan MJ, Selfe J. Patellar taping for patellofemoral pain syndrome in adults. Cochrane Database Syst Rev 2012; 4:CD006717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/76\">",
"      Chew KT, Lew HL, Date E, Fredericson M. Current evidence and clinical applications of therapeutic knee braces. Am J Phys Med Rehabil 2007; 86:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/77\">",
"      Lan TY, Lin WP, Jiang CC, Chiang H. Immediate effect and predictors of effectiveness of taping for patellofemoral pain syndrome: a prospective cohort study. Am J Sports Med 2010; 38:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/78\">",
"      Goss DL, Gross MT. A review of mechanics and injury trends among various running styles. US Army Med Dep J 2012; :62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/79\">",
"      Jenkins DW, Cauthon DJ. Barefoot running claims and controversies: a review of the literature. J Am Podiatr Med Assoc 2011; 101:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/80\">",
"      Lieberman DE. What we can learn about running from barefoot running: an evolutionary medical perspective. Exerc Sport Sci Rev 2012; 40:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/81\">",
"      Kannus P, Natri A, Niittym&auml;ki S, J&auml;rvinen M. Effect of intraarticular glycosaminoglycan polysulfate treatment on patellofemoral pain syndrome. A prospective, randomized double-blind trial comparing glycosaminoglycan polysulfate with placebo and quadriceps muscle exercises. Arthritis Rheum 1992; 35:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/82\">",
"      Bl&oslash;nd L, Hansen L. Patellofemoral pain syndrome in athletes: a 5.7-year retrospective follow-up study of 250 athletes. Acta Orthop Belg 1998; 64:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/83\">",
"      Hoch AZ, Pepper M, Akuthota V. Stress fractures and knee injuries in runners. Phys Med Rehabil Clin N Am 2005; 16:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/84\">",
"      Kettunen JA, Harilainen A, Sandelin J, et al. Knee arthroscopy and exercise versus exercise only for chronic patellofemoral pain syndrome: a randomized controlled trial. BMC Med 2007; 5:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/85\">",
"      Kettunen JA, Harilainen A, Sandelin J, et al. Knee arthroscopy and exercise versus exercise only for chronic patellofemoral pain syndrome: 5-year follow-up. Br J Sports Med 2012; 46:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/86\">",
"      Tjoumakaris FP, Forsythe B, Bradley JP. Patellofemoral instability in athletes: treatment via modified Fulkerson osteotomy and lateral release. Am J Sports Med 2010; 38:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/87\">",
"      Kannus P, Natri A, Paakkala T, J&auml;rvinen M. An outcome study of chronic patellofemoral pain syndrome. Seven-year follow-up of patients in a randomized, controlled trial. J Bone Joint Surg Am 1999; 81:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/88\">",
"      Piva SR, Fitzgerald GK, Wisniewski S, Delitto A. Predictors of pain and function outcome after rehabilitation in patients with patellofemoral pain syndrome. J Rehabil Med 2009; 41:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43993/abstract/89\">",
"      Coppack RJ, Etherington J, Wills AK. The effects of exercise for the prevention of overuse anterior knee pain: a randomized controlled trial. Am J Sports Med 2011; 39:940.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 204 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-2FACFC3B1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43993=[""].join("\n");
var outline_f42_61_43993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Overload",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Malalignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL PRESENTATION AND EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Knee examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Special tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Acute phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Recovery phase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Stretching",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Hip abductor strengthening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Quadriceps strengthening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Core stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Adjunctive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Foot orthoses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Bracing and patellar taping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1144607\">",
"      - Barefoot running and minimalist shoes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Corticosteroids and glycosaminoglycans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      INDICATIONS FOR ORTHOPEDIC REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4147527\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/204\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/204|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/15/16638\" title=\"diagnostic image 1\">",
"      Sunrise xray of patella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/204|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/61/2004\" title=\"figure 1\">",
"      PFPS anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/4/5184\" title=\"figure 2\">",
"      Q angle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/204|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/2/14368\" title=\"picture 1\">",
"      Pes cavus foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/36/4674\" title=\"picture 2\">",
"      Popliteal angle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/15/15615\" title=\"picture 3\">",
"      PFPS dynamic align test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/204|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/44/13004\" title=\"table 1\">",
"      Knee anterior pain ddx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/40/37515\" title=\"table 2\">",
"      PFPS sample phys ther Rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/24/32138?source=related_link\">",
"      Anterior cruciate ligament injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/49/12056?source=related_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/37/11858?source=related_link\">",
"      Patient information: Chondromalacia patella (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24642?source=related_link\">",
"      Patient information: Knee pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/36/7747?source=related_link\">",
"      Patient information: Knee pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/10/18594?source=related_link\">",
"      Patient information: Patellofemoral pain syndrome (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_61_43994="Pharmacology of antiepileptic drugs";
var content_f42_61_43994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacology of antiepileptic drugs",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43994/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43994/contributors\">",
"     Steven C Schachter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43994/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43994/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/61/43994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/61/43994/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/61/43994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased knowledge of mechanisms involved in the development of seizures, as well as improved understanding of the cellular effects of antiepileptic drugs (AEDs), have resulted in links between demonstrated molecular actions of these drugs and the types of seizures against which they are most effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    inhibit voltage-dependent neuronal sodium channels; this action is predictive of efficacy against tonic and tonic-clonic seizures. At the same time, there has been recognition that new AEDs act against novel targets that are increasing the possibilities for even more effective agents as well as suggesting a basis for rational polytherapy in the future. These discoveries highlight the importance of understanding the basic mechanisms of AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the exception of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/31/25079?source=see_link\">",
"     felbamate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"     vigabatrin",
"    </a>",
"    , second generation AEDs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/19/35125?source=see_link\">",
"     lacosamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    ) have a number of potential advantages over older AEDs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ). These include generally lower side-effect rates, little or no need for serum monitoring, once or twice daily dosing for some, and fewer drug interactions. However, these drugs are not a panacea. The National Institute for Clinical Excellence (UK) practice guidance evaluated newer AEDs (excluding zonisamide and felbamate) and made the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monotherapy data in newly diagnosed epilepsy patients do not show significant differences in effectiveness between older and newer AEDs.",
"     </li>",
"     <li>",
"      Insufficient evidence exists to support the claim that newer AEDs are generally associated with an improved quality of life.",
"     </li>",
"     <li>",
"      There is a high degree of uncertainty about the costs and benefits associated with individual drugs.",
"     </li>",
"     <li>",
"      Freedom from seizures, the desired outcome, is infrequently achieved with combination therapy in patients who have failed monotherapy; insufficient evidence exists to determine whether any of the newer AEDs is superior to other AEDs in providing long-term freedom from seizures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pharmacology of AEDs is reviewed here. Their use in a treatment plan for patients with seizures is discussed separately. Risks of AEDs in pregnancy are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link\">",
"     \"Initial treatment of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22633?source=see_link&amp;anchor=H4#H4\">",
"     \"Risks associated with epilepsy and pregnancy\", section on 'Effect of antiepileptic drugs on the fetus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DRUGS THAT AFFECT VOLTAGE-DEPENDENT SODIUM CHANNELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depolarization of neuronal membranes (such as by excitatory neurotransmitters at postsynaptic receptor sites) produces an influx of sodium ions from the extracellular space into the neuron through sodium channels along the neuronal membrane. As the cell membrane depolarizes, this influx further increases the number of open sodium channels in the cell membrane, further increasing the incoming current of sodium ions. Thus, these sodium channels are termed voltage-dependent.",
"   </p>",
"   <p>",
"    The sodium channels are termed resting or closed when the cell is at resting membrane potential. During the process of depolarization, the sodium channels are activated or open. After activation, they are inactivated (closed) or refractory. Sodium channels cannot be further activated by depolarization during the refractory state. Thus, the membrane potential starts to repolarize and the sodium channels eventually resume the resting or closed state.",
"   </p>",
"   <p>",
"    The inactivated period is usually brief enough to allow for rapid, high-frequency action potentials. Blocking voltage-dependent sodium channels (eg, with tetrodotoxin from the puffer fish), or extending their inactivated state (eg, with certain antiepileptic drugs [AEDs]), prevents neurons from firing rapidly, although single action potentials are unaffected. This inhibition also can prevent post-tetanic potentiation, a phenomenon consisting of an unusually large response of a postsynaptic neuron to an incoming single action potential after previous exposure to rapid, high-frequency (tetanic) incoming stimulation. Neurons that undergo post-tetanic potentiation may be responsible for spreading abnormal electrical responses after being exposed to intermittently rapid firing neurons. This action may correlate with the rapid spread of epileptic activity from a circumscribed seizure focus to other cortical areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Carbamazepine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     Carbamazepine",
"    </a>",
"    (CBZ) has been used to treat partial and generalized seizures since being introduced in Switzerland and the United Kingdom over 35 years ago. It is also effective for the treatment of affective illnesses such as bipolar disorder and chronic pain syndromes such as trigeminal neuralgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     Carbamazepine",
"    </a>",
"    is approximately 70 percent protein bound. It is metabolized in the liver by the cytochrome P-450 (CYP) system, an inducible enzyme. The main metabolite, carbamazepine epoxide, has anticonvulsant activity and can be measured in the serum.",
"   </p>",
"   <p>",
"    CBZ binds to voltage-dependent sodium channels, probably after they change from the activated to the inactivated state. This binding extends the inactivated phase and inhibits the generation of rapid action potentials when the cell is experiencing incoming depolarizing trains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/8\">",
"     8",
"    </a>",
"    ]. The effectiveness of CBZ in inhibiting action potentials by extending the inactivated phase of sodium channel function increases with the rate of neuronal firing.",
"   </p>",
"   <p>",
"    CBZ is used for the initial therapy of primary generalized tonic-clonic seizures and for partial seizures, with or without secondary generalization (",
"    <a class=\"graphic graphic_table graphicRef61530 graphicRef79951 graphicRef68910 \" href=\"mobipreview.htm?18/14/18656\">",
"     table 1A-C",
"    </a>",
"    ). The usual initial starting dose is 2 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day given two, three, or four times daily; the dose is increased every five days to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily. Generally, three times daily dosing is recommended. However, if patients experience side effects two to four hours after a dose, then the total daily dosage could be redistributed over four doses. Further increases up to 15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day may be necessary after two to three months because of hepatic autoinduction of the cytochrome P-450 enzyme.",
"   </p>",
"   <p>",
"    Extended-release formulations allow for twice daily dosing with more stable blood levels. Two open-label studies found that switching from immediate-release to extended-release formulation decreased side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The larger of these two studies (453 patients) also showed improved seizure control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum CBZ levels should be measured initially at three, six, and nine weeks, with a goal level of 4 to 12",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Frequent levels are needed early in therapy due to autoinduction, which results in decreased serum concentrations. Serum levels subsequently should be checked at least every two months until successive determinations are constant, more frequently if CBZ dosages or concomitant antiepileptic drug doses are changed. A number of drugs can influence the serum concentration of CBZ (",
"    <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80801 \" href=\"mobipreview.htm?6/29/6621\">",
"     table 3A",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5408138\">",
"    <span class=\"h3\">",
"     Adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common systemic side effects of CBZ include nausea, vomiting, diarrhea, hyponatremia, rash, pruritus, and fluid retention (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"mobipreview.htm?2/17/2334\">",
"     table 4A-B",
"    </a>",
"    ). Patients who develop a rash with CBZ are more likely to develop one with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    and vice versa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/11\">",
"     11",
"    </a>",
"    ]. Men with localization-related (focal) epilepsy taking CBZ have higher rates of sexual dysfunction and low testosterone levels, which may be reversible if CBZ is withdrawn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Decreased thyroid hormone levels of uncertain clinical significance have been reported in patients taking CBZ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurotoxic side effects include drowsiness, dizziness, blurred or double vision, lethargy, and headache. Hyponatremia related to CBZ and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    is discussed separately. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Hyponatremia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other potentially life-threatening adverse events related to CBZ include Stevens-Johnson syndrome and bone marrow suppression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CBZ has been associated with the Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN). Most cases occur during the first eight weeks of therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. This reaction is significantly more common (estimated incidence of 5 percent) in patients with the HLA-B*1502 allele, which occurs almost exclusively in patients of Asian ancestry, including South Asian Indians [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. It is our practice to follow the FDA recommendations to screen for this allele in patients of these ethnic groups prior to starting CBZ [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/19,21\">",
"       19,21",
"      </a>",
"      ]. In one high risk population in Taiwan, a program of screening individuals for the HLA-B*1502 allele prior to initiating CBZ successfully eliminated the cases of SJS-TEN in the 4877 study population; approximately 10 cases would have been expected according to historical incidence estimates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/22\">",
"       22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A genomewide association study of blood samples from Northern European patients who had experienced",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      -induced SJS-TEN found a significant association with the HLA-A*3101 allele; the presence of this allele increased the baseline risk of this reaction from 5 to 26 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/23\">",
"       23",
"      </a>",
"      ]. This allele is prevalent in 2 to 5 percent of Northern Europeans. The number of patients needed to screen to prevent one adverse reaction based upon this data was estimated to be 83, a number similar to that for screening at-risk populations for the HLA-B*1502 allele. This suggests that screening for this allele in at-risk populations will be similarly recommended if this finding is confirmed and an assay becomes available.",
"      <br/>",
"      <br/>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/62/24554?source=see_link&amp;anchor=H11#H11\">",
"       \"An approach to the patient with drug allergy\", section on 'HLA type'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Leukopenia occurs in approximately 12 percent of children and 7 percent of adults with CBZ treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/24\">",
"       24",
"      </a>",
"      ]. It may be transient or persistent and does not usually require immediate discontinuation of CBZ therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. The onset is typically within the first three months of treatment. Patients who have a low or low-normal white blood cell (WBC) or neutrophil count before CBZ treatment may be at higher risk for developing CBZ-induced leukopenia or neutropenia.",
"      <br/>",
"      <br/>",
"      Aplastic anemia (pancytopenia) is a rare, idiosyncratic, non-dose-related side effect that is most likely to occur within the first three or four months after initiating CBZ therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/25\">",
"       25",
"      </a>",
"      ]. Daily laboratory checks would be necessary to monitor for aplastic anemia, agranulocytosis, and thrombocytopenia because of their rapid onset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/24\">",
"       24",
"      </a>",
"      ], and such frequent monitoring is neither practical nor necessary for most patients taking CBZ. A more suitable approach is to monitor for aplastic anemia by informing patients and physicians to carefully watch for signs and symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/586?source=see_link\">",
"       \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Some experts recommend monitoring WBC counts of high-risk patients during the first three months of CBZ treatment, with the monitoring frequency determined by results of each laboratory value. White blood cell counts less than",
"      <span class=\"nowrap\">",
"       3000/microliter",
"      </span>",
"      or neutrophil counts below",
"      <span class=\"nowrap\">",
"       1000/microliter",
"      </span>",
"      warrant either a decrease in CBZ dose with frequent WBC monitoring, or CBZ discontinuation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Phenytoin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     Phenytoin",
"    </a>",
"    was introduced nearly 60 years ago for use in epilepsy and is still widely prescribed for partial and generalized seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/27\">",
"     27",
"    </a>",
"    ]. Similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , it blocks voltage-dependent neuronal sodium channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/28\">",
"     28",
"    </a>",
"    ]. Other effects of phenytoin include diminishing synaptic transmission, limiting fluctuation of neuronal ionic gradients via sodium-potassium ATPase, and affecting second messenger systems by inhibiting calcium-calmodulin protein phosphorylation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The first step in the metabolism of phenytoin, which takes place in the liver, involves arene oxidase, which has nonlinear kinetics.",
"   </p>",
"   <p>",
"    In addition to partial and generalized seizures,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    is a second line agent for patients with mixed seizures (myoclonic and tonic-clonic) (",
"    <a class=\"graphic graphic_table graphicRef61530 graphicRef79951 graphicRef68910 \" href=\"mobipreview.htm?18/14/18656\">",
"     table 1A-C",
"    </a>",
"    ). It is administered orally or intravenously; the latter, or the prodrug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/51/14138?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    , can be used in patients who are having active seizures. The initial oral dose is 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in three divided doses, followed by a maintenance dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily in one or two divided doses. Fosphenytoin is administered in phenytoin equivalents (PE). Maintenance oral and intravenous phenytoin doses are roughly equivalent. Initial blood levels should be obtained two to three weeks after the first dose with a goal concentration of 10 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    in patients with normal renal function. In the presence of low serum albumin or other highly protein bound drugs (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ), free levels should be followed with a goal of 1 to 2",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"   </p>",
"   <p>",
"    After an oral or intravenous loading dose, the initial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    blood level can be drawn several hours after the conclusion of the loading dose. The results can be used to guide the determination of the maintenance dose or the need for additional loading. Given the long half-life of phenytoin, serum levels should always be checked within five to seven days following any change (increase or decrease) in the daily dose in order to determine the steady-state serum concentration at the new maintenance dose.",
"   </p>",
"   <p>",
"    Like all AEDs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    dosing should be guided primarily by effect (ie, seizure control) and tolerability. Most, but not all, patients who have normal renal function and serum albumin levels can achieve seizure freedom without side effects with a serum phenytoin concentration of 10 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"   </p>",
"   <p>",
"    A number of drugs can influence the serum concentration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55399 \" href=\"mobipreview.htm?9/26/9645\">",
"     table 3B",
"    </a>",
"    ). Renal failure impairs the protein-binding of phenytoin; the pharmacologically active free concentration may increase relative to the total concentration.",
"   </p>",
"   <p>",
"    Commercially available brand and generic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    products may differ in phenytoin content and other formulation characteristics that can affect bioavailability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/31\">",
"     31",
"    </a>",
"    ]. These differences may occasionally result in an increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/32\">",
"     32",
"    </a>",
"    ] or decrease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/33-35\">",
"     33-35",
"    </a>",
"    ] in serum phenytoin levels, which in turn might adversely affect seizure control or cause toxicity when patients are switched from one preparation to another. Therefore, more frequent serum levels and heightened clinical vigilance may be warranted when substituting phenytoin formulations in patients with difficult-to-control seizures or those prone to side effects, particularly in light of phenytoin's nonlinear kinetics and relatively narrow therapeutic window.",
"   </p>",
"   <p>",
"    The major systemic side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    are gingival hypertrophy, body hair increase, rash, and lymphadenopathy (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"mobipreview.htm?2/17/2334\">",
"     table 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who develop a rash with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      are more likely to develop one with CBZ and vice versa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/11\">",
"       11",
"      </a>",
"      ]. Phenytoin has been associated with the Stevens-Johnson syndrome and toxic epidermal necrolysis, particularly during the first eight weeks of therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. As with CBZ, this reaction appears to be more common in patients with the HLA-B*1502 allele, which occurs almost exclusively in patients of Asian ancestry, including South Asian Indians [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. However, the magnitude of the risk of phenytoin in these patients is less clear than with CBZ. In a November 2008 alert, the FDA recommends avoiding substituting phenytoin for CBZ in patients who test positive for HLA-B*1502 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       Folic acid",
"      </a>",
"      supplementation 0.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      was associated with a reduced incidence of gingival hyperplasia (21 versus 88 percent) after six months in a randomized trial of children (ages 6 to 15 years) who were recently started on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age-related sexual dysfunction and low testosterone levels are more common in men taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      than in controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neurotoxic side effects include confusion, slurred speech, double vision, ataxia, and neuropathy (with long-term use).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lamotrigine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cellular mechanism of action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    (LTG) is not completely understood, and it may have multiple effects. In rodent brain preparations, LTG blocks the repetitive firing of neurons by inactivating voltage-dependent sodium channels (",
"    <a class=\"graphic graphic_table graphicRef61530 graphicRef79951 graphicRef68910 \" href=\"mobipreview.htm?18/14/18656\">",
"     table 1A-C",
"    </a>",
"    ). However, there is some evidence that LTG, unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , may selectively influence neurons that synthesize glutamate and aspartate, since it diminishes the release of these excitatory neurotransmitters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. These findings suggest that the anticonvulsant effect of LTG may relate to actions on synaptic as well as membrane functions.",
"   </p>",
"   <p>",
"    LTG is approved by the US Food and Drug Administration as adjunctive treatment of partial seizures in adults and children, as well as for adjunctive therapy for primary generalized tonic-clonic seizures and Lennox-Gastaut syndrome (",
"    <a class=\"graphic graphic_table graphicRef61530 graphicRef79951 \" href=\"mobipreview.htm?15/42/16047\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/42-46\">",
"     42-46",
"    </a>",
"    ]. Guidelines issued by the American Academy of Neurology (AAN) state that LTG can be used as initial therapy in patients with newly diagnosed partial epilepsy and idiopathic generalized epilepsy, as well as mixed seizure disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/42\">",
"     42",
"    </a>",
"    ]. LTG may also be used for the treatment of newly diagnosed absence seizures in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/42\">",
"     42",
"    </a>",
"    ]. One prospective study in more than 200 patients suggested that it is safe and possibly efficacious for partial seizures in infants aged 1 to 24 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. However, LTG is not approved by the US Food and Drug Administration (FDA) for these indications.",
"   </p>",
"   <p>",
"    An extended release formulation of LTG, which can be given once as opposed to twice daily, provides more stable serum concentrations than the immediate release formulation, and in one trial was shown to be effective as an adjunctive therapy for partial seizure in individuals greater than 12 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/49\">",
"     49",
"    </a>",
"    ]. This formulation is not currently available in the United States. Substitution of extended-release LTG in the same total daily dose as immediate-release LTG results in maintenance of trough concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LTG is quickly and totally absorbed when given orally, and plasma concentrations have an apparent linear relationship to dose. The drug is approximately 55 percent bound to plasma proteins, and the liver metabolizes LTG to inactive glucuronide conjugates excreted in the urine. Serum concentrations of LTG are not influenced by interactions with most non-AEDs. However, drug levels are markedly increased by an interaction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , which inhibits glucuronidation, the main metabolic pathway of LTG (",
"    <a class=\"graphic graphic_table graphicRef80801 graphicRef55399 graphicRef53463 \" href=\"mobipreview.htm?0/4/72\">",
"     table 3A-C",
"    </a>",
"    ). Levels are decreased in the presence of enzyme-inducing drugs (including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , and to a lesser extent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/51\">",
"     51",
"    </a>",
"    ]. This interaction leads to two different dosing schemes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients taking an AED that induces hepatic enzymes (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , or mysoline), the initial dose is 25 mg twice daily, increasing to 50 mg per day after two weeks and titrating upward by 50 mg per day increments every one to two weeks as needed.",
"     </li>",
"     <li>",
"      For patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , the initial dose is 12.5 to 25 mg every other day, with increases of 25 mg every two weeks as needed to a maximum of 300 to 500 mg per day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therapeutic serum levels of LTG have not been definitively established. However, data from 811 patients who took LTG as monotherapy or adjunctive therapy revealed a significant correlation between LTG serum concentrations and clinical toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/52\">",
"     52",
"    </a>",
"    ]. Toxicity was defined as any side effect that required a dose decrease or discontinuation of LTG. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Toxicity increased with increasing serum LTG levels; 7 percent of patients developed toxicity at &lt;5.0",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      compared with 59 percent at &gt;20",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"     </li>",
"     <li>",
"      Toxicity was uncommon at the most frequently encountered serum concentrations (&lt;10",
"      <span class=\"nowrap\">",
"       microgram/mL).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To put this in perspective, the highest LTG level encountered in any of the major LTG clinical trials was 8.8",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    and most patients in those trials had LTG levels in the low single digits (1.53 to 3.60",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/52\">",
"     52",
"    </a>",
"    ]. Thus, the authors of this study suggest an initial target range of 1.5 to 10",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for LTG therapy, while noting that efficacy may increase at higher levels for patients with refractory seizures.",
"   </p>",
"   <p>",
"    Hormone replacement therapy and oral contraceptive agents increase LTG clearance and are associated with decreased LTG blood levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/53-59\">",
"     53-59",
"    </a>",
"    ]. This can result in increased concentrations during the \"placebo\" week used with many preparations, with decreases when the active drug is resumed. This effect appears to be limited to contraceptives containing ethinyl estradiol; progesterone-only compounds have not been found to alter LTG levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/53\">",
"     53",
"    </a>",
"    ]. LTG clearance also increases by about 65 percent in pregnancy and may lead to an increase in seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Co-medication with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    appears to attenuate the increased clearance of LTG that is associated with pregnancy and oral contraceptive use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/62\">",
"     62",
"    </a>",
"    ]. Frequent monitoring of LTG serum levels and appropriate dose adjustments are advised when oral contraceptive therapy is initiated or withdrawn and during pregnancy and after delivery to avoid significant fluctuations in LTG levels.",
"   </p>",
"   <p>",
"    LTG is excreted in breast milk and may lead to significant serum levels in breast fed infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In older adults, LTG clearance is reduced by approximately 20 percent compared to younger adults, leading to a concomitant increase in adverse effects in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic side effects of LTG include rash and nausea (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"mobipreview.htm?2/17/2334\">",
"     table 4A-B",
"    </a>",
"    ). A benign rash may develop in up to 10 percent of patients during the initial one to two months of therapy and necessitates discontinuation of the drug. Patients who have previously had a rash with another AED are more likely to experience rash with LTG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/11,17,65\">",
"     11,17,65",
"    </a>",
"    ]. The risk of developing a life-threatening rash such as Stevens-Johnson syndrome, toxic epidermal necrolysis, or angioedema is approximately 1 in 1000 adults; this risk is increased in children. LTG is also rarely associated with acute multi-organ failure, hypersensitivity reactions and disseminated intravascular coagulation.",
"   </p>",
"   <p>",
"    Neurotoxic side effects are predominantly dizziness and somnolence. In rare cases, LTG has exacerbated or initiated myoclonus and even myoclonic status in juvenile myoclonic and other idiopathic generalized epilepsies and also in Unverricht-Lundborg disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. This disappears with withdrawal of the medication and sometimes with lowering the dose. The risk of this side effect is low, and LTG is still considered a treatment option in these patients. LTG intoxication after deliberate overdose has been associated with status epilepticus in one patient with localization-related epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aseptic meningitis was reported in the FDA Adverse Event Reporting System in 40 patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , according to a 2012 report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/69\">",
"     69",
"    </a>",
"    ]. Fifteen cases were associated with a recurrence of symptoms on rechallenge, which suggests that the association is likely causal, however, drug-induced meningitis always requires exclusion of an infectious etiology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/3/15417?source=see_link\">",
"     \"Aseptic meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Oxcarbazepine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     Oxcarbazepine",
"    </a>",
"    is a compound with a similar chemical structure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and likely a similar mechanism of action (",
"    <a class=\"graphic graphic_table graphicRef61530 graphicRef79951 graphicRef68910 \" href=\"mobipreview.htm?18/14/18656\">",
"     table 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/70\">",
"     70",
"    </a>",
"    ]. The efficacy of oxcarbazepine is comparable to carbamazepine and other first line therapies for partial and secondarily generalized tonic clonic seizures (",
"    <a class=\"graphic graphic_table graphicRef79951 \" href=\"mobipreview.htm?15/16/15630\">",
"     table 1B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/42,43,70-72\">",
"     42,43,70-72",
"    </a>",
"    ]. However, it is considerably more expensive than the older drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     Oxcarbazepine",
"    </a>",
"    is almost completely absorbed regardless of food intake. Serum concentrations of its active metabolite, 10-monohydroxy metabolite (MHD), reach a peak in four to six hours, with a half-life of 8 to 10 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/70\">",
"     70",
"    </a>",
"    ]. The half-life does not change significantly with chronic administration due to a lack of autoinduction. The concentration of this metabolite decreases during pregnancy and increases after delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/74\">",
"     74",
"    </a>",
"    ]. This, with the observation that oxcarbazepine monotherapy was associated with increased seizures in one large pregnancy registry, supports close clinical monitoring during pregnancy and after delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/75\">",
"     75",
"    </a>",
"    ]. There are little other published data on this drug in pregnancy.",
"   </p>",
"   <p>",
"    Metabolism of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    occurs in the liver, but only minimally affects the cytochrome P450 system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/70\">",
"     70",
"    </a>",
"    ]. This represents a major advantage over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , particularly in patients who require polytherapy.",
"   </p>",
"   <p>",
"    Monotherapy in adults begins with 300 to 600",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    increasing to a dose of 900 to 3000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in two or three divided doses. When more rapid seizure control is desired, oral loading with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    in a dose of 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    appears to be safe and generally well-tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/76\">",
"     76",
"    </a>",
"    ]. In infants and young children, one study showed that higher maintenance doses (60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) were significantly more effective then lower doses (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) when used as adjunctive therapy for partial seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    are sedation, headache, dizziness, rash, vertigo, ataxia, nausea, hyponatremia, and diplopia (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"mobipreview.htm?2/17/2334\">",
"     table 4A-B",
"    </a>",
"    ), which appear to occur in a frequency similar to patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/66,78,79\">",
"     66,78,79",
"    </a>",
"    ]. Studies have also found decreased thyroid hormone levels in patients on both short and long-term treatment with oxcarbazepine; the clinical significance of these findings is not yet known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42632?source=see_link&amp;anchor=H17#H17\">",
"     \"Drug interactions with thyroid hormones\", section on 'Drugs that affect thyroid hormone metabolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rare but serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    use in both children and adults; the median time of onset for reported cases was 19 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/17,82\">",
"     17,82",
"    </a>",
"    ]. These reports prompted the manufacturer and US FDA to issue revised labeling with an updated WARNINGS section in April 2005. In addition, rare multiorgan hypersensitivity reactions have occurred in close temporal association (median time to detection 13 days; range 4 to 60 days) to the initiation of oxcarbazepine therapy in both children and adults. Rare cases of anaphylaxis and angioedema have been reported in patients taking a first or subsequent dose of oxcarbazepine. If a patient develops one of these reactions, the drug should be discontinued permanently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    is due at least in part to increased responsiveness of collecting tubules to antidiuretic hormone, and it is considered to be one of the forms of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of hyponatremia associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    therapy may be higher than that seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. The following observations have been made about the incidence of this complication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyponatremia occurred in 23 percent of patients in a postmarketing study, but only 1 percent of patients discontinued",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      because of hyponatremia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/85\">",
"       85",
"      </a>",
"      ]. Hyponatremia may be less common in children than in adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/86,87\">",
"       86,87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum sodium values below 125",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      emerged during the first months in 3 percent of patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      in clinical trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/88\">",
"       88",
"      </a>",
"      ]. A cross-sectional analysis of an epilepsy patient database found a prevalence of 12.4 percent for sodium levels less than 128",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      among patients taking oxcarbazepine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elderly patients, particularly those on concomitant natriuretic drugs, are significantly more likely to develop hyponatremia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/84,89\">",
"       84,89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyponatremia typically develops gradually in the first few months of therapy, which may explain why most patients are asymptomatic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Evidence for a dose relationship between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      and hyponatremia is conflicting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/84,91,92\">",
"       84,91,92",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although symptoms attributable to hyponatremia are to some degree related to the severity of the abnormality, the rate of onset is of primary importance. Acute hyponatremia can cause cerebral edema, which can lead to encephalopathy and seizures. Because of a cerebral adaptation, the degree of cerebral edema is less with chronic hyponatremia, and most patients seem to be asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     Oxcarbazepine",
"    </a>",
"    -related hyponatremia tends to be mild, asymptomatic, and reversible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/85,90\">",
"     85,90",
"    </a>",
"    ], and overall tolerability of oxcarbazepine appears to be better than that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    . There is no need to measure the serum sodium concentration at baseline or during oxcarbazepine or carbamazepine therapy unless the patient has some other predisposing factor such as renal failure or a central nervous system lesion that itself causes the syndrome of inappropriate ADH secretion, or the patient has suggestive symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cessation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    therapy because of hyponatremia is uncommon, being required in only 1 percent of patients in a postmarketing study. For patients with mild to moderate asymptomatic hyponatremia, the oxcarbazepine can be continued and, if deemed necessary, water restriction and a high salt intake can be initiated in an attempt to raise the serum sodium concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17306?source=see_link\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Zonisamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     Zonisamide",
"    </a>",
"    is a sulfonamide derivative that is chemically and structurally unrelated to other anticonvulsants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/93\">",
"     93",
"    </a>",
"    ]. Its primary mechanism of action appears to be to blocking both voltage dependent sodium and T-type calcium channels (",
"    <a class=\"graphic graphic_table graphicRef61530 graphicRef79951 graphicRef68910 \" href=\"mobipreview.htm?18/14/18656\">",
"     table 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     Zonisamide",
"    </a>",
"    is a broad spectrum agent that has been proven effective in randomized, controlled trials as add-on therapy for both partial and generalized seizures (",
"    <a class=\"graphic graphic_table graphicRef61530 graphicRef79951 graphicRef68910 \" href=\"mobipreview.htm?18/14/18656\">",
"     table 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/42,43,95-97\">",
"     42,43,95-97",
"    </a>",
"    ]. Zonisamide also appears to be effective for myoclonic epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Observational studies and one randomized non-inferiority trial with a comparison to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    suggest that it is effective in monotherapy as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/100-103\">",
"     100-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended initial daily dose is 100 to 200 mg per day in two divided doses. Because of its long half-life, once a day dosing is often effective. The dose is increased at two-week intervals to a target maintenance dose of 400 to 600 mg per day, although higher doses may be necessary in some patients. Drug interactions are limited; however, clearance may be increased when used with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/104\">",
"     104",
"    </a>",
"    ]. Adjustments of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    dose may be required when these drugs are added or removed.",
"   </p>",
"   <p>",
"    The most commonly reported side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    are somnolence, ataxia, anorexia, confusion, abnormal thinking, nervousness, fatigue, and dizziness; in children, decreased sweating and fever have been reported (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"mobipreview.htm?2/17/2334\">",
"     table 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/95,96,102\">",
"     95,96,102",
"    </a>",
"    ]. Most of these are self-limited, and the likelihood of adverse effects can be reduced by gradually titrating the dose over four to eight weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/105\">",
"     105",
"    </a>",
"    ]. However, in one study, cognitive deficits associated with initiation of zonisamide treatment were dose-related and persisted one year after treatment was started [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/106\">",
"     106",
"    </a>",
"    ]. In another study, cognitive and psychiatric side effects (including depression, psychosis, and aggression) led to discontinuation of zonisamide in 5.8 and 6.9 percent respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/107\">",
"     107",
"    </a>",
"    ]. A past history of psychiatric symptoms and symptomatic generalized epilepsy were risk factors for psychiatric side effects.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     Zonisamide",
"    </a>",
"    is a weak carbonic anhydrase inhibitor. Nephrolithiasis was reported in 3.7 percent of patients in an early clinical trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/108\">",
"     108",
"    </a>",
"    ], but later studies found a much lower risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23973?source=see_link&amp;anchor=H5#H5\">",
"     \"Nephrolithiasis in renal tubular acidosis\", section on 'Carbonic anhydrase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lacosamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/19/35125?source=see_link\">",
"     Lacosamide",
"    </a>",
"    selectively enhances slow inactivation of voltage-dependent sodium channels; this results in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/109-111\">",
"     109-111",
"    </a>",
"    ]. Lacosamide also binds to the collapsin response mediator protein 2 (CRMP2), which may be involved in epileptogenesis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/19/35125?source=see_link\">",
"     Lacosamide",
"    </a>",
"    is approved by the European Commission and the FDA as an adjunctive therapy for partial-onset seizures in patients aged 17 years and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/109\">",
"     109",
"    </a>",
"    ]. In three clinical trials, a 50 percent or greater reduction in seizure frequency for placebo, lacosamide 200 mg per day, and lacosamide 400 mg per day occurred in 23, 34, and 40 percent respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/109,110,112-114\">",
"     109,110,112-114",
"    </a>",
"    ]. The efficacy of lacosamide 600 mg per day was similar to 400 mg per day but was less well tolerated. Secondary efficacy analysis suggested that the 600 mg per day dose of lacosamide may provide additional benefits in certain subgroups of patients, specifically those with secondary generalized seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/113\">",
"     113",
"    </a>",
"    ]. An open-label extension of one clinical trial demonstrated that lacosamide was safe and generally well tolerated, with maintenance of efficacy among responders up to five years after treatment initiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/115\">",
"     115",
"    </a>",
"    ]. Other reports document similar efficacy for partial-onset seizures in younger patients, ages 1 to 21 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/116,117\">",
"     116,117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/19/35125?source=see_link\">",
"     Lacosamide",
"    </a>",
"    is available as an oral tablet and intravenous injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/109\">",
"     109",
"    </a>",
"    ]. It is completely absorbed after oral administration with 100 percent bioavailability and is eliminated by renal excretion and biotransformation. Dose adjustment should be made in patients with hepatic or renal impairment and should be supplemented after hemodialysis. Lacosamide is not a significant hepatic-enzyme inducer, and has little drug-drug interaction with other AEDs.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/19/35125?source=see_link\">",
"     Lacosamide",
"    </a>",
"    should be initiated at a dose of 50 mg twice per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/109\">",
"     109",
"    </a>",
"    ]. The dose may be increased at weekly intervals by 100 mg per day to a maintenance dose of 200 to 400 mg per day.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/19/35125?source=see_link\">",
"     Lacosamide",
"    </a>",
"    is well tolerated. Dizziness, nausea, vertigo, abnormal coordination and ataxia are the most frequently reported side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/110,114,115,118\">",
"     110,114,115,118",
"    </a>",
"    ]. One case series described an increase in these symptoms when lacosamide was co-prescribed with other AEDs that block voltage dependent sodium channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/119\">",
"     119",
"    </a>",
"    ]. Observed changes on electrocardiogram in some studied patients suggest caution in prescribing lacosamide to those with preexisting cardiac disease. Symptomatic second-degree atrioventricular block occurred in a patient after lacosamide was added to an AED regimen that included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , which is also associated with prolongation of the PR interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/120\">",
"     120",
"    </a>",
"    ]. One case report describes atrial",
"    <span class=\"nowrap\">",
"     flutter/fibrillation",
"    </span>",
"    in a patient on high-dose lacosamide, which resolved with drug discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/121\">",
"     121",
"    </a>",
"    ]. Another case series describes exacerbation of seizures with lacosamide in three patients with Lennox Gastaut syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rufinamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/30/5606?source=see_link\">",
"     Rufinamide",
"    </a>",
"    is structurally unrelated to other marketed AEDs. Rufinamide modulates the activity of sodium channels, prolonging the inactive state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/123\">",
"     123",
"    </a>",
"    ]. This action is particularly effective in depolarized neurons.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/30/5606?source=see_link\">",
"     Rufinamide",
"    </a>",
"    is approved by the FDA as an adjunctive treatment for seizures associated with Lennox Gastaut syndrome (LGS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/123\">",
"     123",
"    </a>",
"    ]. In a randomized study of 138 patients with LGS, rufinamide was associated with a greater reduction in seizure frequency (33 versus 12 percent), drop attacks (43 versus 1 percent), and seizure severity compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/124\">",
"     124",
"    </a>",
"    ]. Observational studies suggest that rufinamide might be effective in other severe generalized epilepsy syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/125,126\">",
"     125,126",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/30/5606?source=see_link\">",
"     Rufinamide",
"    </a>",
"    may have efficacy in other seizure types as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/127\">",
"     127",
"    </a>",
"    ]. In a randomized trial of 313 adolescents and adults with refractory partial seizures, rufinamide 3200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was effective as an adjunctive agent, producing a &gt;50 percent seizure reduction in 28 percent of patients, compared with 19 percent of placebo-treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/128\">",
"     128",
"    </a>",
"    ]. Another randomized study in 357 patients with refractory partial epilepsy found that rufinamide was effective as adjunctive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacokinetic studies show slow absorption (four to six hours to peak concentration) after oral ingestion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/123\">",
"     123",
"    </a>",
"    ]. Co-ingestion with food increases the extent of absorption.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/30/5606?source=see_link\">",
"     Rufinamide",
"    </a>",
"    is not metabolized by P450 mechanisms and has little effect on the pharmacokinetics of other AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/123,130\">",
"     123,130",
"    </a>",
"    ]. However, potent P450 inducers (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30952?source=see_link\">",
"     primidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ) may increase the clearance of rufinamide.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     Valproate",
"    </a>",
"    is associated with reduced clearance of rufinamide. Rufinamide may reduce the effectiveness of oral hormonal contraceptives. Elimination of rufinamide occurs primarily through renal excretion.",
"   </p>",
"   <p>",
"    In children, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/30/5606?source=see_link\">",
"     rufinamide",
"    </a>",
"    is initiated at a daily dose of 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two divided doses, increased by 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    increments every other day to a target dose of 45",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day or 3200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/123\">",
"     123",
"    </a>",
"    ]. Adults are treated initially at 400 to 800 mg per day in two divided doses, increased by 400 to 800 mg per day every two days until maximum daily dose of 3200 mg is achieved.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/30/5606?source=see_link\">",
"     Rufinamide",
"    </a>",
"    is well-tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/124-126,129,131\">",
"     124-126,129,131",
"    </a>",
"    ]. The most common side effects are somnolence and vomiting. Observed shortening of the QT interval on ECG studies of patients taking rufinamide was not associated with clinical events, however, rufinamide should be avoided in patients with short QT syndrome or taking other drugs that shorten the QT interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/123\">",
"     123",
"    </a>",
"    ]. The multi-organ hypersensitivity syndrome described with other AEDs has been reported in patients taking rufinamide; all cases have occurred within four weeks of start of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DRUGS THAT AFFECT CALCIUM CURRENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three types of calcium channels in neurons, each of which is distinguished by its rate of reactivation and voltage dependency. Low-threshold T-type calcium currents inactivate quickly and have been described in experimental preparations of thalamic relay neurons. These neurons probably are an integral component of the thalamocortical circuits associated with absence seizures, a subtype of generalized seizures associated with brief episodes of staring and a characteristic 3-per-second spike and wave pattern on the electroencephalogram (EEG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ethosuximide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/54/13158?source=see_link\">",
"     Ethosuximide",
"    </a>",
"    diminishes T-type calcium currents in thalamic neurons, which are further reduced as membrane potentials become more hyperpolarized (",
"    <a class=\"graphic graphic_table graphicRef61530 graphicRef79951 graphicRef68910 \" href=\"mobipreview.htm?18/14/18656\">",
"     table 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/133\">",
"     133",
"    </a>",
"    ]. The metabolite of trimethadione, another AED for absence seizures, acts similarly.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/54/13158?source=see_link\">",
"     Ethosuximide",
"    </a>",
"    is effective for the treatment of absence seizures; it has no activity against generalized tonic-clonic or partial seizures (",
"    <a class=\"graphic graphic_table graphicRef61530 graphicRef79951 graphicRef68910 \" href=\"mobipreview.htm?18/14/18656\">",
"     table 1A-C",
"    </a>",
"    ). A randomized clinical trial compared ethosuximide,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    in 453 children with CAE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/134\">",
"     134",
"    </a>",
"    ]. Ethosuximide and valproic acid were found to be more effective than lamotrigine in eliminating seizures; ethosuximide had a more favorable adverse event profile compared with valproic acid.",
"   </p>",
"   <p>",
"    The recommended dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/54/13158?source=see_link\">",
"     ethosuximide",
"    </a>",
"    is 20 to 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in one to three divided doses. Blood levels should be checked initially after one to three weeks, with a goal therapeutic concentration of 40 to 100",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    There are no significant reactions reported with other drugs. The major side effects include nausea, vomiting, sleep disturbance, drowsiness, and hyperactivity (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"mobipreview.htm?2/17/2334\">",
"     table 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DRUGS THAT AFFECT GABA ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma-aminobutyric acid (GABA) is a neurotransmitter that is widely distributed throughout the central nervous system and exerts postsynaptic inhibition. The GABA(A) receptor complex has binding sites for GABA, benzodiazepines, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    . Picrotoxin and other similar proconvulsants bind to the GABA(A) receptor and block chloride channels, thereby preventing postsynaptic inhibition. Thus, reduced GABAergic tone is viewed as epileptogenic, while increasing GABAergic tone generally has an anticonvulsant effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/135-137\">",
"     135-137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Synthesis of GABA is dependent upon the enzyme glutamic acid decarboxylase (GAD), which requires pyridoxine as a coenzyme. Pyridoxine deficient infants lack the capacity to synthesize GABA normally and are prone to seizures. The metabolism of GABA to succinate occurs in presynaptic neurons and glia by means of the mitochondrial enzyme GABA transaminase (GABA-T).",
"   </p>",
"   <p>",
"    Over the past two decades, antiepileptic drugs (AEDs) have been designed to increase the supply of GABA by lowering GABA metabolism by GABA-T, reducing the reuptake of GABA into neurons and glia, or increasing the production of GABA by GAD. Other AEDs have been designed to imitate the action of GABA, while still others improve endogenous GABA-mediated inhibition (",
"    <a class=\"graphic graphic_table graphicRef61530 graphicRef79951 graphicRef68910 \" href=\"mobipreview.htm?18/14/18656\">",
"     table 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Phenobarbital",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    (PBOB) is among the oldest AEDs still in use. It is effective for the treatment of generalized and partial seizures (",
"    <a class=\"graphic graphic_table graphicRef61530 graphicRef79951 \" href=\"mobipreview.htm?15/42/16047\">",
"     table 1A-B",
"    </a>",
"    ). However, its clinical utility is limited by its sedating effects (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"mobipreview.htm?2/17/2334\">",
"     table 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    PBOB binds to the GABA(A) receptor, improving the effect of GABA by extending the duration of GABA-mediated chloride channel openings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/138\">",
"     138",
"    </a>",
"    ]. This process permits an increasing flow of chloride ions across the membrane, causing neuronal hyperpolarization (eg, membrane inhibition to depolarization). Benzodiazepines also bind to the GABA(A) receptor and facilitate the attachment of GABA to its binding site on the receptor. The inhibitory action of endogenous GABA is magnified because benzodiazepines increase the occurrence of chloride channel openings.",
"   </p>",
"   <p>",
"    The oral dose of PBOB is 1 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day; it may also be administered intravenously. Serum PBOB concentrations should be checked three to four weeks after the initial dose, with a goal therapeutic level of 10 to 40",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    A number of drugs can influence the serum concentration of PBOB (",
"    <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80801 graphicRef55399 graphicRef53463 \" href=\"mobipreview.htm?0/4/72\">",
"     table 3A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Tiagabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/22/26982?source=see_link\">",
"     Tiagabine",
"    </a>",
"    (TGB) is a second generation AED that is indicated as adjunctive treatment for partial seizures (",
"    <a class=\"graphic graphic_table graphicRef79951 \" href=\"mobipreview.htm?15/16/15630\">",
"     table 1B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/42,43,139,140\">",
"     42,43,139,140",
"    </a>",
"    ]. It is a potent enhancer of GABA action via specific inhibition of GABA reuptake into presynaptic neurons and glia in vitro (",
"    <a class=\"graphic graphic_table graphicRef61530 graphicRef79951 graphicRef68910 \" href=\"mobipreview.htm?18/14/18656\">",
"     table 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/141\">",
"     141",
"    </a>",
"    ]. Thus it decreases the elimination of GABA from the synaptic space, making endogenously produced GABA more available for post-synaptic inhibitory effects.",
"   </p>",
"   <p>",
"    The initial dose of TGB is 4 to 8",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    It can be titrated in adults at weekly increments of 4 to 8",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    until there is a clinical response, or up to 56",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in divided doses. There are no established therapeutic serum levels. TGB has no significant drug interactions. Major side effects include dizziness, lack of energy, somnolence, nausea, nervousness, tremor, difficulty concentrating, and abdominal pain (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"mobipreview.htm?2/17/2334\">",
"     table 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/140\">",
"     140",
"    </a>",
"    ]. In one study, however, cognitive function after one year of TGB monotherapy was similar to that in untreated controls and those on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/142\">",
"     142",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is concern that TGB has a potential proconvulsive effect. In February 2005, the FDA added a warning label regarding more than 30 reports of seizures, including seven cases of status epilepticus, which were associated with off-label use of TGB for patients without epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/143-145\">",
"     143-145",
"    </a>",
"    ]. This issue is not resolved.",
"   </p>",
"   <p>",
"    TGB has been associated with nonconvulsive status epilepticus in patients being treated for localization-related epilepsy in a number of case reports, but this was not observed in randomized, controlled clinical trials or in long-term safety studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/146\">",
"     146",
"    </a>",
"    ]. In a retrospective review of patients with localization-related epilepsy, 7.8 percent of 90 TGB-treated patients developed nonconvulsive status epilepticus compared with 2.7 percent of the 1165 patients not receiving TGB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/147\">",
"     147",
"    </a>",
"    ]. The frequency of generalized convulsive status epilepticus was not increased. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/1/23578?source=see_link\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The apparent discrepancy between the risk in seizure and nonseizure patients may be explainable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/148\">",
"     148",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TGB was developed and is approved for use as an adjunctive treatment for epilepsy. Virtually all patients treated with TGB in clinical trials were taking at least one hepatic-enzyme inducing AED, which decreased the concentration of TGB; it is likely that patients without epilepsy have increased concentrations of TGB.",
"     </li>",
"     <li>",
"      Another potential contributor is the fact that patients taking TGB for off-label indications (psychiatric disease and pain) are also on other medications that potentially lower seizure threshold.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vigabatrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"     Vigabatrin",
"    </a>",
"    (VGB) is an irreversible inhibitor of GABA-transaminase that raises the concentration of GABA in the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/149\">",
"     149",
"    </a>",
"    ]. It is effective as an add-on agent in patients with refractory partial seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/150\">",
"     150",
"    </a>",
"    ]. It is also useful as monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/151\">",
"     151",
"    </a>",
"    ], although probably less effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    for this purpose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/152,153\">",
"     152,153",
"    </a>",
"    ]. Clinical observations also suggest that it is effective for infantile spasms and partial seizures in children with tuberous sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/154-156\">",
"     154-156",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/28/30154?source=see_link&amp;anchor=H15#H15\">",
"     \"Management and prognosis of infantile spasms\", section on 'Vigabatrin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VGB was approved by the FDA in 2009 for the treatment of infantile spasms and for adjunctive treatment of adults with refractory partial seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/157\">",
"     157",
"    </a>",
"    ]. It is licensed in Canada and in many countries of Europe and Asia. In the United States,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"     vigabatrin",
"    </a>",
"    is available in a limited number of specialty pharmacies as part of a program called SHARE (Support, Help, And Resources for Epilepsy). Only physicians registered with SHARE can prescribe vigabatrin. Further information about registering with SHARE is available at",
"    <span class=\"nowrap\">",
"     file://www.lundbeckshare.com/pg512_important_steps.aspx.",
"    </span>",
"   </p>",
"   <p>",
"    In adults, VGB is started 500 mg twice daily and increased weekly in 500 mg increments to a total recommended dose of 3 g per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/158\">",
"     158",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A boxed warning for VGB alerts clinicians to safety concerns regarding permanent vision loss with this medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/157\">",
"     157",
"    </a>",
"    ]. As many as 30 to 50 percent of patients with long-term exposure to VGB have developed irreversible concentric visual field loss of varying severity that is often asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/159-164\">",
"     159-164",
"    </a>",
"    ]. Most studies have found that higher cumulative dose, as well as older age and male gender increase the risk of vision loss. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/161,164-167\">",
"     161,164-167",
"    </a>",
"    ]. Only 1 of 16 children who had had infantile spasms and were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"     vigabatrin",
"    </a>",
"    for a mean of 21 months had visual field abnormalities at age 6 to12 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/167\">",
"     167",
"    </a>",
"    ]. However, the sample size is small and there may have been selection bias. Visual field deficits have been noted as early as nine months after initiation of treatment, with a mean time to onset of about five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/168\">",
"     168",
"    </a>",
"    ]. VGB treatment in laboratory rats is associated with irreversible injury of cone photoreceptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/169\">",
"     169",
"    </a>",
"    ]. These findings indicate that VGB should be reserved for patients with epilepsy that is refractory to other drugs. Visual field testing should be performed before starting therapy and repeated every six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/168,170\">",
"     168,170",
"    </a>",
"    ]. Optical coherence tomography may be useful to monitor vision in patients who are unable to perform visual field perimetry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/171\">",
"     171",
"    </a>",
"    ]. While animal studies suggest the possibility that reduced light exposure and dietary supplementation with taurine may ameliorate this adverse event, this has not been established in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/172\">",
"     172",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"     Vigabatrin",
"    </a>",
"    has also been reported to produce MRI abnormalities, specifically hyperintense lesions on T2-weighted images with restricted diffusion on diffusion weighted imaging in the basal ganglia, thalamus, brainstem, and dentate nucleus of the cerebellum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/173-175\">",
"     173-175",
"    </a>",
"    ]. These abnormalities appear to occur primarily in infants and only in those who are treated for infantile spasms. The incidence overall is 32 percent and appears to be a dose-related phenomenon. These abnormalities are not clearly associated with new neurologic deficits and normalize when vigabatrin is discontinued. In a few cases, they have been observed to resolve even while vigabatrin was continued.",
"   </p>",
"   <p>",
"    Other frequent adverse events with VGB include drowsiness, fatigue, headache, and dizziness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/152\">",
"     152",
"    </a>",
"    ]. Depression and weight gain also have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines enhance GABA inhibition by increasing the frequency of GABA-mediated chloride channel openings.",
"   </p>",
"   <p>",
"    As a class, the benzodiazepines may be associated with the development of tolerance, limiting their usefulness in the chronic treatment of epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/176\">",
"     176",
"    </a>",
"    ]. Side effects include sedation, irritability, ataxia, and depression. Sudden discontinuation of benzodiazepines may lead to withdrawal seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28483427\">",
"    <span class=\"h3\">",
"     Clobazam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/49/40727?source=see_link\">",
"     Clobazam",
"    </a>",
"    is approved by the US FDA for as an adjunctive therapy in patients &gt;2 years of age with Lennox-Gastaut syndrome (LGS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/177\">",
"     177",
"    </a>",
"    ]. In two clinical trials, adjunctive therapy with clobazam (0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) was associated with significant reduction in seizure frequency compared to patients taking placebo or low dose clobazam (0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/178,179\">",
"     178,179",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33769?source=see_link&amp;anchor=H8#H8\">",
"     \"Epilepsy syndromes in children\", section on 'Lennox-Gastaut syndrome'",
"    </a>",
"    .) Clobazam is widely used in other countries for the treatment of partial seizures.",
"   </p>",
"   <p>",
"    Common adverse effects include those common to benzodiazepines in general as noted above and included somnolence and sedation, as well as drooling, insomnia, aggression, infections, constipation, and others. In more recent clinical trials, the incidence of adverse effects was not significantly different in low-dose, high-dose, or placebo treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/178,179\">",
"     178,179",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients greater than two years of age,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/49/40727?source=see_link\">",
"     clobazam",
"    </a>",
"    may be started at 5 mg per day in one dose, typically given at bedtime. The dose may be increased in intervals no shorter than every five days to a maximum of 40 mg per day. Doses greater than 30 mg per day should be given in a divided schedule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28483420\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     Clonazepam",
"    </a>",
"    is most often used as an adjunctive therapy for myoclonic and atonic seizures.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14023?source=see_link\">",
"     Clorazepate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    are effective for those seizure types as well as for partial and generalized tonic-clonic seizures.",
"   </p>",
"   <p>",
"    The starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    in adults is 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    with weekly increments of 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    as needed.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    (especially rectal diazepam) are usually used as PRN medications for acute repetitive seizures or status epilepticus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1668567\">",
"    <span class=\"h1\">",
"     DRUGS THAT AFFECT GLUTAMATE RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutamate is the most prevalent excitatory neurotransmitter. There are two types of glutamate receptors: ionotropic, which form ion channels that are activated by glutamate binding, and metabotropic, which indirectly activate ion channels via G protein signalling cascade. Two ionotropic glutamate receptors, N-methyl-D-aspartae (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA), are thought to play a role in the generation and spread of seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/180\">",
"     180",
"    </a>",
"    ]. There is currently one AMPA antagonist approved for treatment of seizures, and two other AEDs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/31/25079?source=see_link\">",
"     felbamate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ) that are thought to act in part through NMDA antagonism. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1668575\">",
"    <span class=\"h2\">",
"     Perampanel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/18/7462?source=see_link\">",
"     Perampanel",
"    </a>",
"    is an orally active, noncompetitive AMPA-type glutamate receptor antagonist. It appears to inhibit AMPA-induced increases in intracellular calcium, reducing neuronal excitability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/181\">",
"     181",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is approved by the FDA as an adjunctive treatment of partial-onset seizures in patients aged 12 years and older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/182\">",
"     182",
"    </a>",
"    ]. Randomized trials have found that adjunctive therapy with once daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/18/7462?source=see_link\">",
"     perampanel",
"    </a>",
"    (4 mg to 12 mg per day) resulted in a &gt;50 percent reduction in seizure frequency in 29 to 36 percent of patients with refractory partial epilepsy, compared with 14 to 26 percent in placebo patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/183-185\">",
"     183-185",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/18/7462?source=see_link\">",
"     Perampanel",
"    </a>",
"    is extensively metabolized by the liver, primarily via CYP3A4, CYP3A5, glucuronidation, and potentially other pathways. It has a prolonged and variable half-life (mean 105 hours), which may complicate dose titration and safety wash-out. Dose adjustments are recommended for patients with mild and moderate hepatic impairment, and the drug is not recommended for patients with severe hepatic or renal impairment, including those on hemodialysis. Clearance of perampanel is increased in patients taking concomitant enzyme-inducing AEDs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef80801 \" href=\"mobipreview.htm?6/29/6621\">",
"     table 3A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef55399 \" href=\"mobipreview.htm?9/26/9645\">",
"     table 3B",
"    </a>",
"    ). Strong inhibitors of CYP34A may modestly increase perampanel exposure (",
"    <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"     table 5",
"    </a>",
"    ). When dosed at 12 mg daily, perampanel can decrease the efficacy of levonorgestrel-containing hormonal contraception (",
"    <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"     table 2",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    The recommended starting dose is 2 mg taken once daily at bedtime, increasing by 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    no more frequently than once per week, to a maximum dose of 12 mg daily. Given the long half-life of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/18/7462?source=see_link\">",
"     perampanel",
"    </a>",
"    , it may take up to two weeks to evaluate the full effect (steady state) of a dose adjustment. In patients taking enzyme-inducing AEDs, the recommended starting dose is 4 mg.",
"   </p>",
"   <p>",
"    The most common side effects observed in randomized trials include dizziness, somnolence, fatigue, irritability, gait disturbance, falls, nausea and weight gain (",
"    <a class=\"graphic graphic_table graphicRef59755 \" href=\"mobipreview.htm?3/28/3533\">",
"     table 4A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/183,184\">",
"     183,184",
"    </a>",
"    ]. The licensing information includes a boxed warning of serious neuropsychiatric effects including alteration of mood and aggression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/182\">",
"     182",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DRUGS WITH MULTIPLE MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of antiepileptic drugs (AEDs) have multiple mechanisms by which they prevent seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Valproate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     Valproate",
"    </a>",
"    (valproic acid, VPA) is a broad-spectrum AED used alone and in combination for the treatment of generalized and partial seizures (",
"    <a class=\"graphic graphic_table graphicRef61530 graphicRef79951 \" href=\"mobipreview.htm?15/42/16047\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     \"Valproate: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has multiple cellular mechanisms of action consistent with its broad clinical effectiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/186-189\">",
"     186-189",
"    </a>",
"    ]. VPA seems to suppress high frequency, repetitive neuronal firing by blocking voltage-dependent sodium channels, but at sites different than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    . VPA increases brain gamma-aminobutyric acid (GABA) concentrations at clinically relevant doses, although the basis of this effect is debated. VPA does not seem to have any direct effects on the GABA-alpha receptor, but GABA release may be enhanced by a presynaptic effect of VPA on GABA-beta receptors. Inhibition of nerve terminal GABA transaminase (GABA-T) probably also increases presynaptic GABA levels. Furthermore, VPA may increase GABA synthesis by activating glutamic acid decarboxylase (GAD). Finally, VPA acts against T-type calcium currents, although this action is weaker than that observed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/54/13158?source=see_link\">",
"     ethosuximide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    VPA is tightly protein-bound. It is metabolized in the liver by means of several processes involving oxidation and conjugation. The initial dose is 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses; it may be increased by 5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day every week as needed. A serum level should be checked one to two weeks after the initial dose; therapeutic concentrations are usually in the 50 to 150",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    range. A number of drugs affect the serum level of VPA (",
"    <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53463 \" href=\"mobipreview.htm?38/36/39500\">",
"     table 3C",
"    </a>",
"    ). Oral contraceptive agents may increase VPA clearance and their use is associated with decreased VPA blood levels (median decline 23 percent) during active treatment and higher concentrations during the \"placebo\" week that is used with many preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VPA is available in several formulations, listed here with the corresponding US brand name:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Valproic acid capsule, as Depakene",
"     </li>",
"     <li>",
"      Valproic acid syrup, as Depakene",
"     </li>",
"     <li>",
"      Delayed-release valproic acid, as Stavzor",
"     </li>",
"     <li>",
"      Divalproex sodium capsule sprinkles, as Depakote Sprinkle",
"     </li>",
"     <li>",
"      Delayed release divalproex sodium tablet, as Depakote",
"     </li>",
"     <li>",
"      Extended release divalproex sodium tablet, as Depakote ER",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       Valproate",
"      </a>",
"      sodium injection solution, as Depacon",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    VPA can be delivered by both oral and intravenous (IV) routes. Current prescribing information recommends slow administration of IV VPA (Depacon) over 60 minutes at a rate of &le;20",
"    <span class=\"nowrap\">",
"     mg/minute,",
"    </span>",
"    or more rapid infusion of single doses up to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over 5 to 10 minutes at 1.5 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute. Accumulating evidence suggests that IV VPA can be safely infused at rates up to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute without adverse effects on blood pressure or heart rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/190-195\">",
"     190-195",
"    </a>",
"    ]. Rapid IV loading may be desirable as a way to achieve serum concentrations &gt;100",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    quickly.",
"   </p>",
"   <p>",
"    Side effects of VPA include nausea, vomiting, hair loss, easy bruising, and tremor (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"mobipreview.htm?2/17/2334\">",
"     table 4A-B",
"    </a>",
"    ). VPA is associated with weight gain, obesity, insulin resistance, and the metabolic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/196-199\">",
"     196-199",
"    </a>",
"    ]. VPA can also cause thrombocytopenia and other coagulation disturbances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/200,201\">",
"     200,201",
"    </a>",
"    ] and has also been associated with subclinical hypothyroidism with mild to moderate elevations in thyrotropin (TSH) levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/14,80,202,203\">",
"     14,80,202,203",
"    </a>",
"    ]. VPA has also been linked to the polycystic ovarian syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/204,205\">",
"     204,205",
"    </a>",
"    ]. A number of case reports have linked VPA to Fanconi syndrome in children with severe disabilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/206\">",
"     206",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42632?source=see_link&amp;anchor=H17#H17\">",
"     \"Drug interactions with thyroid hormones\", section on 'Drugs that affect thyroid hormone metabolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40568?source=see_link\">",
"     \"Epidemiology and pathogenesis of the polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VPA-exposure in utero is associated with major malformations and other adverse effects. VPA should be avoided in pregnancy when possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22633?source=see_link&amp;anchor=H6#H6\">",
"     \"Risks associated with epilepsy and pregnancy\", section on 'Valproate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22633?source=see_link&amp;anchor=H12#H12\">",
"     \"Risks associated with epilepsy and pregnancy\", section on 'Long-term effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States between 1978 and 1998, there were 37 fatalities due to hepatic failure attributed to VPA use. Among those receiving monotherapy, the calculated rate of fatality was 1 per 37,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/207\">",
"     207",
"    </a>",
"    ]. The rate was much higher for children under the age of two years and for children receiving polytherapy. There were no liver-related fatalities reported in patients over the age of 10 years who were receiving monotherapy. However, a survey of physicians in Germany revealed nine cases of fatal hepatotoxicity between 1994 and 2003, which included two adults on VPA monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/208\">",
"     208",
"    </a>",
"    ]. Although routine monitoring of hepatic function has not been shown to permit early identification of serious toxicity or improve outcome, many physicians choose to obtain liver function tests (LFTs) once or twice a year in patients who are clinically asymptomatic. The FDA recommends checking LFTs prior to initiating treatment and at frequent intervals thereafter, especially during the first six months.",
"   </p>",
"   <p>",
"    VPA-related hyperammonemic encephalopathy (VHE) causes lethargy, increased seizures, and rarely coma and death. VHE can occur without abnormalities of liver function tests or elevated serum VPA levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/209\">",
"     209",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28264?source=see_link&amp;anchor=H7#H7\">",
"     \"Valproic acid poisoning\", section on 'Valproate-related hyperammonemic encephalopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VPA can rarely cause acute pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/210,211\">",
"     210,211",
"    </a>",
"    ]. Symptoms (abdominal pain and vomiting) are similar to those from pancreatitis from other causes. Patients typically recover, but deaths have been reported. This adverse effect is idiosyncratic and is not related to dose or duration of therapy; rechallenge frequently results in relapse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14297?source=see_link&amp;anchor=H13#H13\">",
"     \"Etiology of acute pancreatitis\", section on 'Drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of case reports and case series have described a syndrome of reversible parkinsonism and cognitive decline associated with VPA use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/212-216\">",
"     212-216",
"    </a>",
"    ]. The reported frequency of this adverse effect ranges from 1.4 to 5 percent among patients with epilepsy who are treated with VPA. Advanced age and prolonged duration of therapy may be risk factors. The parkinsonism does not respond to levodopa therapy, but usually reverses within a few weeks to months after VPA is discontinued.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     Valproate",
"    </a>",
"    has been associated with increased sleep duration in children over six years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/217\">",
"     217",
"    </a>",
"    ]. This is significant only in a minority of patients and appears to resolve off treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Felbamate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/31/25079?source=see_link\">",
"     felbamate",
"    </a>",
"    is not well understood. It blocks the channel at the N-methyl-D-aspartate (NMDA) excitatory amino acid receptor and augments GABA function in rat hippocampal neuronal cultures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/218\">",
"     218",
"    </a>",
"    ]. It is almost totally absorbed by the gastrointestinal tract, approximately 30 percent bound to plasma protein, and metabolized by the hepatic cytochrome P-450 system.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/31/25079?source=see_link\">",
"     Felbamate",
"    </a>",
"    can be used to treat partial seizures; Felbamate can also be used to treat the Lennox-Gastaut syndrome, a mixed seizure disorder of childhood onset associated with multiple seizure types, slow spike-wave electroencephalograms, mental retardation, and resistance to standard AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/219,220\">",
"     219,220",
"    </a>",
"    ]. However, felbamate has been associated with fatal aplastic anemia and hepatic failure (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"mobipreview.htm?2/17/2334\">",
"     table 4A-B",
"    </a>",
"    ). Aplastic anemia may not occur for several months after the start of therapy, may not be reliably detected by routine testing, and may continue to be a risk for patients even after cessation of the drug. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/586?source=see_link\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic blood levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/31/25079?source=see_link\">",
"     felbamate",
"    </a>",
"    have not been established, but patients should have baseline laboratory testing including a complete blood count and liver enzymes. These tests should continue to be monitored every one to two months, and monitoring of the blood counts should continue following cessation of therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/31/25079?source=see_link\">",
"     Felbamate",
"    </a>",
"    is not recommended for first-line therapy of seizures because of the potential for serious adverse reactions; use of this drug is mostly confined to cases of Lennox-Gastaut syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/221\">",
"     221",
"    </a>",
"    ]. The manufacturer recommends that written consent be obtained prior to beginning therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Topiramate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    (TPM) also has multiple mechanisms of action. It blocks voltage-dependent sodium channels, enhances the activity of GABA at a nonbenzodiazepine site on GABA(A) receptors, and antagonizes an NMDA&ndash;glutamate receptor. It also weakly inhibits carbonic anhydrase in the central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/222\">",
"     222",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TPM is effective as adjunctive therapy for the treatment of adults and children over two years in age with partial seizures, and may have efficacy for other seizure types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/42,43,223,224\">",
"     42,43,223,224",
"    </a>",
"    ]. One randomized trial in 151 children (ages 6 to 15 years), reported efficacy for TPM as monotherapy for newly diagnosed epilepsy; seizures were partial onset or generalized-onset tonic clonic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/225\">",
"     225",
"    </a>",
"    ]. A randomized study in infants aged 1 to 24 months found that adjunctive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    (5, 15, or 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) was not effective in reducing refractory partial-onset seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/226\">",
"     226",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    American Academy of Neurology (AAN) guidelines state that TPM may be used as initial therapy for newly diagnosed partial and mixed seizure disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/43\">",
"     43",
"    </a>",
"    ]; the guidelines also state that TPM may be used as monotherapy for refractory generalized tonic-clonic convulsions and partial seizures in adults and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/223\">",
"     223",
"    </a>",
"    ]. However, TPM is not approved by the US Food and Drug administration (FDA) for initial therapy or monotherapy; it is approved for adjunct therapy of partial and primary generalized tonic-clonic seizures.",
"   </p>",
"   <p>",
"    The starting dose of TPM is 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for one week, titrated at weekly increments of 50 mg to an effective dose. One study suggests that the dose can be started at 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    without significant adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/227\">",
"     227",
"    </a>",
"    ]. The recommended total daily dose for adjunctive therapy is 200 mg twice daily. Therapeutic levels have not been established. TPM's clearance is increased twofold by enzyme-inducing agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ), requiring twofold increased dosages in this setting. TPM may increase phenytoin concentration, but there do not appear to be any clinically significant interactions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef80801 graphicRef55399 graphicRef53463 \" href=\"mobipreview.htm?0/4/72\">",
"     table 3A-C",
"    </a>",
"    ). One case series reported that TPM serum levels decline by about 30 percent during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/228\">",
"     228",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weight loss is a common dose-related side effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/229,230\">",
"     229,230",
"    </a>",
"    ]. In a double-blind placebo-controlled trial of TPM added to existing AEDs in 264 patients, TPM was associated with a 2.0 kg mean decrease in weight at three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/230\">",
"     230",
"    </a>",
"    ]. A smaller, uncontrolled trial found that at one year weight loss occurred in 86 percent with a mean cumulative weight loss of 5.9 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/231\">",
"     231",
"    </a>",
"    ]. Weight loss is associated with fat loss and correlates with reduced caloric intake. Follow-up studies suggest that weight loss stabilizes after two to three years of taking the medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/232\">",
"     232",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Impaired cognition is a reported side effect in a minority of patients taking TPM, but it is a common reason for discontinuing therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/230,233\">",
"     230,233",
"    </a>",
"    ]. Studies suggest that this may be a more common phenomenon than patient complaints would indicate, and at least in some studies, appears to be dose-related [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/234-239\">",
"     234-239",
"    </a>",
"    ]. Impaired cognitive measures with TPM have been recorded in studies of healthy adult volunteers compared to their own baseline as well as to non-drug control patients and to patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/234-236,240\">",
"     234-236,240",
"    </a>",
"    ]. Cognitive and behavioral worsening have also been observed in children with mental retardation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/241\">",
"     241",
"    </a>",
"    ]. Adults treated for epilepsy and children treated for obesity have similar cognitive side effects from TPM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/237,238\">",
"     237,238",
"    </a>",
"    ]. The observed cognitive deficits are broad in spectrum but appear to be reversible when the drug is discontinued and attenuated with dose reductions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/235,238,242\">",
"     235,238,242",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other side effects of TPM include paresthesias, headache, fatigue, dizziness, depression, and mood problems (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"mobipreview.htm?2/17/2334\">",
"     table 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/243\">",
"     243",
"    </a>",
"    ]. The incidence of most side effects decreases with continued dosing; weight loss and paresthesia are the exceptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/230\">",
"     230",
"    </a>",
"    ]. Slower titration of the dose following initiation of therapy may also improve tolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/244\">",
"     244",
"    </a>",
"    ]. Despite reports of a high frequency of somnolence when TPM was used as add-on therapy in patients with epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/245\">",
"     245",
"    </a>",
"    ], monotherapy with TPM 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    does not appear to impair daytime vigilance in adult patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/246\">",
"     246",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TPM has been associated with decreased sweating leading to heat intolerance and hyperthermia, particularly in children; there have also been case reports of decreased sweating in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/247,248\">",
"     247,248",
"    </a>",
"    ]. Acute myopia and secondary angle glaucoma, characterized by the acute onset of decreased visual acuity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ocular pain, also have been reported with TPM therapy (23 cases out of approximately 825,000 users), typically within one month of initiating treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/249,250\">",
"     249,250",
"    </a>",
"    ]. Chronic users of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    do not appear to be at increased risk of glaucoma. A few case reports have linked TPM with an apparently irreversible maculopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/251\">",
"     251",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Metabolic acidosis may result from renal bicarbonate loss due to the inhibitory effect of TPM on carbonic anhydrase, which can cause both proximal and distal acidification defects. The following observations have been made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/252,253\">",
"     252,253",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic acidosis is common, occurring in 32 to 44 percent of adults and 67 percent of children.",
"     </li>",
"     <li>",
"      It is dose-related and usually mild with an average decrease in serum bicarbonate of 4",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      at daily doses of TPM 400 mg in adults and 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in children. However, reductions in serum bicarbonate of as much as 10",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      have been described.",
"     </li>",
"     <li>",
"      It is most likely to occur early in treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The main clinical manifestation of metabolic acidosis is tachypnea, although calcium phosphate nephrolithiasis can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/254\">",
"     254",
"    </a>",
"    ], presumably via a mechanism similar to that seen with other carbonic anhydrase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/255,256\">",
"     255,256",
"    </a>",
"    ] and perhaps",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/3\">",
"     3",
"    </a>",
"    ]. It is not known if the risk of nephrolithiasis is increased when two carbonic anhydrase inhibitors are used concurrently. In one series of children on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    for one year or longer, an ultrasound revealed asymptomatic kidney stones in 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/257\">",
"     257",
"    </a>",
"    ]. If this finding is confirmed, this frequency may warrant use of baseline and follow-up ultrasound in children on chronic topiramate therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23973?source=see_link&amp;anchor=H5#H5\">",
"     \"Nephrolithiasis in renal tubular acidosis\", section on 'Carbonic anhydrase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measuring serum bicarbonate at baseline and periodically (for example, every two to four months) is recommended. Gradual dose reduction or cessation of TPM (after tapering) is advised if significant metabolic acidosis develops. Alkali treatment may be helpful if TPM is continued in patients with symptoms or more marked acidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/252\">",
"     252",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5860?source=see_link\">",
"     \"Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    exposure in utero may be associated with an increased risk of oral clefts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/258-260\">",
"     258-260",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22633?source=see_link&amp;anchor=H26477904#H26477904\">",
"     \"Risks associated with epilepsy and pregnancy\", section on 'Topiramate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DRUGS WITH OTHER MECHANISMS OF ACTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Gabapentin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    binds to the auxiliary alpha-2-delta subunit of a voltage-dependent calcium channel, which may inhibit inward calcium currents and attenuate neurotransmitter release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/261\">",
"     261",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     Structure/activity",
"    </span>",
"    studies of gabapentin and related compounds show a strong correlation between binding at this receptor and anticonvulsant activity, further supporting that this is the site of action relevant in epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/262,263\">",
"     262,263",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    is used as add-on therapy for refractory partial seizures (",
"    <a class=\"graphic graphic_table graphicRef79951 \" href=\"mobipreview.htm?15/16/15630\">",
"     table 1B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/43\">",
"     43",
"    </a>",
"    ]. The American Academy of Neurology (AAN) guidelines state that gabapentin may also be used as initial monotherapy in newly diagnosed partial epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/42\">",
"     42",
"    </a>",
"    ], although it is not approved by the United States Food and Drug administration (FDA) for this indication. Gabapentin has not been approved in the United States for use in children.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    is absorbed by means of amino acid transport systems in the gut [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/264\">",
"     264",
"    </a>",
"    ]. The drug does not bind to plasma protein and is not metabolized; it is excreted entirely in the urine, corresponding with the creatinine clearance; the dose should be adjusted in patients with impaired renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/265,266\">",
"     265,266",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    is 300 mg the first day, 300 mg twice daily the second day, 300 mg three times a day on the third day, and then increased as needed to 1800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in three divided doses. A rapid initiation schedule, with a starting dose of 900",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    also appears to be well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/267\">",
"     267",
"    </a>",
"    ]. There are no established therapeutic serum levels.",
"   </p>",
"   <p>",
"    A major advantage of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    is that it has no significant drug interactions, making it ideal for use in combination with other antiepileptic drugs (AEDs). However, it should be taken at least two hours after the use of antacids since concurrent administration decreases the bioavailability of gabapentin. The major side effect is sedation (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"mobipreview.htm?2/17/2334\">",
"     table 4A-B",
"    </a>",
"    ); it appears to have fewer adverse cognitive effects than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/268\">",
"     268",
"    </a>",
"    ]. In the setting of chronic kidney disease, toxic side effects are more common, especially in older patients and those with comorbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/266\">",
"     266",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In studies of six women taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    during pregnancy, there was evidence of active transplacental transport and accumulation of the drug in the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/269\">",
"     269",
"    </a>",
"    ]. Gabapentin is also transferred to breast milk. In this limited series, no adverse consequences of gabapentin on the newborn were seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Levetiracetam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"     Levetiracetam",
"    </a>",
"    (LEV) is a broad spectrum AED and is approved as adjunctive therapy to treat partial-onset seizures in patients aged 4 years or older with epilepsy, as adjunctive therapy in treating myoclonic seizures in patients aged 12 years or older with juvenile myoclonic epilepsy, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (",
"    <a class=\"graphic graphic_table graphicRef61530 graphicRef79951 graphicRef68910 \" href=\"mobipreview.htm?18/14/18656\">",
"     table 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/42,43,270-278\">",
"     42,43,270-278",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized, placebo-controlled trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/279\">",
"     279",
"    </a>",
"    ], as well as other open-label studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/280-283\">",
"     280-283",
"    </a>",
"    ], has found that LEV is also effective as adjunctive therapy in very young children (neonates to age 4 years). Uncontrolled studies suggest that LEV may also be effective as monotherapy in patients with partial seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/284-286\">",
"     284-286",
"    </a>",
"    ]. In a randomized clinical trial in adults with newly diagnosed epilepsy, LEV had similar efficacy and tolerability compared with controlled-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/287\">",
"     287",
"    </a>",
"    ]. Finally, uncontrolled studies support the use of LEV as adjunctive therapy in patients with infantile spasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/288-290\">",
"     288-290",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of action for LEV is unknown. However, LEV binds to the synaptic vesicle protein SV2A, which has been linked in animal models to epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/291,292\">",
"     291,292",
"    </a>",
"    ]. Binding at this site may modulate synaptic transmission through alteration of vesicle fusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/293\">",
"     293",
"    </a>",
"    ]. There is also evidence that LEV indirectly modulates GABA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/294,295\">",
"     294,295",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LEV is an attractive AED for several reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/93\">",
"     93",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolism is independent of the cytochrome P450 (CYP) system, limiting the potential for pharmacokinetic interaction with other antiepileptic drugs. Some studies have found that coadministration of enzyme-inducing antiepileptic drugs is associated with an approximate 25 percent increase in LEV clearance; however, this is felt to have limited clinical significance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/296\">",
"       296",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      LEV does not act as an inducer of the CYP system; thus, there is little potential for pharmacokinetic interactions with other drugs, such as oral contraceptives, or immunosuppressant drugs commonly used in organ transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/297,298\">",
"       297,298",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      LEV does not require a titration period, and it appears to have a very rapid onset of action as demonstrated by a significant increase in the proportion of patients who achieved seizure-free status on the first day of LEV 500 mg twice daily treatment compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/299\">",
"       299",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The drug is relatively well tolerated. The most common adverse events include fatigue, somnolence, dizziness, and infection (upper respiratory) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/277\">",
"       277",
"      </a>",
"      ]. Most adverse events associated with LEV are mild to moderate in intensity and most often occur during the initial titration phase (",
"      <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"mobipreview.htm?2/17/2334\">",
"       table 4A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      An intravenous formulation of LEV has been approved for use in clinical situations when patients are temporarily unable to take oral medication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/281,300,301\">",
"       281,300,301",
"      </a>",
"      ]. Intravenous infusion of LEV is bioequivalent to oral tablets.",
"     </li>",
"     <li>",
"      An extended-release formulation of LEV is available; studies suggest that it is comparably effective and well tolerated as a once-daily medication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/302-304\">",
"       302-304",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a postmarketing surveillance study of 373 patients at a single epilepsy center, both the efficacy of LEV and cumulative probability of 74 percent for remaining on LEV at 12 months compared favorably with published data for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"     vigabatrin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/305\">",
"     305",
"    </a>",
"    ]. This was corroborated in a larger, multicenter study in which a 58 percent three-year retention rate was estimated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/306\">",
"     306",
"    </a>",
"    ]. Sedation was the most common side effect of LEV, occurring in 38 patients (10.7 percent), but mood disturbance was not rare (17 patients or 4.8 percent), and was more likely to lead to discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/305\">",
"     305",
"    </a>",
"    ]. Psychiatric adverse effects led to discontinuation in an additional nine patients (2.5 percent), including behavioral disturbance in eight and psychosis in one. Other anecdotal reports and observational studies describe increased agitation and aggression with LEV that may be problematic in some patients, particularly those who are intellectually disabled and have baseline behavioral problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/307-309\">",
"     307-309",
"    </a>",
"    ]. This patient population may also be at increased risk of a paradoxical worsening of seizures in the first few weeks of starting LEV, particularly when high doses are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/310\">",
"     310",
"    </a>",
"    ]. Some have reported that problematic weight loss occurs in a small proportion of patients taking LEV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/311-313\">",
"     311-313",
"    </a>",
"    ]. A reversible thrombocytopenia has been linked to LEV in a small number of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/314-316\">",
"     314-316",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of LEV is initiated at 500 mg twice daily. It is titrated by 1000 mg every two weeks, as needed for seizure control, to a maximum dose of 4000 mg daily. In one report, an oral load of 1500 mg in a single dose was well tolerated and rapidly yielded therapeutic serum concentrations in 37 adult patients with epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/317\">",
"     317",
"    </a>",
"    ]. Weight-based dosing is recommended for children under 16 years: 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily producing levels approximating those of the 500 mg twice daily dose in adults, with 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice daily a usual target dose for therapeutic concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/318\">",
"     318",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pregabalin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    is chemically related to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/319\">",
"     319",
"    </a>",
"    ]. Pregabalin also has multiple potential mechanisms of action. It binds to the alpha2-delta subunit of voltage-gated calcium channels and modulates calcium currents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/320,321\">",
"     320,321",
"    </a>",
"    ]. Pregabalin also modulates the release of several neurotransmitters including glutamate, noradrenaline, and substance P. The net result of pregabalin's action appears to be inhibition of neuronal excitability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/322\">",
"     322",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    was approved by the European Medicines Agency (EMA) in July 2004 as adjunctive therapy for partial seizures and for the treatment of peripheral neuropathic pain. Pregabalin has also received FDA approval for the adjunctive treatment of partial seizures in adults, as well as for neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia and for fibromyalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/323\">",
"     323",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    is renally excreted virtually unchanged, and it is not hepatically metabolized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/322,324\">",
"     322,324",
"    </a>",
"    ]. Pregabalin does not induce or inhibit the cytochrome P450 system. In addition, it does not bind to plasma proteins. Thus, pregabalin does not have significant interactions with other AEDs and is not expected to have pharmacokinetic interactions with other drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/325-327\">",
"     325-327",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    exhibits linear pharmacokinetics, has a time to maximal plasma drug concentration (Tmax) of about one hour and a plasma half-life",
"    <span class=\"nowrap\">",
"     (T1/2)",
"    </span>",
"    of about six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/324\">",
"     324",
"    </a>",
"    ]. Experimental data suggest that the pharmacodynamic half-life (ie, anticonvulsant effect) of pregabalin is longer than the six-hour pharmacokinetic half-life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/328\">",
"     328",
"    </a>",
"    ]. The Tmax may be delayed to about three hours if the drug is taken with food, but total absorption is not affected by food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/326\">",
"     326",
"    </a>",
"    ]. Steady state is achieved within 24 to 48 hours.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     Pregabalin",
"    </a>",
"    is effective for the adjunctive treatment of partial seizures as demonstrated in randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/329-332\">",
"     329-332",
"    </a>",
"    ] In a study that tested pregabalin at the highest anticipated total daily dose of 600 mg, 313 patients with medically refractory partial seizures were randomly assigned to 12 weeks of treatment with pregabalin (either 300 mg twice daily or 200 mg three times daily) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/330\">",
"     330",
"    </a>",
"    ]. Both pregabalin regimens were significantly more effective in reducing the frequency of partial-onset seizures than placebo (43 and 53 percent reductions versus a 1 percent increase). Pooled analysis of open-label studies suggests that this benefit is sustained, at least over two years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/333\">",
"     333",
"    </a>",
"    ]. An open-label study in 19 children with refractory epilepsy suggested that pregabalin may be effective in this population as well; however, worsening of seizures was noted in two patients with myoclonic epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/334\">",
"     334",
"    </a>",
"    ]. In the only randomized trial testing pregabalin as monotherapy for newly diagnosed partial seizures, pregabalin was less effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    but similarly tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/335\">",
"     335",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    for the treatment of partial seizures is 150 mg daily given with or without food in either two or three divided doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/332,336\">",
"     332,336",
"    </a>",
"    ]. Pregabalin may be increased to a daily dose of 300 mg after one week and to a maximum daily dose of 600 mg after an additional week, based on patient response and tolerability.",
"   </p>",
"   <p>",
"    The most common side effects with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    in randomized trials were dizziness, somnolence, and ataxia (",
"    <a class=\"graphic graphic_table graphicRef59755 graphicRef78896 \" href=\"mobipreview.htm?2/17/2334\">",
"     table 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/329-331,337,338\">",
"     329-331,337,338",
"    </a>",
"    ]. Other side effects include weight gain, peripheral edema, blurred or double vision, asthenia, tremor, and abnormal thinking (most often impaired concentration). Pregabalin may also cause euphoria and is classified as a schedule V controlled substance. New onset myoclonus has been reported in patients taking pregabalin for epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/339\">",
"     339",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9738475\">",
"    <span class=\"h2\">",
"     Ezogabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/13/41172?source=see_link\">",
"     Ezogabine",
"    </a>",
"    or retigabine is believed to exert its antiepileptic effect by opening",
"    <span class=\"nowrap\">",
"     KCNQ2/3",
"    </span>",
"    voltage-gated potassium channels, activating M-current, which regulates neuronal excitability and suppresses epileptic activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/340-342\">",
"     340-342",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/13/41172?source=see_link\">",
"     Ezogabine",
"    </a>",
"    is approved by the FDA as an adjunctive treatment of partial seizures in adults. Three randomized trials have found that adjunctive therapy with ezogabine (900 to 1200 mg per day) resulted in a &gt;50 percent reduction in seizure frequency in 33 to 47 percent of patients with refractory partial epilepsy, compared with 16 to 19 percent in placebo patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/340,343,344\">",
"     340,343,344",
"    </a>",
"    ]. In open-label extensions of these trials, the efficacy appeared to be maintained over at least 12 months.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/13/41172?source=see_link\">",
"     Ezogabine",
"    </a>",
"    is metabolized in the liver and excreted by the kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/345\">",
"     345",
"    </a>",
"    ]. It is not metabolized by the cytochrome P450 system but by N-glucuronidation and N-acetylation and as a result, has minimal drug interactions with other AEDs. Mean half life is eight hours.",
"   </p>",
"   <p>",
"    Overall, the drug is well tolerated. The most common adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/13/41172?source=see_link\">",
"     ezogabine",
"    </a>",
"    are dizziness and vertigo, fatigue and weakness, confusion, somnolence, tremor, ataxia, blurred or double vision, dysarthria, inattention, and memory impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/340,343,344,346\">",
"     340,343,344,346",
"    </a>",
"    ]. Ezogabine can also cause urinary retention, usually, but not always, within the first six months of initiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/347\">",
"     347",
"    </a>",
"    ]. Urinary tract infection, urinary hesitation, dysuria, and chromaturia were seen more often in ezogabine than placebo-treated patients, but were not serious. &nbsp;Neuropsychiatric symptoms, including confusion, hallucinations, and psychosis occur in a few patients and resolve within a few days with discontinuation.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/13/41172?source=see_link\">",
"     Ezogabine",
"    </a>",
"    is initiated at a dose of 100 mg three times daily and increased weekly in 150 mg per day increments to achieve a target dose of 900 mg per day; doses up to 1200 mg per day appear to be well tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/61/43994/abstract/348\">",
"     348",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3242513\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While sharing a common property of suppressing epileptic seizures, antiepileptic drugs (AEDs) have many different pharmacologic profiles that are relevant when selecting and prescribing these agents in patients with epilepsy and other conditions. These include pharmacokinetic properties, propensity for drug-drug interactions as well as side effect profiles and toxicities. For drug-specific summaries refer to specific drug headings above. Summaries of different properties are also listed in the Tables:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Important pharmacologic properties (",
"      <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Common and rare side effects (",
"      <a class=\"graphic graphic_table graphicRef59755 \" href=\"mobipreview.htm?3/28/3533\">",
"       table 4A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78896 \" href=\"mobipreview.htm?29/34/30252\">",
"       table 4B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Some important drug interactions (",
"      <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef80801 \" href=\"mobipreview.htm?6/29/6621\">",
"       table 3A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef55399 \" href=\"mobipreview.htm?9/26/9645\">",
"       table 3B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef53463 \" href=\"mobipreview.htm?38/36/39500\">",
"       table 3C",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another important feature of these drugs is there different rates of efficacy for partial-onset versus primary generalized onset seizures as well as other seizures types (",
"      <a class=\"graphic graphic_table graphicRef61530 \" href=\"mobipreview.htm?26/41/27293\">",
"       table 1A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef79951 \" href=\"mobipreview.htm?15/16/15630\">",
"       table 1B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef68910 \" href=\"mobipreview.htm?22/53/23389\">",
"       table 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A discussion of AED selection in specific patient situations is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link&amp;anchor=H5#H5\">",
"       \"Initial treatment of epilepsy in adults\", section on 'Selection of an AED'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     New Antiepileptic Drug Development: Preclinical and Clinical Aspects, French JA, Dichter MA, Leppi, IE (Eds), Elsevier, Amsterdam 1993. p.255.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/2\">",
"      Schachter SC. Review of the mechanisms of action of antiepileptic drugs. CNS Drugs 1995; 4:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/3\">",
"      LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004; 291:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/4\">",
"      Perucca E. NICE guidance on newer drugs for epilepsy in adults. BMJ 2004; 328:1273.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Clinical Excellence (UK). Newer drugs for epilepsy in adults, full guidance. Technology Appraisal Guidance 76, Mar. 2004. www.nice.org.uk/TA076guidance (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/6\">",
"      Post RM, Uhde TW. Treatment of mood disorders with antiepileptic medications: clinical and theoretical implications. Epilepsia 1983; 24 Suppl 2:S97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/7\">",
"      Rose, FC, Johnson, FN. Carbamazepine in the treatment of non-seizure disorders: trigeminal neuralgia, other painful disorders, and affective disorders. Rev Contemp Pharmacother 1997; 8:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/8\">",
"      Macdonald RL. Antiepileptic drug actions. Epilepsia 1989; 30 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/9\">",
"      Ficker DM, Privitera M, Krauss G, et al. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology 2005; 65:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/10\">",
"      Miller AD, Krauss GL, Hamzeh FM. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine. Acta Neurol Scand 2004; 109:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/11\">",
"      Hirsch LJ, Arif H, Nahm EA, et al. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 2008; 71:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/12\">",
"      Herzog AG, Drislane FW, Schomer DL, et al. Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy. Neurology 2005; 65:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/13\">",
"      Lossius MI, Taub&oslash;ll E, Mowinckel P, et al. Reversible effects of antiepileptic drugs on reproductive endocrine function in men and women with epilepsy--a prospective randomized double-blind withdrawal study. Epilepsia 2007; 48:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/14\">",
"      Aggarwal A, Rastogi N, Mittal H, et al. Thyroid hormone levels in children receiving carbamazepine or valproate. Pediatr Neurol 2011; 45:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/15\">",
"      Verrotti A, Laus M, Scardapane A, et al. Thyroid hormones in children with epilepsy during long-term administration of carbamazepine and valproate. Eur J Endocrinol 2009; 160:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/16\">",
"      Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/17\">",
"      Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007; 68:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/18\">",
"      Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/19\">",
"      Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/20\">",
"      Wu XT, Hu FY, An DM, et al. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China. Epilepsy Behav 2010; 19:405.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/cder/drug/InfoSheets/HCP/carbamazepineHCP.htm (Accessed on December 12, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/22\">",
"      Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011; 364:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/23\">",
"      McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/24\">",
"      Sobotka JL, Alexander B, Cook BL. A review of carbamazepine's hematologic reactions and monitoring recommendations. DICP 1990; 24:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/25\">",
"      Porter RJ. How to initiate and maintain carbamazepine therapy in children and adults. Epilepsia 1987; 28 Suppl 3:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/26\">",
"      Bertolino JG. Carbamazepine. What physicians should know about its hematologic effects. Postgrad Med 1990; 88:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/27\">",
"      Merritt HH, Putnam TJ. Sodium diphenyl hydantoinate in the treatment of convulsive disorders. JAMA 1938; 111:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/28\">",
"      Yaari Y, Selzer ME, Pincus JH. Phenytoin: mechanisms of its anticonvulsant action. Ann Neurol 1986; 20:171.",
"     </a>",
"    </li>",
"    <li>",
"     Ferrendelli JA, Mathews GC. Neuropharmacology of antiepileptic medications: mechanisms of action. In: The Treatment of Epilepsy: Principles and Practice, Wyllie E (Ed), Lea and Febiger, Philadelphia 1993. p.735.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/30\">",
"      Delgado-Escueta AV, Horan MP. Phenytoin: biochemical membrane studies. Adv Neurol 1980; 27:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/31\">",
"      Soryal I, Richens A. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. J Neurol Neurosurg Psychiatry 1992; 55:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/32\">",
"      Mikati M, Bassett N, Schachter S. Double-blind randomized study comparing brand-name and generic phenytoin monotherapy. Epilepsia 1992; 33:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/33\">",
"      Rosenbaum DH, Rowan AJ, Tuchman L, French JA. Comparative bioavailability of a generic phenytoin and Dilantin. Epilepsia 1994; 35:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/34\">",
"      Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003; 25:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/35\">",
"      Burkhardt RT, Leppik IE, Blesi K, et al. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Neurology 2004; 63:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/36\">",
"      Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008; 49:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/37\">",
"      L&ouml;scher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/CDER/Drug/InfoSheets/HCP/phenytoin_fosphenytoinHCP.htm (Accessed on January 30, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/39\">",
"      Arya R, Gulati S, Kabra M, et al. Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children. Neurology 2011; 76:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/40\">",
"      Leach MJ, Marden CM, Miller AA. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986; 27:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/41\">",
"      Lee CY, Fu WM, Chen CC, et al. Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus. Epilepsia 2008; 49:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/42\">",
"      French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/43\">",
"      French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/44\">",
"      Schachter SC. Efficacy and safety of lamotrigine, a new anticonvulsant. Today's Therapeutic Trends 1995; 12:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/45\">",
"      Biton V, Sackellares JC, Vuong A, et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005; 65:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/46\">",
"      Biton V, Di Memmo J, Shukla R, et al. Adjunctive lamotrigine XR for primary generalized tonic-clonic seizures in a randomized, placebo-controlled study. Epilepsy Behav 2010; 19:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/47\">",
"      Pi&ntilde;a-Garza JE, Levisohn P, Gucuyener K, et al. Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months. Neurology 2008; 70:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/48\">",
"      Pi&ntilde;a-Garza JE, Elterman RD, Ayala R, et al. Long-term tolerability and efficacy of lamotrigine in infants 1 to 24 months old. J Child Neurol 2008; 23:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/49\">",
"      Naritoku DK, Warnock CR, Messenheimer JA, et al. Lamotrigine extended-release as adjunctive therapy for partial seizures. Neurology 2007; 69:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/50\">",
"      Tompson DJ, Ali I, Oliver-Willwong R, et al. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). Epilepsia 2008; 49:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/51\">",
"      Weintraub D, Buchsbaum R, Resor SR Jr, Hirsch LJ. Effect of antiepileptic drug comedication on lamotrigine clearance. Arch Neurol 2005; 62:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/52\">",
"      Hirsch LJ, Weintraub D, Du Y, et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004; 63:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/53\">",
"      Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005; 46:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/54\">",
"      Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia 2006; 47:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/55\">",
"      O'Brien MD, Guillebaud J. Contraception for women with epilepsy. Epilepsia 2006; 47:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/56\">",
"      Contin M, Albani F, Ambrosetto G, et al. Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy. Epilepsia 2006; 47:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/57\">",
"      Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 2007; 48:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/58\">",
"      Herzog AG, Blum AS, Farina EL, et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology 2009; 72:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/59\">",
"      Wegner I, Edelbroek PM, Bulk S, Lindhout D. Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. Neurology 2009; 73:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/60\">",
"      Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002; 59:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/61\">",
"      de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004; 63:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/62\">",
"      Tomson T, Luef G, Sabers A, et al. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology 2006; 67:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/63\">",
"      Rambeck B, Specht U, Wolf P. Pharmacokinetic interactions of the new antiepileptic drugs. Clin Pharmacokinet 1996; 31:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/64\">",
"      Arif H, Svoronos A, Resor SR Jr, et al. The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. Epilepsia 2011; 52:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/65\">",
"      Hirsch LJ, Weintraub DB, Buchsbaum R, et al. Predictors of Lamotrigine-associated rash. Epilepsia 2006; 47:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/66\">",
"      Crespel A, Genton P, Berramdane M, et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 2005; 65:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/67\">",
"      Magaudda A, Ferlazzo E, Nguyen VH, Genton P. Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients. Epilepsia 2006; 47:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/68\">",
"      Dinnerstein E, Jobst BC, Williamson PD. Lamotrigine intoxication provoking status epilepticus in an adult with localization-related epilepsy. Arch Neurol 2007; 64:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/69\">",
"      Simms KM, Kortepeter C, Avigan M. Lamotrigine and aseptic meningitis. Neurology 2012; 78:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/70\">",
"      Tecoma ES. Oxcarbazepine. Epilepsia 1999; 40 Suppl 5:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/71\">",
"      Reinikainen KJ, Ker&auml;nen T, Halonen T, et al. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987; 1:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/72\">",
"      Schachter SC, Vazquez B, Fisher RS, et al. Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology 1999; 52:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/73\">",
"      Two new drugs for epilepsy. Med Lett Drugs Ther 2000; 42:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/74\">",
"      Mazzucchelli I, Onat FY, Ozkara C, et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 2006; 47:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/75\">",
"      EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006; 66:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/76\">",
"      Kim DW, Gu N, Jang IJ, et al. Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy. Epilepsia 2012; 53:e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/77\">",
"      Pi&ntilde;a-Garza JE, Espinoza R, Nordli D, et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology 2005; 65:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/78\">",
"      Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev 2009; :CD006453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/79\">",
"      Buggy Y, Layton D, Fogg C, Shakir SA. Safety profile of oxcarbazepine: results from a prescription-event monitoring study. Epilepsia 2010; 51:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/80\">",
"      Cansu A, Serdaro��lu A, Camurdan O, et al. The evaluation of thyroid functions, thyroid antibodies, and thyroid volumes in children with epilepsy during short-term administration of oxcarbazepine and valproate. Epilepsia 2006; 47:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/81\">",
"      Vainionp&auml;&auml; LK, Mikkonen K, R&auml;tty&auml; J, et al. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia 2004; 45:197.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration MedWatch. 2005 Medical Product Safety Alerts. Trileptal (oxcarbazepine) Tablets and Oral Solution. www.fda.gov/medwatch/SAFETY/2005/safety05.htm#triletpal (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/83\">",
"      Asconap&eacute; JJ. Some common issues in the use of antiepileptic drugs. Semin Neurol 2002; 22:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/84\">",
"      Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005; 65:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/85\">",
"      Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/86\">",
"      Gaily E, Granstr&ouml;m ML, Liukkonen E. Oxcarbazepine in the treatment of early childhood epilepsy. J Child Neurol 1997; 12:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/87\">",
"      Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology 2000; 54:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/88\">",
"      Glauser TA. Oxcarbazepine in the treatment of epilepsy. Pharmacotherapy 2001; 21:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/89\">",
"      Kutluay E, McCague K, D'Souza J, Beydoun A. Safety and tolerability of oxcarbazepine in elderly patients with epilepsy. Epilepsy Behav 2003; 4:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/90\">",
"      Schmidt D, Arroyo S, Baulac M, et al. Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view. Acta Neurol Scand 2001; 104:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/91\">",
"      Nielsen OA, Johannessen AC, Bardrum B. Oxcarbazepine-induced hyponatremia, a cross-sectional study. Epilepsy Res 1988; 2:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/92\">",
"      Pendlebury SC, Moses DK, Eadie MJ. Hyponatraemia during oxcarbazepine therapy. Hum Toxicol 1989; 8:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/93\">",
"      Schachter SC. The next wave of anticonvulsants. Focus on levetiracetam, oxcarbazepine and zonisamide. CNS Drugs 2000; 14:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/94\">",
"      Leppik IE. Zonisamide. Epilepsia 1999; 40 Suppl 5:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/95\">",
"      Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/96\">",
"      Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997; 38:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/97\">",
"      Brodie MJ, Duncan R, Vespignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005; 46:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/98\">",
"      Henry TR, Leppik IE, Gumnit RJ, Jacobs M. Progressive myoclonus epilepsy treated with zonisamide. Neurology 1988; 38:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/99\">",
"      Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998; 29:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/100\">",
"      Tosches WA, Tisdell J. Long-term efficacy and safety of monotherapy and adjunctive therapy with zonisamide. Epilepsy Behav 2006; 8:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/101\">",
"      Kothare SV, Kaleyias J, Mostofi N, et al. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatr Neurol 2006; 34:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/102\">",
"      Stephen LJ, Kelly K, Wilson EA, et al. A prospective audit of adjunctive zonisamide in an everyday clinical setting. Epilepsy Behav 2010; 17:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/103\">",
"      Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2012; 11:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/104\">",
"      Sills G, Brodie M. Pharmacokinetics and drug interactions with zonisamide. Epilepsia 2007; 48:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/105\">",
"      Bergen D. Incidence of adverse events is reduced with titrated dosing of Zonegran (zonisamide) for partial seizures in the United States [abstract]. Epilepsia 1999; 40 Suppl 7:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/106\">",
"      Park SP, Hwang YH, Lee HW, et al. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav 2008; 12:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/107\">",
"      Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/108\">",
"      Leppik IE, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993; 14:165.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration (FDA). FDA labelling information. file://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory (Accessed on January 20, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/110\">",
"      Perucca E, Yasothan U, Clincke G, Kirkpatrick P. Lacosamide. Nat Rev Drug Discov 2008; 7:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/111\">",
"      Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007; 13:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/112\">",
"      Hal&aacute;sz P, K&auml;lvi&auml;inen R, Mazurkiewicz-Beldzi��ska M, et al. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/113\">",
"      Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010; 51:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/114\">",
"      Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/115\">",
"      Husain A, Chung S, Faught E, et al. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. Epilepsia 2012; 53:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/116\">",
"      Guilhoto LM, Loddenkemper T, Gooty VD, et al. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol 2011; 44:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/117\">",
"      Rastogi RG, Ng YT. Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study. J Child Neurol 2012; 27:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/118\">",
"      Zaccara G, Perucca P, Loiacono G, et al. The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2013; 54:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/119\">",
"      Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav 2011; 20:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/120\">",
"      Nizam A, Mylavarapu K, Thomas D, et al. Lacosamide-induced second-degree atrioventricular block in a patient with partial epilepsy. Epilepsia 2011; 52:e153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/121\">",
"      Degiorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav 2010; 18:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/122\">",
"      Cuzzola A, Ferlazzo E, Italiano D, et al. Does lacosamide aggravate Lennox-Gastaut syndrome? Report on three consecutive cases. Epilepsy Behav 2010; 19:650.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration (FDA). FDA labelling information. file://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist (Accessed on January 20, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/124\">",
"      Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008; 70:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/125\">",
"      Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 2009; 14:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/126\">",
"      Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010; 17:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/127\">",
"      Verrotti A, Loiacono G, Ballone E, et al. Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis. Pediatr Neurol 2011; 44:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/128\">",
"      Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009; 50:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/129\">",
"      Biton V, Krauss G, Vasquez-Santana B, et al. A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia 2011; 52:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/130\">",
"      Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008; 49:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/131\">",
"      Wheless JW, Conry J, Krauss G, et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009; 24:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/132\">",
"      Coulter DA, Huguenard JR, Prince DA. Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci Lett 1989; 98:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/133\">",
"      Coulter DA, Huguenard JR, Prince DA. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 1989; 25:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/134\">",
"      Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010; 362:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/135\">",
"      Dichter MA, Ayala GF. Cellular mechanisms of epilepsy: a status report. Science 1987; 237:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/136\">",
"      Meldrum BS. Epilepsy and gamma-aminobutyric acid-mediated inhibition. Int Rev Neurobiol 1975; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/137\">",
"      Meldrum B. GABA-agonists as anti-epileptic agents. Adv Biochem Psychopharmacol 1981; 26:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/138\">",
"      Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989; 25:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/139\">",
"      Schachter SC. Tiagabine: current status and potential clinical applications. Exp Opin Invest Drugs 1996; 5:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/140\">",
"      Pulman J, Marson AG, Hutton JL. Tiagabine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2012; 5:CD001908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/141\">",
"      Braestrup C, Nielsen EB, Sonnewald U, et al. (R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier. J Neurochem 1990; 54:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/142\">",
"      Aiki&auml; M, Jutila L, Salmenper&auml; T, et al. Comparison of the cognitive effects of tiagabine and carbamazepine as monotherapy in newly diagnosed adult patients with partial epilepsy: pooled analysis of two long-term, randomized, follow-up studies. Epilepsia 2006; 47:1121.",
"     </a>",
"    </li>",
"    <li>",
"     FDA public health advisory: seizure in patients without epilepsy being treated with Gabitril (tiagabine). February 18, 2005. file://www.fda.gov/cder/drug/advisory/gabitril.htm/ (Accessed on March 07, 2006).",
"    </li>",
"    <li>",
"     The FDA Safety Information and Adverse Event Reporting Program. 2005 Safety Alert: Gabitril (tiagabine HCl): important drug warnging. February 14, 2005. file://www.fda.gov/MEDWATCH/SAFETY/2005/gabitril_DHCP.htm/ (Accessed on March 07, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/145\">",
"      Jette N, Cappell J, VanPassel L, Akman CI. Tiagabine-induced nonconvulsive status epilepticus in an adolescent without epilepsy. Neurology 2006; 67:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/146\">",
"      Shinnar S, Berg AT, Treiman DM, et al. Status epilepticus and tiagabine therapy: review of safety data and epidemiologic comparisons. Epilepsia 2001; 42:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/147\">",
"      Koepp MJ, Edwards M, Collins J, et al. Status epilepticus and tiagabine therapy revisited. Epilepsia 2005; 46:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/148\">",
"      Flowers CM, Racoosin JA, Kortepeter C. Seizure activity and off-label use of tiagabine. N Engl J Med 2006; 354:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/149\">",
"      Petroff OA, Rothman DL, Behar KL, et al. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology 1996; 47:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/150\">",
"      Hemming K, Maguire MJ, Hutton JL, Marson AG. Vigabatrin for refractory partial epilepsy. Cochrane Database Syst Rev 2013; 1:CD007302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/151\">",
"      Tanganelli P, Regesta G. Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study. Epilepsy Res 1996; 25:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/152\">",
"      Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet 1999; 354:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/153\">",
"      K&auml;lvi&auml;inen R, Aiki&auml; M, Saukkonen AM, et al. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 1995; 52:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/154\">",
"      Camposano SE, Major P, Halpern E, Thiele EA. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia 2008; 49:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/155\">",
"      Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 2005; 4:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/156\">",
"      Bombardieri R, Pinci M, Moavero R, et al. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol 2010; 14:146.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm179855.htm (Accessed on April 30, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/158\">",
"      Vigabatrin (Sabril) for epilepsy. Med Lett Drugs Ther 2010; 52:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/159\">",
"      Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/160\">",
"      K&auml;lvi&auml;inen R, Nousiainen I, M&auml;ntyj&auml;rvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/161\">",
"      Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings. Neurology 1999; 53:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/162\">",
"      Daneshvar H, Racette L, Coupland SG, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999; 106:1792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/163\">",
"      K&auml;lvi&auml;inen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001; 15:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/164\">",
"      Maguire MJ, Hemming K, Wild JM, et al. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia 2010; 51:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/165\">",
"      Wild JM, Ahn HS, Baulac M, et al. Vigabatrin and epilepsy: lessons learned. Epilepsia 2007; 48:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/166\">",
"      Conway M, Cubbidge RP, Hosking SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 2008; 49:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/167\">",
"      Gaily E, Jonsson H, Lappi M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia 2009; 50:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/168\">",
"      Willmore LJ, Abelson MB, Ben-Menachem E, et al. Vigabatrin: 2008 update. Epilepsia 2009; 50:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/169\">",
"      Duboc A, Hanoteau N, Simonutti M, et al. Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats. Ann Neurol 2004; 55:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/170\">",
"      Hardus P, Verduin WM, Engelsman M, et al. Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia 2001; 42:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/171\">",
"      Clayton LM, D&eacute;vil&eacute; M, Punte T, et al. Retinal nerve fiber layer thickness in vigabatrin-exposed patients. Ann Neurol 2011; 69:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/172\">",
"      Jammoul F, Wang Q, Nabbout R, et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol 2009; 65:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/173\">",
"      Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009; 50:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/174\">",
"      Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 2009; 50:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/175\">",
"      Dracopoulos A, Widjaja E, Raybaud C, et al. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. Epilepsia 2010; 51:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/176\">",
"      Cook PJ, Flanagan R, James IM. Diazepam tolerance: effect of age, regular sedation, and alcohol. Br Med J (Clin Res Ed) 1984; 289:351.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm276932.htm (Accessed on October 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/178\">",
"      Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 2009; 50:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/179\">",
"      Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011; 77:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/180\">",
"      Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011; 11:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/181\">",
"      Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010; 92:89.",
"     </a>",
"    </li>",
"    <li>",
"     FDA-approved labeling information available at  file://dailymed.nlm.nih.gov/dailymed/about.cfm (Accessed on September 30, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/183\">",
"      French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012; 79:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/184\">",
"      Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012; 78:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/185\">",
"      French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013; 54:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/186\">",
"      McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 237:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/187\">",
"      Gram L. Experimental studies and controlled clinical testing of valproate and vigabatrin. Acta Neurol Scand 1988; 78:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/188\">",
"      L&ouml;scher W. Valproate induced changes in GABA metabolism at the subcellular level. Biochem Pharmacol 1981; 30:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/189\">",
"      L&ouml;scher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/190\">",
"      Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 2000; 55:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/191\">",
"      Ramsay RE, Cantrell D, Collins SD, et al. Safety and tolerance of rapidly infused Depacon. A randomized trial in subjects with epilepsy. Epilepsy Res 2003; 52:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/192\">",
"      Wheless JW, Vazquez BR, Kanner AM, et al. Rapid infusion with valproate sodium is well tolerated in patients with epilepsy. Neurology 2004; 63:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/193\">",
"      Limdi NA, Shimpi AV, Faught E, et al. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005; 64:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/194\">",
"      Limdi NA, Knowlton RK, Cofield SS, et al. Safety of rapid intravenous loading of valproate. Epilepsia 2007; 48:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/195\">",
"      Rai A, Aggarwal A, Mittal H, Sharma S. Comparative efficacy and safety of intravenous valproate and phenytoin in children. Pediatr Neurol 2011; 45:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/196\">",
"      Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/197\">",
"      Kim JY, Lee HW. Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia 2007; 48:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/198\">",
"      Abaci A, Saygi M, Yis U, et al. Metabolic alterations during valproic acid treatment: a prospective study. Pediatr Neurol 2009; 41:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/199\">",
"      Verrotti A, Manco R, Agostinelli S, et al. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia 2010; 51:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/200\">",
"      Gerstner T, Teich M, Bell N, et al. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia 2006; 47:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/201\">",
"      Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia 2008; 49:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/202\">",
"      Castro-Gago M, Novo-Rodr&iacute;guez MI, G&oacute;mez-Lado C, et al. Evolution of subclinical hypothyroidism in children treated with antiepileptic drugs. Pediatr Neurol 2007; 37:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/203\">",
"      Sahu JK, Gulati S, Kabra M, et al. Evaluation of subclinical hypothyroidism in ambulatory children with controlled epilepsy on valproate monotherapy. J Child Neurol 2012; 27:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/204\">",
"      Sahota P, Prabhakar S, Kharbanda PS, et al. Seizure type, antiepileptic drugs, and reproductive endocrine dysfunction in Indian women with epilepsy: a cross-sectional study. Epilepsia 2008; 49:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/205\">",
"      Verrotti A, D'Egidio C, Mohn A, et al. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 2011; 52:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/206\">",
"      Endo A, Fujita Y, Fuchigami T, et al. Fanconi syndrome caused by valproic acid. Pediatr Neurol 2010; 42:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/207\">",
"      Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/208\">",
"      Koenig SA, Buesing D, Longin E, et al. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 2006; 47:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/209\">",
"      Garcia M, Huppertz HJ, Ziyeh S, et al. Valproate-induced metabolic changes in patients with epilepsy: assessment with H-MRS. Epilepsia 2009; 50:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/210\">",
"      Gerstner T, B&uuml;sing D, Bell N, et al. Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol 2007; 42:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/211\">",
"      Werlin SL, Fish DL. The spectrum of valproic acid-associated pancreatitis. Pediatrics 2006; 118:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/212\">",
"      Risti�� AJ, Vojvodi�� N, Jankovi�� S, et al. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia 2006; 47:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/213\">",
"      Armon C, Shin C, Miller P, et al. Reversible parkinsonism and cognitive impairment with chronic valproate use. Neurology 1996; 47:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/214\">",
"      Easterford K, Clough P, Kellett M, et al. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology 2004; 62:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/215\">",
"      Masmoudi K, Gras-Champel V, Masson H, Andr&eacute;jak M. Parkinsonism and/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry 2006; 39:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/216\">",
"      Jamora D, Lim SH, Pan A, et al. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord 2007; 22:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/217\">",
"      Schmitt B, Martin F, Critelli H, et al. Effects of valproic acid on sleep in children with epilepsy. Epilepsia 2009; 50:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/218\">",
"      Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors. Ann Neurol 1994; 35:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/219\">",
"      Bourgeois BF. Felbamate in the treatment of partial-onset seizures. Epilepsia 1994; 35 Suppl 5:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/220\">",
"      Leppik IE. Felbamate: a new drug for the treatment of patients with epilepsy. Neurology Forum 1992; 3:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/221\">",
"      Troupin AS, Montouris G, Hussein G. Felbamate: therapeutic range and other kinetic information. J Epilepsy 1997; 10:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/222\">",
"      Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996; 37 Suppl 6:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/223\">",
"      Ben-Menachem E. Clinical efficacy of topiramate as add-on therapy in refractory partial epilepsy: the European experience. Epilepsia 1997; 38 Suppl 1:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/224\">",
"      Reife RA, Pledger GW. Topiramate as adjunctive therapy in refractory partial epilepsy: pooled analysis of data from five double-blind, placebo-controlled trials. Epilepsia 1997; 38 Suppl 1:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/225\">",
"      Glauser TA, Dlugos DJ, Dodson WE, et al. Topiramate monotherapy in newly diagnosed epilepsy in children and adolescents. J Child Neurol 2007; 22:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/226\">",
"      Novotny E, Renfroe B, Yardi N, et al. Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures. Neurology 2010; 74:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/227\">",
"      Ramsay E, Faught E, Krumholz A, et al. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia 2010; 51:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/228\">",
"      Westin AA, Nakken KO, Johannessen SI, et al. Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia 2009; 50:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/229\">",
"      Cho YJ, Heo K, Kim WJ, et al. Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study. Epilepsia 2009; 50:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/230\">",
"      Majkowski J, Neto W, Wapenaar R, Van Oene J. Time course of adverse events in patients with localization-related epilepsy receiving topiramate added to carbamazepine. Epilepsia 2005; 46:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/231\">",
"      Ben-Menachem E, Axelsen M, Johanson EH, et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003; 11:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/232\">",
"      El Yaman SH, Mroueh SM, Sinno DD, Mikati MA. Long-term patterns of weight changes during topiramate therapy: an observational study. Neurology 2007; 69:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/233\">",
"      Cirulli ET, Urban TJ, Marino SE, et al. Genetic and environmental correlates of topiramate-induced cognitive impairment. Epilepsia 2012; 53:e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/234\">",
"      Salinsky MC, Storzbach D, Spencer DC, et al. Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 2005; 64:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/235\">",
"      Meador KJ, Loring DW, Vahle VJ, et al. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 2005; 64:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/236\">",
"      Smith ME, Gevins A, McEvoy LK, et al. Distinct cognitive neurophysiologic profiles for lamotrigine and topiramate. Epilepsia 2006; 47:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/237\">",
"      Blum D, Meador K, Biton V, et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 2006; 67:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/238\">",
"      Aarsen FK, van den Akker EL, Drop SL, Catsman-Berrevoets CE. Effect of topiramate on cognition in obese children. Neurology 2006; 67:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/239\">",
"      Loring DW, Williamson DJ, Meador KJ, et al. Topiramate dose effects on cognition: a randomized double-blind study. Neurology 2011; 76:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/240\">",
"      Kang HC, Eun BL, Wu Lee C, et al. The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia 2007; 48:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/241\">",
"      Coppola G, Verrotti A, Resicato G, et al. Topiramate in children and adolescents with epilepsy and mental retardation: a prospective study on behavior and cognitive effects. Epilepsy Behav 2008; 12:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/242\">",
"      Chadwick D, Privitera M. How skeptical should we be about industry-sponsored studies? Neurology 2006; 67:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/243\">",
"      Sankar R, Ramsay E, McKay A, et al. A multicenter, outpatient, open-label study to evaluate the dosing, effectiveness, and safety of topiramate as monotherapy in the treatment of epilepsy in clinical practice. Epilepsy Behav 2009; 15:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/244\">",
"      Mula M, Hesdorffer DC, Trimble M, Sander JW. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia 2009; 50:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/245\">",
"      Glauser TA. Topiramate. Epilepsia 1999; 40 Suppl 5:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/246\">",
"      Bonanni E, Galli R, Maestri M, et al. Daytime sleepiness in epilepsy patients receiving topiramate monotherapy. Epilepsia 2004; 45:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/247\">",
"      de Carolis P, Magnifico F, Pierangeli G, et al. Transient hypohidrosis induced by topiramate. Epilepsia 2003; 44:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/248\">",
"      Cerminara C, Seri S, Bombardieri R, et al. Hypohidrosis during topiramate treatment: a rare and reversible side effect. Pediatr Neurol 2006; 34:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/249\">",
"      Stavskaia SS, Krivets IA, Nastoiashchaia NI. [Reorganization of the strain's cellular lipids--degradation of anionic surfactants during \"detergent\" stress]. Mikrobiol Z 2001; 63:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/250\">",
"      Etminan M, Maberley D, Mikelberg FS. Use of topiramate and risk of glaucoma: a case-control study. Am J Ophthalmol 2012; 153:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/251\">",
"      Beyenburg S, Weyland C, Reuber M. Presumed topiramate-induced maculopathy. Epilepsy Behav 2009; 14:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/252\">",
"      Mukhin NA, Kozlovskaia LV, Bobkova IN, et al. [The key role of tubulointerstitium remodeling in progression of chronic renal diseases]. Arkh Patol 2004; 66:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/253\">",
"      Takeoka M, Holmes GL, Thiele E, et al. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia 2001; 42:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/254\">",
"      Kuo RL, Moran ME, Kim DH, et al. Topiramate-induced nephrolithiasis. J Endourol 2002; 16:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/255\">",
"      Ahlstrand C, Tiselius HG. Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 1987; 21:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/256\">",
"      Tawil R, Moxley RT 3rd, Griggs RC. Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders. Neurology 1993; 43:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/257\">",
"      Mahmoud AA, Rizk T, El-Bakri NK, et al. Incidence of kidney stones with topiramate treatment in pediatric patients. Epilepsia 2011; 52:1890.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm245085.htm (Accessed on March 30, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/259\">",
"      Margulis AV, Mitchell AA, Gilboa SM, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012; 207:405.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/260\">",
"      Hern&aacute;ndez-D&iacute;az S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/261\">",
"      van Hooft JA, Dougherty JJ, Endeman D, et al. Gabapentin inhibits presynaptic Ca(2+) influx and synaptic transmission in rat hippocampus and neocortex. Eur J Pharmacol 2002; 449:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/262\">",
"      Bryans JS, Davies N, Gee NS, et al. Identification of novel ligands for the gabapentin binding site on the alpha2delta subunit of a calcium channel and their evaluation as anticonvulsant agents. J Med Chem 1998; 41:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/263\">",
"      Belliotti TR, Capiris T, Ekhato IV, et al. Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein. J Med Chem 2005; 48:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/264\">",
"      Leiderman DB. Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials. Epilepsia 1994; 35 Suppl 5:S74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/265\">",
"      McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology 1994; 44:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/266\">",
"      Zand L, McKian KP, Qian Q. Gabapentin toxicity in patients with chronic kidney disease: a preventable cause of morbidity. Am J Med 2010; 123:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/267\">",
"      Fisher RS, Sachdeo RC, Pellock J, et al. Rapid initiation of gabapentin: a randomized, controlled trial. Neurology 2001; 56:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/268\">",
"      Meador KJ, Loring DW, Ray PG, et al. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 1999; 40:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/269\">",
"      Ohman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? Epilepsia 2005; 46:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/270\">",
"      Shorvon SD, L&ouml;wenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000; 41:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/271\">",
"      Tsai JJ, Yen DJ, Hsih MS, et al. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia 2006; 47:72.",
"     </a>",
"    </li>",
"    <li>",
"     Shorvon SD. Levetiracetam's potential in generalized seizures.. In: Levetiracetam: profile of a novel anti-epileptic drug. Summary from Satellite Symposia in Quebec and Milan, UCB Pharma, 1999. p.10.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/273\">",
"      Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007; 69:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/274\">",
"      Glauser TA, Ayala R, Elterman RD, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006; 66:1654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/275\">",
"      Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008; 70:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/276\">",
"      Wu XY, Hong Z, Wu X, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Epilepsia 2009; 50:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/277\">",
"      Delanty N, Jones J, Tonner F. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Epilepsia 2012; 53:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/278\">",
"      Mbizvo GK, Dixon P, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. Cochrane Database Syst Rev 2012; 9:CD001901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/279\">",
"      Pi&ntilde;a-Garza JE, Nordli DR Jr, Rating D, et al. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures. Epilepsia 2009; 50:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/280\">",
"      Perry MS, Benatar M. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review. Epilepsia 2007; 48:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/281\">",
"      Goraya JS, Khurana DS, Valencia I, et al. Intravenous levetiracetam in children with epilepsy. Pediatr Neurol 2008; 38:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/282\">",
"      Krief P, Maytal J. Efficacy of levetiracetam in children with epilepsy younger than 2 years of age. J Child Neurol 2008; 23:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/283\">",
"      Khan O, Chang E, Cipriani C, et al. Use of intravenous levetiracetam for management of acute seizures in neonates. Pediatr Neurol 2011; 44:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/284\">",
"      Ben-Menachem E. Preliminary efficacy of levetiracetam in monotherapy. Epileptic Disord 2003; 5 Suppl 1:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/285\">",
"      Falip M, Carre&ntilde;o M, Amaro S, et al. Use of levetiracetam in hospitalized patients. Epilepsia 2006; 47:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/286\">",
"      Khurana DS, Kothare SV, Valencia I, et al. Levetiracetam monotherapy in children with epilepsy. Pediatr Neurol 2007; 36:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/287\">",
"      Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/288\">",
"      Mikati MA, El Banna D, Sinno D, Mroueh S. Response of infantile spasms to levetiracetam. Neurology 2008; 70:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/289\">",
"      Lagae L, Buyse G, Deconinck A, Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Paediatr Neurol 2003; 7:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/290\">",
"      Lawlor KM, Devlin AM. Levetiracetam in the treatment of infantile spasms. Eur J Paediatr Neurol 2005; 9:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/291\">",
"      Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004; 101:9861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/292\">",
"      Crowder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci U S A 1999; 96:15268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/293\">",
"      Custer KL, Austin NS, Sullivan JM, Bajjalieh SM. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 2006; 26:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/294\">",
"      Doelken MT, Doelken MT, Hammen T, et al. Alterations of intracerebral &gamma;-aminobutyric acid (GABA) levels by titration with levetiracetam in patients with focal epilepsies. Epilepsia 2010; 51:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/295\">",
"      Meehan AL, Yang X, Yuan LL, Rothman SM. Levetiracetam has an activity-dependent effect on inhibitory transmission. Epilepsia 2012; 53:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/296\">",
"      Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia 2007; 48:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/297\">",
"      Glass GA, Stankiewicz J, Mithoefer A, et al. Levetiracetam for seizures after liver transplantation. Neurology 2005; 64:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/298\">",
"      Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia 2007; 48:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/299\">",
"      French J, Arrigo C. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia 2005; 46:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/300\">",
"      Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 2006; 47:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/301\">",
"      Baulac M, Brodie MJ, Elger CE, et al. Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures. Epilepsia 2007; 48:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/302\">",
"      Peltola J, Coetzee C, Jim&eacute;nez F, et al. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Epilepsia 2009; 50:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/303\">",
"      Ulloa CM, Towfigh A, Safdieh J. Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. Neuropsychiatr Dis Treat 2009; 5:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/304\">",
"      Richy FF, Banerjee S, Brabant Y, Helmers S. Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques. Epilepsy Behav 2009; 16:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/305\">",
"      Nicolson A, Lewis SA, Smith DF. A prospective analysis of the outcome of levetiracetam in clinical practice. Neurology 2004; 63:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/306\">",
"      Depondt C, Yuen AW, Bell GS, et al. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry 2006; 77:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/307\">",
"      Hurtado B, Koepp MJ, Sander JW, Thompson PJ. The impact of levetiracetam on challenging behavior. Epilepsy Behav 2006; 8:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/308\">",
"      Helmstaedter C, Fritz NE, Kockelmann E, et al. Positive and negative psychotropic effects of levetiracetam. Epilepsy Behav 2008; 13:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/309\">",
"      de la Loge C, Hunter SJ, Schiemann J, Yang H. Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial. Epilepsy Behav 2010; 18:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/310\">",
"      Szucs A, Clemens Z, Jakus R, et al. The risk of paradoxical levetiracetam effect is increased in mentally retarded patients. Epilepsia 2008; 49:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/311\">",
"      Gelisse P, Juntas-Morales R, Genton P, et al. Dramatic weight loss with levetiracetam. Epilepsia 2008; 49:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/312\">",
"      Hadjikoutis S, Pickersgill TP, Smith PE. Drug points: Weight loss associated with levetiracetam. BMJ 2003; 327:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/313\">",
"      Cramer JA, Leppik IE, Rue KD, et al. Tolerability of levetiracetam in elderly patients with CNS disorders. Epilepsy Res 2003; 56:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/314\">",
"      Sahaya K, Goyal MK, Sarwal A, Singh NN. Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study. Epilepsia 2010; 51:2492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/315\">",
"      Meschede A, Runge U, Sabolek M. Thrombocytopenia during levetiracetam therapy. Epilepsy Res 2008; 80:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/316\">",
"      Kimland E, H&ouml;jeberg B, von Euler M. Levetiracetam-induced thrombocytopenia. Epilepsia 2004; 45:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/317\">",
"      Koubeissi MZ, Amina S, Pita I, et al. Tolerability and efficacy of oral loading of levetiracetam. Neurology 2008; 70:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/318\">",
"      Chhun S, Jullien V, Rey E, et al. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. Epilepsia 2009; 50:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/319\">",
"      Bryans JS, Wustrow DJ. 3-substituted GABA analogs with central nervous system activity: a review. Med Res Rev 1999; 19:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/320\">",
"      Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996; 271:5768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/321\">",
"      Fink K, Dooley DJ, Meder WP, et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002; 42:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/322\">",
"      Lauria-Horner BA, Pohl RB. Pregabalin: a new anxiolytic. Expert Opin Investig Drugs 2003; 12:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/323\">",
"      Pregabalin (lyrica) for neuropathic pain and epilepsy. Med Lett Drugs Ther 2005; 47:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/324\">",
"      Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45 Suppl 6:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/325\">",
"      Brodie MJ, Wilson EA, Wesche DL, et al. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005; 46:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/326\">",
"      Bockbrader HN, Burger P, Knapp L, Corrigan BW. Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. Epilepsia 2011; 52:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/327\">",
"      Bockbrader HN, Burger P, Knapp L. Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. Epilepsia 2011; 52:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/328\">",
"      Feng MR, Turluck D, Burleigh J, et al. Brain microdialysis and PK/PD correlation of pregabalin in rats. Eur J Drug Metab Pharmacokinet 2001; 26:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/329\">",
"      Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004; 45:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/330\">",
"      Beydoun A, Uthman BM, Kugler AR, et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005; 64:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/331\">",
"      Lozsadi D, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2008; :CD005612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/332\">",
"      Lee BI, Yi S, Hong SB, et al. Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: a double-blind, randomized, placebo-controlled, multicenter trial. Epilepsia 2009; 50:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/333\">",
"      Uthman BM, Bazil CW, Beydoun A, et al. Long-term add-on pregabalin treatment in patients with partial-onset epilepsy: pooled analysis of open-label clinical trials. Epilepsia 2010; 51:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/334\">",
"      Jan MM, Zuberi SA, Alsaihati BA. Pregabalin: preliminary experience in intractable childhood epilepsy. Pediatr Neurol 2009; 40:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/335\">",
"      Kwan P, Brodie MJ, K&auml;lvi&auml;inen R, et al. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol 2011; 10:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/336\">",
"      Warner G, Figgitt DP. Pregabalin: as adjunctive treatment of partial seizures. CNS Drugs 2005; 19:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/337\">",
"      Salinsky M, Storzbach D, Munoz S. Cognitive effects of pregabalin in healthy volunteers: a double-blind, placebo-controlled trial. Neurology 2010; 74:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/338\">",
"      Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011; 52:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/339\">",
"      Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001; 42:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/340\">",
"      French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011; 76:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/341\">",
"      Stafstrom CE, Grippon S, Kirkpatrick P. Ezogabine (retigabine). Nat Rev Drug Discov 2011; 10:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/342\">",
"      Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia 2012; 53:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/343\">",
"      Porter RJ, Partiot A, Sachdeo R, et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007; 68:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/344\">",
"      Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010; 75:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/345\">",
"      Weisenberg JL, Wong M. Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures. Neuropsychiatr Dis Treat 2011; 7:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/346\">",
"      Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs 2011; 25:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/347\">",
"      Brickel N, Gandhi P, VanLandingham K, et al. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia 2012; 53:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/61/43994/abstract/348\">",
"      Faught E. Ezogabine: a new angle on potassium gates. Epilepsy Curr 2011; 11:75.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2221 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43994=[""].join("\n");
var outline_f42_61_43994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3242513\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DRUGS THAT AFFECT VOLTAGE-DEPENDENT SODIUM CHANNELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Carbamazepine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5408138\">",
"      - Adverse events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Phenytoin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lamotrigine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Oxcarbazepine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Zonisamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lacosamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rufinamide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DRUGS THAT AFFECT CALCIUM CURRENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ethosuximide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DRUGS THAT AFFECT GABA ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Phenobarbital",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Tiagabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vigabatrin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28483427\">",
"      - Clobazam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28483420\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1668567\">",
"      DRUGS THAT AFFECT GLUTAMATE RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1668575\">",
"      Perampanel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DRUGS WITH MULTIPLE MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Valproate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Felbamate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Topiramate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DRUGS WITH OTHER MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Gabapentin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Levetiracetam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pregabalin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9738475\">",
"      Ezogabine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3242513\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/2221\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2221|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/41/27293\" title=\"table 1A\">",
"      AED for primary generalized tonic-clonic seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/16/15630\" title=\"table 1B\">",
"      AEDs for focal seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/53/23389\" title=\"table 1C\">",
"      AEDs for other primary generalized seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/44/32461\" title=\"table 2\">",
"      AED nonAED drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/29/6621\" title=\"table 3A\">",
"      Carbamazepine interactions with other AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/26/9645\" title=\"table 3B\">",
"      Phenytoin interactions with other AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/36/39500\" title=\"table 3C\">",
"      Valproate interactions with other AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/28/3533\" title=\"table 4A\">",
"      Common side effects of AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/34/30252\" title=\"table 4B\">",
"      Rare serious side effects AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/46/27374\" title=\"table 5\">",
"      AED pharmacologic properties",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/62/24554?source=related_link\">",
"      An approach to the patient with drug allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/3/15417?source=related_link\">",
"      Aseptic meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42632?source=related_link\">",
"      Drug interactions with thyroid hormones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40568?source=related_link\">",
"      Epidemiology and pathogenesis of the polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/28/30154?source=related_link\">",
"      Management and prognosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/26/23973?source=related_link\">",
"      Nephrolithiasis in renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22633?source=related_link\">",
"      Risks associated with epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5860?source=related_link\">",
"      Treatment of distal (type 1) and proximal (type 2) renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=related_link\">",
"      Valproate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/38/28264?source=related_link\">",
"      Valproic acid poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_61_43995="Components and administration of IXIARO";
var content_f42_61_43995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Components and administration of IXIARO Japanese encephalitis vaccine",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inactivated Vero cell-derived vaccine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Trade name",
"        </strong>",
"       </td>",
"       <td>",
"        IXIARO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         JEV strain",
"        </strong>",
"       </td>",
"       <td>",
"        SA",
"        <sub>",
"         14",
"        </sub>",
"        -14-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Preparation",
"        </strong>",
"       </td>",
"       <td>",
"        Liquid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Adjuvant",
"        </strong>",
"       </td>",
"       <td>",
"        Aluminum hydroxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Stabilizer",
"        </strong>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Preservative",
"        </strong>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Primary series",
"        </strong>",
"       </td>",
"       <td>",
"        2 doses at 0 and 28 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         &nbsp;Booster",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;&ge;1 year after primary series if potential for JEV exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Dose",
"        </strong>",
"       </td>",
"       <td>",
"        0.5 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Route",
"        </strong>",
"       </td>",
"       <td>",
"        Intramuscular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Age indication",
"        </strong>",
"       </td>",
"       <td>",
"        &ge;17 years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     JEV: Japanese encephalitis virus.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43995=[""].join("\n");
var outline_f42_61_43995=null;
var title_f42_61_43996="The inherited salt-losing renal tubulopathies";
var content_f42_61_43996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The inherited salt-losing renal tubulopathies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene affected",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene product",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical presentation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Functional studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bartter syndrome type I",
"       </td>",
"       <td>",
"        SLC12A1",
"       </td>",
"       <td>",
"        NKCC2",
"       </td>",
"       <td>",
"        Antenatal Bartter syndrome (Hyperprostaglandin E syndrome)",
"       </td>",
"       <td>",
"        Concentrating capacity reduced and diluting capacity reduced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bartter syndrome type II",
"       </td>",
"       <td>",
"        KCNJ1",
"       </td>",
"       <td>",
"        ROMK",
"       </td>",
"       <td>",
"        Antenatal Bartter syndrome",
"       </td>",
"       <td>",
"        Concentrating capacity reduced and diluting capacity reduced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bartter syndrome type III",
"       </td>",
"       <td>",
"        CLCKB",
"       </td>",
"       <td>",
"        CLC-Kb",
"       </td>",
"       <td>",
"        Classical Bartter syndrome",
"       </td>",
"       <td>",
"        Concentrating capacity reduced and diluting capacity reduced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bartter syndrome type IV",
"       </td>",
"       <td>",
"        BSND",
"       </td>",
"       <td>",
"        Barttin (B-subunit of CLC-Ka and CLC-Kb)",
"       </td>",
"       <td>",
"        Antenatal Bartter syndrome (Hyperprostaglandin E syndrome) and sensorineural deafness*",
"       </td>",
"       <td>",
"        Concentrating capacity reduced and diluting capacity reduced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bartter syndrome type IVB",
"       </td>",
"       <td>",
"        CLCNKA and CLCNKB",
"       </td>",
"       <td>",
"        CLC-Ka and CLC-Kb",
"       </td>",
"       <td>",
"        Antenatal Bartter syndrome (Hyperprostaglandin E syndrome) and sensorineural deafness*",
"       </td>",
"       <td>",
"        Concentrating capacity reduced and diluting capacity reduced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bartter syndrome type V",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        CaSR gene",
"       </td>",
"       <td>",
"        CaSR",
"       </td>",
"       <td>",
"        Bartter syndrome with hypocalcemia",
"       </td>",
"       <td>",
"        Concentrating capacity reduced and diluting capacity reduced",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gitelman syndrome",
"       </td>",
"       <td>",
"        SLC12A3",
"       </td>",
"       <td>",
"        NCCT",
"       </td>",
"       <td>",
"        Gitelman syndrome",
"       </td>",
"       <td>",
"        Concentrating capacity normal/near normal and diluting capacity reduced",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Genetics and presentation of Bartter and Gitelman syndromes. There are six Bartter syndrome subtypes (I, II, III, IV, IVB, and V) corresponding to six genetic defects.",
"    <div class=\"footnotes\">",
"     NKCC2: furosemide-sensitive sodium-potassium-2 chloride cotransporter; ROMK: renal outer medullary potassium channel; CLC-Kb: chloride channel Kb; CLC-Ka: chloride channel Ka; CaSR: calcium sensing receptor; NCCT: thiazide-sensitive sodium-chloride cotransporter.",
"     <br>",
"      * Sensorineural deafness occurs because ClC-Ka and CLC-Kb are highly expressed in the inner ear and interact with other transport proteins (eg, NKCC1) to maintain the high potassium concentration in the endolymph that is required for normal hearing.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Some experts classify the mild salt-losing effect of gain-of-function mutations in the calcium-sensing receptor as Bartter syndrome type V.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted by permission from: Macmillan Publishers Ltd: from: Seyberth HW. An improved terminology and classification of Bartter-like syndromes. Nat Clin Pract Nephrol 2008; 4:560. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43996=[""].join("\n");
var outline_f42_61_43996=null;
var title_f42_61_43997="TmHCO3 in normals";
var content_f42_61_43997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F71017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F71017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bicarbonate reabsorptive capacity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 238px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Filtration, reabsorption, and excretion of bicarbonate as a function of plasma concentration in normal humans.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Pitts, RF, Ayer, J, Shiess, W, J Clin Invest 1949; 28:35, by copyright permission of the American Society for Clinical Investigation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43997=[""].join("\n");
var outline_f42_61_43997=null;
var title_f42_61_43998="Enlarged temporal artery";
var content_f42_61_43998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enlarged temporal artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 286px; height: 181px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Visibly enlarged temporal artery in a patient with giant cell arteritis (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gene G Hunder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_61_43998=[""].join("\n");
var outline_f42_61_43998=null;
var title_f42_61_43999="Contents: Senior health";
var content_f42_61_43999=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Senior health",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Senior health",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Arthritis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/10/30881\">",
"           Patient information: Arthritis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/62/28645\">",
"           Patient information: Arthritis and exercise (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/22/9571\">",
"           Patient information: Arthritis and exercise (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/25/43409\">",
"           Patient information: Hip pain in older people (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/34/23075\">",
"           Patient information: Hip replacement (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/50/29474\">",
"           Patient information: Knee replacement (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/46/16098\">",
"           Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/29/21975\">",
"           Patient information: Osteoarthritis treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/30/21987\">",
"           Patient information: Total hip replacement (arthroplasty) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/13/21717\">",
"           Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chronic pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/12/23746\">",
"           Patient information: Chronic pain (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/6/11363\">",
"           Patient information: Narcotic pain medicines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/42/8867\">",
"           Patient information: Neuropathic pain (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Elder abuse",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/3/7218\">",
"           Patient information: Elder abuse (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         End of life",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/61/25554\">",
"           Patient information: Advance directives (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/21/25939\">",
"           Patient information: Medical care during advanced illness (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fecal incontinence",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/55/6006\">",
"           Patient information: Fecal incontinence (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/50/38690\">",
"           Patient information: Fecal incontinence (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hearing loss",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/26/33186\">",
"           Patient information: Age-related hearing loss (presbycusis) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Managing medicines",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/49/33554\">",
"           Patient information: Acetaminophen poisoning (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/30/483\">",
"           Patient information: Dealing with side effects from medicines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/21/26962\">",
"           Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/3/23603\">",
"           Patient information: Drug allergy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/22/4451\">",
"           Patient information: Latest medicines for hepatitis C (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/11/14515\">",
"           Patient information: Latest medicines to prevent blood clots (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/43/37554\">",
"           Patient information: Medicine brand and generic names (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/27/21940\">",
"           Patient information: Medicines after a heart attack (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/37/36435\">",
"           Patient information: Medicines after an ischemic stroke (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/8/34947\">",
"           Patient information: Medicines for Parkinson disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/35/1587\">",
"           Patient information: Medicines for angina (chest pain) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/22/30052\">",
"           Patient information: Medicines for asthma (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/36/17986\">",
"           Patient information: Medicines for atrial fibrillation (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/41/36499\">",
"           Patient information: Medicines for heart failure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/40/23171\">",
"           Patient information: Medicines for high blood pressure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/41/6803\">",
"           Patient information: Medicines for osteoporosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/6/11363\">",
"           Patient information: Narcotic pain medicines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/13/2262\">",
"           Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/15/40178\">",
"           Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/21/7506\">",
"           Patient information: Prescription drug abuse (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/61/32726\">",
"           Patient information: Reducing the costs of medicines (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/21/6483\">",
"           Patient information: Reducing the costs of medicines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/30/482\">",
"           Patient information: Serotonin syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/57/37778\">",
"           Patient information: Steroid medicines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/38/12898\">",
"           Patient information: Stevens-Johnson syndrome (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/34/32290\">",
"           Patient information: Taking medicines when you're older (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/12/12483\">",
"           Patient information: What you should know about antibiotics (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Memory loss and dementia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/37/14934\">",
"           Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/14/31970\">",
"           Patient information: Dementia (including Alzheimer disease) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/12/35009\">",
"           Patient information: Dementia with HIV (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/3/18482\">",
"           Patient information: Dementia with Lewy bodies (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/3/31793\">",
"           Patient information: Evaluating memory and thinking problems (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/20/2370\">",
"           Patient information: Mild cognitive impairment (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/22/32098\">",
"           Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Multiple illnesses",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/36/27202\">",
"           Patient information: When you have multiple health problems (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Osteoporosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/29/1491\">",
"           Patient information: Bone density testing (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/6/23650\">",
"           Patient information: Bone density testing (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/60/23491\">",
"           Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/12/36034\">",
"           Patient information: Calcium and vitamin D for bone health (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/33/14867\">",
"           Patient information: Hip fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/62/29665\">",
"           Patient information: Kyphosis in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/41/6803\">",
"           Patient information: Medicines for osteoporosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/58/35746\">",
"           Patient information: Osteoporosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/49/25366\">",
"           Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/4/42050\">",
"           Patient information: Preventing falls (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/63/27635\">",
"           Patient information: Vertebral compression fracture (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/62/15331\">",
"           Patient information: Vitamin D deficiency (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/45/10962\">",
"           Patient information: Vitamin D deficiency (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pressure sores",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/53/39761\">",
"           Patient information: Pressure sores (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Preventive healthcare",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/40/36481\">",
"           Patient information: Breast cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/59/19379\">",
"           Patient information: Breast cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/63/10227\">",
"           Patient information: Cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/53/8019\">",
"           Patient information: Cervical cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/23/7541\">",
"           Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/34/25123\">",
"           Patient information: Colon and rectal cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/9/25747\">",
"           Patient information: Colon polyps (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/5/9298\">",
"           Patient information: Colon polyps (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/30/9698\">",
"           Patient information: Colonoscopy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/11/18611\">",
"           Patient information: Colonoscopy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/28/5570\">",
"           Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/13/11475\">",
"           Patient information: Lung cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/15/6386\">",
"           Patient information: Ovarian cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/14/27874\">",
"           Patient information: Ovarian cancer screening (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/8/15491\">",
"           Patient information: Pap tests (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/54/867\">",
"           Patient information: Preventive healthcare for older adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/55/38770\">",
"           Patient information: Prostate cancer screening (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/27/32176\">",
"           Patient information: Prostate cancer screening (PSA tests) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/24/1411\">",
"           Patient information: Time to stop driving? (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Safety",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/4/42050\">",
"           Patient information: Preventing falls (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/24/1411\">",
"           Patient information: Time to stop driving? (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sex",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/20/16706\">",
"           Patient information: Sex as you get older (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary incontinence",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/0/16386\">",
"           Patient information: Neurogenic bladder in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/0/19456\">",
"           Patient information: Pelvic floor muscle exercises (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/60/11202\">",
"           Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/56/35714\">",
"           Patient information: Surgery to treat stress urinary incontinence in women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/36/43586\">",
"           Patient information: Treatments for urge incontinence in women (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/8/22658\">",
"           Patient information: Urinary incontinence (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/9/35987\">",
"           Patient information: Urinary incontinence in men (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/16/9474\">",
"           Patient information: Urinary incontinence in women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/19/19764\">",
"           Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vision loss",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/11/24754\">",
"           Patient information: Age-related macular degeneration (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/35/11826\">",
"           Patient information: Age-related vision loss (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/62/6114\">",
"           Patient information: Cataracts (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/34/11810\">",
"           Patient information: Diabetic retinopathy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/13/2258\">",
"           Patient information: Glaucoma (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/6/28769\">",
"           Patient information: Presbyopia and refractive errors (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-84A0E3C614-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f42_61_43999=[""].join("\n");
var outline_f42_61_43999=null;
